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SUMMARY
The use of biological specimens other than blood and urine for the detection of drugs, 
usually referred to as alternative specimens, has been the focus of many scientific studies 
over the past two decades. The type of biological sample analysed affects the type of 
information obtained and the aims of this project were to investigate hair, saliva and nail as 
alternative specimens and to evaluate their diagnostic use in Forensic Toxicology.
The potential of hair analysis as a diagnostic tool in Forensic Toxicology was investigated 
by developing and validating a robust and reliable method for the simultaneous 
determination of opiates and methadone in hair samples. An assessment was made of the 
ability of three different pretreatment steps involving enzymatic hydrolysis, acid hydrolysis 
and solvent washing to extract morphine, codeine, 6-monoacetylmorphine, methadone and 
EDDP from hair. The methanol procedure was the only one that did not hydrolyse a 
percentage of 6-monoacetylmorphine to morphine and this was used for subsequent 
analyses, followed by solid phase extraction (SPE) and gas chromatography-mass 
spectrometry (GC/MS).
Post-mortem hair samples from suspected heroin overdose cases were analysed using the 
validated method to determine whether each individual was a heroin user and their history 
of heroin exposure. An overall indication of drug use was produced for each individual 
from the results of analyses of hair and post-mortem blood. Known drug use history was 
established from police reports and the hair analysis results were evaluated against the 
available information. The ranges of concentrations of analytes found in hair were: 
morphine 0.10 - 9.79 ng/mg, codeine 0.12 - 3.47 ng/mg, 6-monoacetylmorphine 0.14 -
70.07 ng/mg, methadone 0.15 - 1.15 ng/mg and EDDP 0.27 - 1.55 ng/mg. A total of 31 
hair samples was analysed, the majority of which were shown to be from regular heroin 
users. Criteria were established from the data which allowed users to be categorised into 
low, medium and high regular users with respect to their heroin habit. Periods of 
compliance with methadone programmes or drug rehabilitation programmes were also 
evident. The data supported the conclusion that hair analysis can successfully determine 
the drug use history of heroin users.
The number o f cases involving fluoxetine and paroxetine has increased in the last 5 years 
and has required the development of improved methods to quantitate these drugs in whole 
blood. In addition, blood analysis provides the reference data for evaluation of analytical
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results from alternative specimens. An SPE method using cyanopropyl columns was 
developed and evaluated initially for the extraction of fluoxetine and its metabolite, 
norfluoxetine. This method was compared with existing liquid-liquid extraction methods 
and validated using both high performance liquid chromatography (HPLC) and GC/MS. 
The HPLC method was found to work well with clinical blood samples but was subject to 
problems caused by co-extracted interferences from some post-mortem blood samples. By 
contrast, the GC/MS method did not exhibit this problem and was selected for further 
analyses. The method was validated for the simultaneous analysis of fluoxetine, 
norfluoxetine and paroxetine and was shown to achieve significantly improved limits of 
detection for each of these analytes of approximately 1 ng/ml. Post-mortem and clinical 
blood samples from antidepressant users were successfully analysed using this improved 
method. These results provided the foundation for further research into the diagnostic use 
of alternative biological specimens and were compared with data from hair, saliva and 
urine from the same cases.
The method developed for antidepressants in blood was also found to extract these analytes 
efficiently from saliva. Saliva samples were collected by expectoration and with Omni- 
Sal® devices. Validation of the Omni-Sal® method included investigating the in-vitro 
recovery of drugs from the swab. Recoveries were determined to be reproducible but much 
lower than those obtained from saliva collected by expectoration and this was also true for. 
clinical saliva samples. Saliva samples were collected serially from volunteers who were 
given a single dose of 20 mg Prozac® or Seroxat® and concentration-time curves were 
produced. Peak saliva concentrations were reached at approximately 7 hours following 
administration of fluoxetine for three individuals and 5 and 7 hours for two individuals 
who were administered paroxetine. The saliva half-lives were found to be 24-48 hours for 
fluoxetine and 5 - 8  hours for paroxetine. The saliva concentrations of drugs found in 
individuals prescribed 20 mg/day varied from 0.022 - 0.223 mg/L for fluoxetine and 0.011 
- 0.143 mg/L for norfluoxetine. In one paroxetine sample a concentration of 0.031 mg/L 
was detected. In some of these cases blood samples were also collected simultaneously 
and saliva/blood concentrations were determined. Four out of six saliva/blood ratios for 
fluoxetine were shown to fall within the theoretical range calculated for a saliva pH range 
of 6.0-7.2 using the Henderson-Hasselbalch equation and the saliva/blood ratio for 
paroxetine in one case also fell within its theoretical limits. One conclusion from this
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study was that saliva can be used as an alternative specimen to blood or urine to indicate 
recent drug exposure.
The analysis of hair as a means of determining chronic administration of prescription drugs 
was assessed by developing a procedure for the analysis of fluoxetine, norfluoxetine and 
paroxetine in hair samples obtained from geriatric and clinical patients. Methanol wash and 
acidic hydrolysis pre-treatments were assessed for these drugs. The latter produced higher 
recoveries without deterioration of the analytes and was used for analysis of hair samples 
from antidepressant users, to give a history of their drug administration, and these results 
were assessed against information obtained from each patient’s medical records. Hair 
concentrations of each drug were evaluated to find if there was any correlation between 
individuals receiving the same doses. Concentrations of fluoxetine, norfluoxetine and 
paroxetine were found to vary from 0.34 - 5.52 ng/mg, 0.15 - 8.09 ng/mg and 0.22 - 6.23 
ng/mg respectively and the drug use history as given by the hair samples correlated well 
with the patients' medical records. There was no dose-concentration correlation between 
individuals and therefore no information could be derived from hair analysis about the 
amount of drug consumed. However, within an individual, a constant dose-concentration 
correlation was apparent and this could be used to test for compliance. The influence of 
hair colour on the amount of drug incorporated was also investigated in these cases. 
Darker hair was found to incorporate a greater amount of drug than grey or white hair. The 
diagnostic use of hair as an indicator of chronic drug use was established using the 
validated method.
The potential of nail as an alternative to hair for the determination of chronic drug use was 
studied by validating a simple extraction method and using it to determine levels of 
antidepressants in nails obtained from clinical patients. Analyte concentrations in nail 
were evaluated using each patient’s medical records and were assessed against the 
concentrations determined in the hair o f each individual, to find if there was any 
correlation between the concentrations in these different biological samples. Nail 
concentrations were found to vary from 0.16 - 4.49 ng/mg for fluoxetine, 0.06 - 2.37 ng/mg 
for norfluoxetine and 0.01 - 0.84 ng/mg for paroxetine and in most cases a good correlation 
was seen with medical records. Hair and nail concentrations were compared for each 
individual and these generally showed that, as the hair concentration increased, the nail 
concentration also increased. The use of nails for the detection of these drugs was 
demonstrated to be a good alternative to hair as an indicator of chronic use.
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1 Introduction
The use of alternate biological samples for the detection of drugs has been the focus of 
many scientific investigations in the past two decades. The decision as to which biological 
specimen is to be analyzed is important because different specimens will render different 
types of information. Traditional biological samples used in toxicological investigations 
are blood and urine. These specimens give information about an individual's recent drug 
use. However, these samples can be awkward to collect and information about the chronic 
use of drugs cannot be obtained from them. In the case of urine analysis, the detected drug 
concentrations do not give the same information as blood concentrations. Urine 
concentrations are accumulated over a period of time and do not give a true reflexion of the 
amount of drug in the body at the time of collection. They only indicate that the individual 
has taken a particular drug. On the other hand, blood concentrations can indicate the 
amount of drug in the system at a specific time. Saliva concentrations have also been 
shown to be a better indicator of concentrations in the system at a specific time than urine.
Saliva, as a biological sample for the testing of drugs gives an indication of the short term 
use of drugs in an individual. Its major advantage over blood analysis lies in its non- 
invasive collection procedure. The collection of blood samples requires a medically 
qualified person to carry out a standard venepuncture procedure which can often cause 
discomfort to the person giving the sample and urine collection is intrusive. Saliva testing 
for drugs has been used in the past for therapeutic drug monitoring.1 However, in recent 
years it has become of interest to law enforcement agencies for the roadside testing of 
potentially intoxicated drug drivers.2, 3 In the region of Strathclyde, Scotland, the number 
o f blood samples obtained in incidents involving intoxicated drivers which were found 
positive for drugs increased from 86 cases in 1996 to 139 cases in 1999.4 In many o f these 
cases the identified drugs were substances controlled under the Misuse of Drugs Act 1971. 
However, drugs of interest in drivers do not only include controlled drugs, but also 
prescription drugs and over the counter drugs which have the ability to impair driving 
performance either alone or in combination with other drugs. It is therefore important to be 
able to measure them as well as controlled drugs in saliva. The primary disadvantages of 
using saliva as a test medium are that drug excretion in saliva can vary due to salivary pH 
changes and contamination of the oral cavity due to drug administration by oral, smoked or 
intranasal routes can lead to high saliva concentrations of the drug.
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Blood, urine and saliva samples can all provide information on the recent use of different 
drugs. However, hair analysis can give a different perspective on drug consumption in that 
chronic drug use can be determined. Drugs may be incorporated into hair via several routes 
including passive diffusion from blood into the hair follicle, by transfer from sweat and 
sebum and by external contamination. Much of the incorporated drug will remain in the 
hair during its life. For the average individual, hair grows at approximately one centimetre 
per month. Sectioning of the hair from the root end towards the tip provides segments 
which are approximately equivalent to a period of time and this means that it can be 
estimated when a person was using or not using a particular drug. This has proven useful in 
monitoring individuals involved in drug maintenance programmes, employee screening, 
child custody and adoption cases, criminal cases and athletics to either prove or disprove 
the use of drugs. Hair has the added advantages over conventional fluids that it is relatively 
stable and can retain drugs over long periods o f time. Collection is simple and can be 
carried out under close supervision and adulteration is not a problem as it can be with urine 
analysis. However, there are still many controversies surrounding hair analysis and these 
include drug loss through chemical treatment of hair or environmental factors, the 
possibility of an ethnic bias or hair colour affecting the amount of drug incorporated and 
external contamination to hair through smoking or by secondary transfer.
Nail analysis for drugs is also a means of detecting chronic use. It has many of the same 
merits as hair analysis. Its collection procedure is non-invasive and the stability o f the 
matrix allows drugs to be stored within the structure for long periods of time. However, it 
cannot give the same information as hair analysis can about when a drug was used. This 
can be explained by recent studies that have provided evidence into the way in which drugs 
are incorporated into nails. Incorporation of drugs into nail may be through cells in the nail 
bed and also in the nail matrix. Therefore, drugs can be detected in nail a few weeks after 
administration.
The understanding of the structures of each biological matrix and the incorporation of 
drugs into these samples is crucial in evaluating and interpreting the results from their 
analysis. In the following chapters these areas amongst others will be addressed for each 
alternate biological sample.
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2 Hair
2.1 INTRODUCTION
Hair testing for drugs has been used in Europe and the United States for various purposes 
including monitoring individuals who are involved in drug maintenance programmes, 
employee screening, criminal cases, athletics and child custody cases. In Italy hair analysis 
has been used to test the hair of drivers who have lost their licences through drug use prior 
to reissuing their licence.5,6) 7
The hair matrix is a relatively stable matrix which can retain drugs over long periods of 
time, and can provide a much longer record of drug use in comparison to matrices such as 
blood, urine and saliva.8 Collection of hair samples is non-invasive, can be carried out 
under close supervision and invasion of privacy is not an issue as with urine sampling. Hair 
samples cannot be adulterated and temporary abstention from drug use only means that the 
drug will not be detected over that short period, but hair growing at the time o f drug use 
will still indicate drug exposure. A second hair sample can always be collected if required. 
The hair matrix, unlike other biological matrices is stable even under extreme 
environmental conditions and it can be easily stored and transported without refrigeration.
For drug analysis in hair, the understanding o f the anatomy of human hair appears to be an 
important factor in evaluating and interpreting hair analysis data. For this reason an 
overview of hair anatomy, hair growth cycle and drug incorporation into hair is given.
2.2 STRUCTURE OF THE HAIR SHAFT
The hair shaft is composed of three regions, namely the cuticle, the cortex and the medulla 
(Figure 2.1). Within the cortex and medulla (and very rarely in the cuticle) there exist 
pigment granules. Each of these components will be discussed separately.
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Figure 2.1: Cross-section of a hair shaft showing the three principle regions (Copyright © 
Elsevier Scientific Publishers, Harkey, M.R. "Anatomy and Physiology of hair." Forensic 
Science International 1993, 63, p9-18.
2.2.1 CUTICLE
The cuticle is made up of six to ten layers of cells that overlap one another from root to tip. 
The average hair has 4 pm of cuticular covering surrounding the cortex.9 Its purpose is to 
shield the inner fibres from damage and to fix the hair shaft in the hair follicle, a small sac- 
shaped secretory gland that contains the hair root.10
2.2.2 CORTEX
The cortex constitutes the bulk of the hair. Closely packed elongated cells are aligned 
along the axis of the hair to form long keratin fibres that are contained in the cortex. In the 
proximal end of the cortex, fluid filled spaces exist between the long keratinized cells. As 
the hair grows, the fluid dries up and air spaces called fusi are formed.10
2.2.3 MEDULLA
The medulla forms the central core of the hair and it has a tendency to vary along the hair 
strand. At the follicle end it consists of loosely packed cells that dehydrate leaving 
vacuoles along the fibre further away from the follicle. In general, the larger the fibre 
diameter, the more medullar cells are present, such that fine hair may contain no medullar 
cells whereas thick hair may contain many. In human hair the medulla can be continuous, 
discontinuous or absent and in beard hair a double medulla can sometimes be present.9,10
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2.2.4 PIGMENT GRANULES
Pigment granules exist in the cortex and the medulla. The main pigment in hair is melanin 
which is produced by cells called melanocytes during the growth or anagen phase of the 
hair. These melanin granules are fixed between keratinous fibrils in the cortex and are 
distributed throughout the cortex with a higher density occuring towards the outer edges of 
the cortex.9 It is these melanin granules which define hair colour depending on the 
amounts, size, distribution and types of melanin present. These factors vary for different 
races for example melanin granules are more abundant in Negroid hair than Caucasian 
hair.
2.3 THE HAIR FOLLICLE
The hair follicle is a small sac-shaped secretory gland containing the hair root. It extends 3- 
4 mm below the surface of the skin and it is associated with the sebaceous and apocrine 
glands and also the sweat glands in axillary and pubic regions.
The follicle is composed of three sections. Hair synthesis takes place in the bulb area, 
which extends furthest into the skin. Above the bulb is the keratogenous zone where 
keratinization or hair solidification takes place and in the final region dehydrated, comified 
cells make up the hair shaft (Figure 2.2).10
Apocrine gland
Eccrine sweat 
gland
Eccrine sweat 
duct
Papillary 
plexus \
y /  comeum 
—  Epidermis
Cutaneous
plexus
Hair follicle
Dermal papilla
Sebaceous
gland
Stratum
Dermis
Figure 2.2: The hair follicle and surrounding components (Copyright © Elsevier Scientific 
Publishers, Harkey, M.R. "Anatomy and Physiology of hair." Forensic Science 
International 1993, 63, p9-18.
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2.4 HAIR GROWTH CYCLE
Hair growth is an intermittent, regenerative process made up o f a series of cycles 
alternating between irregular periods of growth and rest. 11 The growth and rest periods 
vary between areas of the body and also in any one specific area . 10 There are three main 
stages involved in the hair growth cycle: anagen, catagen and telogen phases.
2.4.1 ANAGEN PHASE
The anagen phase is the growing stage of the hair which involves mitotic activity of the 
matrix cells in the hair follicle. 12 Newly produced cells elongate forming fine filaments 
which are forced up into the follicular canal. At this stage protein synthesis or 
keratinization occurs and new hair is formed. The growing stage lasts between 2 to 3 years. 
In the vertex region of the scalp, a maximum of 85 % of hair is in the growing stage at any 
one time, with the remaining 15 % in the resting stage . 10
2.4.2 CATAGEN PHASE
The mitotic activity of the matrix cells suddenly ceases and the catagen phase commences. 
This is a transitional phase between active growth and a resting phase. During this phase, 
the hair root is partially destroyed: a mass of keratin is formed at the base of the hair shaft 
and this becomes separated from the bulb of the hair follicle. The hair follicle eventually 
returns to its normal length. 12
2.4.3 TELOGEN PHASE
The telogen phase is one where all hair growth activity has ceased and at this stage the hair 
is completely detached from the bulb with the hair lying in the upper section of the 
follicular canal. As a result, hair can be easily pulled or plucked at this stage . 10 Individual 
hairs have their own growth cycle of 2-8 years including the telogen stage o f about 3-4 
months . 13 For hair analysis, it is preferable to sample hair from a position where the 
minimum amount of hair is in the telogen or resting phase because telogen hairs will cause 
a shift in the distribution of drugs found that may be equivalent to several months.
2.5 HAIR GROWTH RATE
Reported hair growth rates for head hair have varied greatly, most likely due to the 
complex, non-continuous growth mechanism of hair and the fact that growth rate varies 
between individuals and amongst the hair shafts within an individual. However, it is
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generally accepted that head hair grows at a rate of 1 cm/month . 14 Factors affecting hair 
growth rate primarily are hair type and location and to a certain extent age, race and sex. 
Growth rate is highest for head hair, followed by axillary and pubic hair and then beard 
hair. Head hair growth rate decreases with age, is faster in Caucasians than Asians and is 
faster in females than males . 10
2.6 DRUG INCORPORATION INTO HAIR
The exact mechanism of the incorporation of drugs into hair has not yet been established. 
However, the model commonly proposed is one of passive diffusion of drug via blood 
capillaries into the base of the hair follicle where hair formation takes place. As hair 
strands are produced they solidify and drug is encapsulated in the hair shaft. 15 Then, as the 
hair grows, the encapsulated drug moves away from the bulb with the piece o f hair to 
which it has been affixed. Using this model, it is assumed that the amount o f drug 
incorporated into the hair is proportional to the amount in the blood and therefore to that 
ingested and also, that hair growth is constant so a history of drug use can be established. 
Methoxyphenamine was administered to individuals and was shown to move along the hair 
shaft according to hair growth, without diffusion . 16
However, it has been brought to light through experimental evidence and speculation that 
the process of drug incorporation may not be as straightforward as first believed and that 
the amount of drug deposited in hair is due to the contribution of several factors. The 
simple passive diffusion model assumes that all of the drug enters the hair follicle via 
blood capillaries. However, it has been speculated that external contamination, from sweat 
or sebum, or skin surrounding the hair as it is produced could be a source of drug transfer 
into hair.15, 17 Other routes of external contamination are by drugs which can be smoked 
such as nicotine, cannabis, cocaine and heroin. In these cases careful wash procedures must 
be employed to remove as much external contamination as possible.
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2.7 DRUG PROPERTIES AFFECTING INCORPORATION INTO HAIR
Drug incorporation into hair appears to be the result of three main physicochemical 
properties, namely, lipophilicity, basicity and melanin affinity. Membrane affinity has also 
been a proposed factor.
It has been suggested that drug incorporation into hair can be put down to a combination of 
two factors, melanin affinity and lipophilicity. The aspect of membrane affinity can be 
associated with lipophilicity, and likewise basicity could be strongly linked with melanin 
affinity since the chemical structure of melanin is composed of many carboxylic acid 
groups that will attract basic structures . 18 However, this idea has not been entirely proven 
and for the purpose of this thesis lipophilicity, basicity and melanin affinity will be 
discussed and also structural factors that seem to have a role in incorporation of drugs into 
hair.
2.7.1 LIPOPHILICITY
The lipophilicity of a drug will have a large influence on how it enters the hair. In order to 
pass from the blood capillary to the hair follicle, the drug must be able to cross the cell 
membrane. Substances that are most likely to be successful at this are chemically nonpolar 
parent drugs. 17 This may well explain why in many cases parent drugs are detected in 
higher quantities in hair than their respective hydrophilic metabolites.
The results of a study to test the incorporation of a group of amphetamine analogues into 
hair indicated that small structural changes increasing the lipophilicity also increased the 
concentration of drug found in hair. 19
The lipophilicity of 19 basic drugs of abuse was shown to correlate with their incorporation 
rate into hair giving a correlation factor of 0.766.20
2.7.2 BASICITY
The ionization of a drug at physiological pH affects how much drug incorporates into the 
hair. In a study involving rats, hair and blood concentration ratios were compared for 
codeine and phenobarbital. The weak base, codeine, which is cationic at physiological pH 
incorporated into hair to a greater extent than the weak acid, phenobarbital which has no
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cationic properties at physiological pH, concluding that at the same plasma concentration, 
cations will incorporate into hair with a higher concentration than anions . 17
Another study investigated the incorporation rates of a range of acidic, basic and neutral 
drugs into rat hair. Basic drugs had the highest incorporation rates with cocaine featuring 
highest out of those tested. 11 -nortetrahydrocannabinol-9-carboxylic acid had the lowest 
incorporation rate. It was concluded that the higher incorporation rates o f basic drugs over 
neutral or acidic drugs was highly associated to the membrane permeability of the drug . 20
2.7.3 MELANIN AFFINITY
In an investigation involving 20 drugs, it was shown that different drugs have different 
affinities to bind to melanin and the evidence pointed to the fact that melanin in hair could 
be associated with drug incorporation into hair. Cocaine, benzphetamine and phencyclidine 
were shown to have the highest affinity for melanin out of those drugs investigated . 20
The incorporation of seven phenylamines was investigated in white and black rat hair. Six 
o f these were detected at high concentrations in black hair, however, hardly any were 
detected in white hair indicating that for basic drugs to incorporate into hair, melanin is an 
essential component. 21
Melanin affinity was shown to be affected by different groups substituted at the para- 
position on the benzene ring of methamphetamine. Nitro-, amino-, and methylene dioxy- 
groups all showed significantly higher affinities compared with the unsubstituted 
methamphetamine . 18
In an experiment investigating the different incorporation rates of phenethylamines, it was 
shown that drugs incorporated into black rat hair in four different manners: rapidly over a 
long period of time, rapidly over a short period of time, slowly over a long period of time 
and slowly over a short period of time. However, these same drugs were shown to be 
scarcely incorporated into white hair. This showed that the presence of melanin was 
essential for effective incorporation into hair . 21
2.7.4 STRUCTURAL FACTORS
Small changes in chemical structure can have a large effect on whether a substance is 
easily incorporated into hair. A group of methamphetamines with different para-
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substituents on the benzene ring (nitro-, hydroxy-, bromo-, amino-, methoxy- and 
methylenedioxy- groups) all possesed different drug incorporation rates which showed the 
strong effect that functional groups place on drug incorporation . 18 A series of these types 
of experiments was carried out to evaluate different structural factors influencing the 
incorporation rate into hair and these again showed that small changes in functional groups 
alter the incorporation rate and have a considerable influence on whether a drug is easily 
detected or not. 22
2.7.5 OTHER FACTORS AFFECTING DRUG INCORPORATION INTO HAIR
There are still many unresolved issues involving drug transfer into hair. Factors such as 
gender23, age, differences in hair structure between individuals, seasonal variation, 
condition of hair, for example, damage by exposure to sunlight24 have all been questioned 
as having an effect on incorporation.
2.8 COLLECTION OF HAIR
Several considerations need to be taken into account when collecting hair samples from 
humans. For instance, is the sample being collected from a live or dead individual? What 
size of sample is required? Can any type of body hair be used? These will be discussed 
below.
2.8.1 METHODS
In postmortem cases, it is the pathologist who takes the specimens and it is necessary for 
the hair sample to be taken prior to the postmortem to prevent unwarranted contamination 
from blood or other bodily fluids. This hair can be pulled which will include the roots in 
the sample or cut close to the scalp. Collecting hair from living individuals will involve 
cutting the hair close to the scalp and this will usually be carried out by a General 
Practitioner. Whichever method is used, the root end should be labelled clearly (although 
this is often obvious where the roots are included in the sample), the sample tied with 
string or rolled in cigarette wrappers to hold it together and placed in a labelled tube.
2.8.2 SAMPLE SIZE
The sample size is important and will depend on the type of investigation and how many 
analytical investigations are to be carried out. Preferably a bundle of hair at least 0.5
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centimetres in diameter is required for each analysis, but this will be dependent on the 
amount of hair an individual has.
2.8.3 HAIR TYPE
Location of the hair sample is another important factor. For head hair, this should be taken 
from the posterior vertex where hair growth is at its densest and most consistent in its 
growth pattern, except in some older males. Other hair types have also been used for 
analysis of drugs. Pubic hair can be used where there is no other hair available, but this has 
the disadvantage o f providing a sample contaminated by urine. Drug concentrations in 
various types of hair of an individual vary according to the location of the hair sample . 25 
The most likely explanation of this difference is due to the varying growth rates of these 
different hair types. Beard hair would be the preferable hair type for detection of drugs a 
few days after use, in addition to urine analysis . 26 On the whole, pubic, axillary and beard 
hair hold no major advantages over head hair. They are still susceptible to contamination 
through urine, sweat and the environment and so if obtainable, head hair is the preferred 
sample for analysis.
2.9 STABILITY OF DRUGS IN HAIR
The stability of drugs in hair has been examined by several authors who have shown that 
positive opiate levels decreased to produce negative results in hair samples which were 
exposed to soil and water for a period of six months . 27 Concentrations detected in hair have 
been shown to decrease when hair was bleached, coloured or treated with perming 
reagents.28, 29 Other studies have also shown that when a constant amount of drug is 
administered, the concentration of drug detected in hair decreases with time. These 
decreases were explained by some of the drug being removed by washing hair that had 
been damaged because of environmental factors16 and hair having been treated with henna 
products . 30 These findings infer that quantitative results of drugs in hair positioned further 
away from the root require careful interpretation.
2.10 ETHNIC BIAS
It has already been mentioned in 2.2.4 that the composition of hair from different races 
varies in the number of melanin granules such that Negroid hair contains more granules 
than Caucasian hair. Studies have shown that drugs have a tendency to incorporate into
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hair which has a higher melanin content, and therefore certain races, African-Americans, 
Asians, Hispanics could experience a bias in drug testing. Many studies have been set up to 
resolve this controversial issue. Some authors have concluded from their work that there 
was no conclusive evidence of hair colour or racial bias and that differences were a result 
of the varying drug use of different races and cultures . 31 However, several animal 
investigations have pointed towards the fact that hair colour and therefore melanin content 
has a large part to play in drug binding. Drugs such as methadone32, buprenorphine33, 
haloperidol34, codeine35 and phencyclidine17 did not incorporate into white hair to the same 
extent as black hair.
Statistical evaluations have been applied to reported analytical results where hair colour 
was clearly identified. Although there were apparent differences in the drug levels detected 
within the various samples, they found that there was no significant difference between the 
drug levels measured in different hair colours. The authors concluded that hair colour does 
have a role to play in the incorporation of drugs, however, it only contributes a fraction in 
the process which is statistically undetectable. Attention should be given, however, to 
cosmetic treatments and laboratory procedures that may impact on the amount of drug 
measured in the sample . 36
2.11 CONTAMINATION
External contamination of hair by drugs through smoking or by secondary transfer from 
handling drugs and then hair can cause problems for the analyst. This contamination 
should be eliminated by decontamination wash procedures prior to analysis. Washes 
should be monitored to ensure that all of the contamination is removed. It has been 
reported that certain wash procedures may remove drugs from within the hair shaft, 37 
whereas others have reported the failure to remove all external contamination from hair. 
This questioned whether some of the drug had adsorbed into the hair shaft and not solely 
onto the surface . 38 Several mechanisms have been indicated to be responsible for the 
binding of drugs to hair. Hair is composed of keratin, melanin and lipids which may all 
play a part in the binding process. Keratin is composed of several basic and acidic amino 
acid residues and multiple hydrogen bonds which will have the potential to interact with 
drugs. The most abundant amino acid in keratin is cystine which containes a disulphide 
bond which can potentially bind nucleophilic molecules. Also, dipole-dipole interactions
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may be possible between peptide bonds in keratin and polarizable molecules. It has already 
been mentioned that different drugs appear to have different affinities to bind to melanin. 
The actual structures of pheomelanin and eumelanin have not yet been determined. 
However, the quantity and type of melanin in hair should dictate the extent of drug 
binding. Hair consists of 1-9 % lipid content. It has also been suggested that non-specific 
binding of drugs to lipid components in hair cell membranes can occur. A constituent of 
lipid membranes are fatty acids containing negatively and positively charged groups which 
can bind cationic and anionic drugs respectively. 39
Other authors have also reported the failure to remove all external contamination using 
different wash procedures . 4 0 , 41 ’ 42, 43 As a consequence, it is not always easy to differentiate 
environmental contamination from actual drug use. It has been reported that the hair of 
cigarette smokers and non-smokers could not be differentiated because of contamination 
due to secondary smoke . 44 However, in another report aimed to distinguish smokers from 
non-smokers a cut-off level of 2  ng/mg for nicotine was suggested, based on the authors' 
results . 45
For certain drugs, the identification of metabolites can be used to distinguish between 
passive exposure and actual drug use . 46 Metabolites of drugs such as cocaine, however, are 
also produced by degradation and have been found on the surface of hair o f non-users. 
The idea to use unique metabolites which are only found when the drug has been injested 
have also been evaluated , 41 however it was suggested that even these metabolites could be 
found in illicit cocaine samples. 47
2.12 ANALYSIS
In general, four main steps are used in hair analysis. These will be discussed briefly.
2.12.1 DECONTAMINATION
Before hair samples are extracted, they must be washed to remove extraneous material 
including oils, grime and externally applied drug. This procedure should help clean the 
extract whilst preventing false positives from occurring, but should not remove drug which 
has been incorporated into hair through drug use. This stage is necessary to produce the 
correct drug historical record of an individual. Wash steps often involve using a detergent 
and a combination of solvents.
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2.12.2 REMOVAL OF DRUG FROM HAIR MATRIX
Drug can be removed from the hair matrix by alkaline hydrolysis, acid hydrolysis, 
enzymatic hydrolysis or by treatment with solvent, for example methanol. The choice of 
extraction procedure is influenced by the drug and its chemical stability. Drugs which are 
chemically unstable are usually extracted using enzyme or solvent methods since alkali 
hydrolysis is generally too harsh a method and destroys the drug. Also, if  the hydrolysis 
product is a metabolite of the analyte then this can lead to erroneous results. With drugs 
which are chemically stable, alkaline hydrolysis has often been the preferred method as it 
efficiently solubilizes the keratin matrix. Enzyme, solvent and acid methods do not 
completely solubilize the hair and can lead to lower recoveries . 48
Various types of enzyme digestion have been used. The advantages o f this method are that 
the extraction can be carried out at an optimum pH and the results are often better than 
those obtained with solvents only. Enzymes act on keratins without altering the chemical 
structure of the analytes in hair. 49
2.12.3 EXTRACTION
Clean-up procedures generally involve using either liquid-liquid or solid phase extraction 
procedures. However, other less conventional methods involving solid-phase 
microextraction and supercritical fluid extraction are now also being used.
2.12.4 ANALYSIS
Analytes in hair are generally detected using mass spectrometry, following 
chromatographic separation because it is a sensitive and specific means of detection. Gas 
chromatography-mass spectrometry has been the most useful tool in the past, but now 
newer techniques involving tandem mass spectrometry, high resolution mass spectrometry 
and liquid-chromatography mass spectrometry are becoming more popular because o f their 
increased sensitivity. However, these instruments are not available in most laboratories.
2.13 INTERPRETATION OF AMOUNTS OF DRUG DETECTED IN HAIR
2.13.1 DOSE-CONCENTRATION CORRELATIONS
Many studies have been carried out to find if there is a relationship between the amount of 
a drug administered to the concentration detected in hair. Some of these studies were 
conducted in humans and some in animals. Findings have shown that there is a significant
Chapter 2: Hair Testing for Drugs Page 15
correlation for some drugs such as methadone , 30 nicotine and cotinine , 50 
methoxyphenamine , 16 opiates,24, 51, 52 cocaine,24, 52 methamphetamine, 52 amphetamine , 52 
6 -acetylmorphine , 52 and phencyclidine. 24 On the otherhand, a lack of correlation was 
observed for drugs morphine , 53 cocaine , 54 dothiepin , 55 amitriptyline, 55 cannabis , 24 nicotine , 56 
and benzodiazepines. 57 It has been suggested that lack of correlation is not surprising 
since several of the studies have employed self-reported usage which could easily be 
underestimated, the purity of street-drugs is unknown and there is a high degree of inter­
individual variation which can affect drug incorporation . 53 Whilst there are many unknown 
factors remaining about drug incorporation into hair, determining the amount of drug 
consumed from quantitative measurements in hair will remain inapplicable.
2.13.2 CUT-OFF LEVELS
Cut-off levels are very important when controversial issues such as racial bias or hair 
colour bias have not been fully resolved. If incorporation rates are different in, for 
example, two different hair colours, black hair and blond hair, then at low concentrations 
the drug may be detected in the black hair but not in the blond hair because it is below the 
cut off point. Cut-off levels must provide an acceptable balance between false positives 
and false negatives. A false positive result is one in which a drug is found present in a 
sample when in fact it is not and a false negative result is one in which a certain drug is not 
found to be present in a particular sample when in fact it is. Both of these are undesirable 
factors in the analysis of drugs. The finding of false positives is especially of great concern 
in drug analysis because of the consequences they can have on the individual concerned. 
After its third meeting in Texas, May, 1999, the Hair Testing Work Group reached a final 
consensus recommending cut-off levels for different drugs of abuse in hair. 58
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3 Hair Analysis for Opiates and Methadone
3.1 AIM
The aims of the following project were to develop a reliable method for the analysis o f 
opiates and methadone in hair and to investigate postmortem hair samples from suspected 
heroin overdose cases for the presence of morphine, codeine, 6 -monoacetylmorphine (6 - 
MAM), methadone and its metabolite, 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP).
Hair samples were to be analyzed in sections to give a history of each individual's drug use 
and these results compared with the concentrations found in postmortem blood. From these 
results it could then be ascertained whether the overdose victim was a regular or naive drug 
user.
3.2 INTRODUCTION
3.2.1 OPIATES
Opiates are naturally occurring compounds which are derived from opium in the poppy 
plant, Papaver somniferum. These include morphine and codeine which are 
pharmacologically active alkaloids and these have the primary effect of analgesia. Pure 
form heroin or diamorphine can be synthesized by acetylation of morphine and it is this 
highly potent substance which is the major active component in street heroin. Opiates are 
controlled under the Misuse of Drugs Act 1971 making possession or supplying without a 
prescription and unauthorised production, import or export illegal.
Heroin abuse is a growing health problem in many countries including Germany , 59 
Australia , 60 England and Wales61 and Scotland. In recent years the increase in availability 
and the cheaper cost of heroin have been largely responsible for this growth in Scotland. In 
the region of Strathclyde, the number of drug related deaths where morphine was 
implicated rose from 48 % of the total drug related deaths in 1990 to 71 % of the total drug 
related deaths in 1999.4
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3.2.2 METHADONE
Methadone is a synthetic opioid which has been available clinically in the United States 
since 1947.62 It is used in detoxification and maintenance programmes for the treatment of 
opiate dependence in heroin addiction . 63 Similar to the opiates, it is controlled under the 
Misuse of Drugs Act 1971 and it is illegal to possess or supply it without a prescription.
Up until 1996, methadone was dispensed by pharmacists, but administration was not under 
the pharmacists' supervision. This led to some of the prescribed drug being diverted by the 
patient by various methods towards illicit users. In 1996, it became good practice for 
prescribed methadone users to be supervised whilst taking their dose to prevent illicit use 
as far as possible. In the region of Strathclyde, the number of drug related deaths where 
methadone was implicated rose from 0 % of the total drug related deaths in 1990 to 37 % 
of the total drug related deaths in 1996. This figure then fell to 19 % by 1999. This decline 
was largely due to supervised methadone administration. The Drug Problem Service in 
Glasgow have 99 % supervised methadone administration . 4
3.3 CHEMISTRY
3.3.1 OPIATES
CH 
17/ ' 
N
Figure 3.1: Chemical structure of morphine
The structure o f morphine is given in Figure 3.1. Many semisynthetic derivatives are made 
by modifications to its structure. Codeine is methylmorphine where the methyl group is 
substituted on the phenol group at position 3. Diamorphine is made by acetylation at the 3 
and 6  positions64 and 6 -monoacetylmorphine, metabolite of diamorphine is acetylated in 
position 6 .
Chapter 3: Hair Analysis for Opiates and Methadone Page 18
3.3.2 METHADONE
C2 H5 COCCH2 CHN(CH3),
Figure 3.2: Chemical structure of methadone
Methadone is chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanone and is a 
synthetic opioid, structurally unrelated to morphine. Its structure is shown above in 
Figure 3.2.
3.4 METABOLISM AND EXCRETION
3.4.1 OPIATES
Administration of heroin is usually through intravenous or intramuscular injection, by 
smoking or snorting. After administration, heroin is rapidly metabolized to 
6 -monoacetylmorphine (6 -MAM) by deacetylation and 6 -MAM is further hydrolyzed to 
morphine. Morphine metabolizes in the liver to mostly morphine-3-glucuronide, with 
smaller amounts of morphine-6 -glucuronide and normorphine, which also further 
metabolizes to normorphine-glucuronide. The metabolic route of diamorphine is shown in 
Figure 3.3.
The primary metabolites of heroin found in urine are morphine and conjugated morphine, 
but diamorphine and 6 -MAM can also be found depending on the dose and time of 
collection. Codeine can also be found in the urine of a heroin user due to illicit heroin 
containing acetylcodeine and codeine.
The presence of codeine and morphine in a sample is not conclusive evidence of heroin 
intake. Both of these opiates are found naturally in poppy seeds and concentrations found 
in urine can be similar to those found in heroin users. The presence o f the metabolite 
6 -monoacetylmorphine is indicative of heroin exposure.
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Figure 3.3: Metabolic route of diamorphine
3.4.2 METHADONE
Methadone is generally taken orally due to its complete oral bioavailability. It is 
metabolized in the liver mainly by demethylation with immediate cyclization to give 
2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) which is further demethylated 
producing 2-ethyl-5-methyl-3,3-diphenylpyrrolidine (EMDP). Hydroxylation of the three 
compounds occurs to a small extent and glucuronide formation follows. A minor 
proportion of methadone is metabolized to methadol and then normethadol which are the 
only metabolites with pharmacologic activity (Figure 3.4).
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3.5 PHARMACOKINETICS
3.5.1 OPIATES
Peak diamorphine concentrations are reached rapidly (1 to 5 minutes) after smoking or 
intravenous use . 65 The half-life of diamorphine is very short as it is rapidly deacetylated to 
6 -monoacetylmorphine. Pharmacokinetic data for opiates is summarized in Table 3 .1. 62
Table 3.1: Pharmacokinetic data for opiates
Diamorphine Morphine Codeine 6-MAM |
Half life 2 - 6  min 2-3 hours 1.9-3.9 hours 6-25 min I
Vd (L/kg) 25 2-5 3.5 -
Protein Binding (%) 40 35 82 -
pKa 7.6 8.1, 9.5 8 . 2 1
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3.5.2 METHADONE
Methadone is generally administered orally and reaches peak plasma levels four hours after 
ingestion . 64 A peak plasma concentration of 75 ng/ml was reported66 after a single oral 
dose of 15 mg and concentrations were shown to decrease slowly with a half-life o f 15 
hours. Methadone is highly plasma protein bound and distributes rapidly to tissues. 
Pharmacokinetic parameters for methadone are summarized in Table 3.2 . 62
Table 3.2: Pharmacokinetic data for methadone
Methadone |
Half life 15-55 hours
Vd (L/kg) 4-5 |
Protein Binding (%) 87 I
pKa 8 6  1
3.6 TOXICITY
3.6.1 OPIATES
Sedation is the first sign of opiate intoxication. Excessive doses of opiates can cause stupor 
and coma and lead to respiratory failure especially in cases where a loss of tolerance or 
unexpected potency has been experienced or when other depressant drugs are present. 67 
Where street heroin is involved there are a number of uncertainties such as the composition 
and actual purity of the sample and adverse reactions not only due to the active component, 
but adulterants are possible. For morphine, administration of 30 mg parenterally and 
1 0 0  mg orally are toxic to a nontolerant individual, and death may occur following a 1 2 0  
mg dose of morphine . 62 In the Department of Forensic Medicine and Science, University of 
Glasgow, blood concentrations found in individuals where morphine was implicated in 
their deaths either alone or in combination with other drugs ranged from 0 .02-4 .7  mg/L . 4
3.6.2 METHADONE
Overdosage with methadone can produce stupor, respiratory depression, muscle flaccidity, 
cold and clammy skin, pupillary constriction, hypotension, coma and circulatory collapse . 62 
The Department of Forensic Medicine and Science, University of Glasgow has detected 
methadone concentrations ranging from 0.02 - 11.3 mg/L in postmortem cases where 
methadone was considered a cause of death either alone or in combination with other 
drugs . 4
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3.7 DECONTAMINATION OF HAIR
Before hair samples are extracted, they must be washed to remove extraneous material 
including oils, grime and externally applied drug. This procedure should help clean the 
extract whilst preventing false positives from occurring. This stage is necessary to produce 
the correct drug historical record of an individual.
3.7.1 OPIATES
Numerous wash procedures have been carried out on hair samples being tested for opiates. 
All of these have involved several combinations of solvents such as methanol, ethanol, 
dichloromethane, acetone, distilled water and sodium dodecyl sulphate solution. However, 
few of these procedures have been rigorously tested for their efficiency.
3.7.2 METHADONE
Wash procedures have been compared for methadone analysis. These showed that the 
concentration detected in hair decreased when the hair was washed with a methanol-water 
method or a dodecylsulphate-water method . 68 These steps appeared to remove drug which 
was bound to the surface o f the hair which had come from sweat contamination or possible 
drug handling. Like the opiates, various wash steps have been used by different authors. 
Water and acetone washes were a common combination, but methanol, sodium 
dodecylsulphate, dichloromethane and hexane have all been used as well.
3.8 SEPARATION OF ANALYTES FROM HAIR MATRIX
Analytes can be separated from the hair matrix in one of four ways: alkaline hydrolysis, 
acid hydrolysis, enzyme hydrolysis or direct solvent extraction with methanol or ethanol.
3.8.1 OPIATES
The first published method to extract opioids from hair involved refluxing the hair in 
methanol for 2 hours and subsequent analysis used radioimmunoassay (RIA ) . 69 Since this 
initial discovery, other authors have made comparisons of several methods to find the most 
efficient method of separation. These methods have included treatment with 0.1M 
hydrochloric acid,70, 7 1 , 72 0.1 M sodium hydroxide solution , 70 methanol,42,70, 7 2 , 73 water, 70 pH
7.4 buffer, 70 1M sodium hydroxide solution,74, 75, 76 methanol-5M HC1, 72 methanol- 
trifluoroacetic acid , 72 enzymes such as 1 mg/ml pronase solution76 or helicase . 72 When the 
detection of 6 -MAM in hair was discovered complete hydrolysis of the hair using strong
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alkaline solutions could not be used as a method due to the hydrolysis of 6 -MAM to 
morphine by this technique. In one study, a mixture of methanol-TFA was shown to be the 
best solvent for extracting 6 -MAM and morphine from hair with minimum hydrolysis and 
maximium efficiency . 77 Other authors78 demonstrated that out o f ten solvents of varying 
polarities and hydrophilicities, the highest recoveries for morphine were obtained using 
methanol with 1 % acetic acid or methanol with 1 % triethylamine. However, a reduction 
in heroin recoveries occurred and in the majority o f cases a reduction in 6 -MAM was also 
reported. These solvent systems undoubtly caused hydrolysis of heroin to 6 -MAM and 
hydrolysis of 6 -MAM to morphine and it was concluded that methanol was the most 
suitable solvent for opiate extraction from hair.
3.8.2 METHADONE
The first method used to remove methadone from hair was acid hydrolysis using 
hydrochloric acid.79, 80, 81 Other methods have included mechanical pulverization followed 
by solid phase extraction , 30 alkaline hydrolysis prior to solid phase microextraction,82’ 83 
enzyme hydrolysis, 30, 84, 85 methanol86 and methanol-trifluoroacetic acid extraction . 87
3.9 EXTRACTION
3.9.1 OPIATES AND METHADONE
The majority of hair analysis papers have involved using liquid-liquid extraction (LLE) or 
solid phase extraction (SPE). Several authors have reported the advantages of using SPE 
over LLE. However, other newer extraction methods such as supercritical fluid extraction 
for opiates88 and solid phase microextraction for methadone82,83,85, 89 have been employed.
3.10 ANALYSIS
Analytical methods for hair analysis require sensitive techniques to measure the small 
quantities of drug incorporated into hair. GC/MS is the most commonly used technique for 
the detection of drugs in hair although the use of more sensitive methods such as liquid 
chromatography-mass spectrometry, tandem mass spectrometry, high resolution mass 
spectrometry and capillary electrophoresis is increasing. However, these instruments are 
not often available in many laboratories due to their expense.
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3.10.1 OPIATES
Opiates have been detected by immunoassay methods such as radioimmunoassay , 6 9 , 7 0 , 7 1 , 7 4 , 76 
enzyme immunoassay (ElA)75, 87 and fluorescence polarization immunoassay (FPIA ) . 75 
High Performance Liquid Chromatography (HPLC) is less commonly used for detection of 
drugs in hair. HPLC with fluorescence detection , 90 HPLC with an electrochemical 
coulometric-array detector, 91 tandem mass spectrometry,92, 93 ion trap GC/MS in chemical 
ionization mode94 and capillary electrophoresis95, 96 have all been used for morphine, but 
most methods have employed GC/MS analysis.
3.10.2 METHADONE
Immunoassay procedures for methadone have included radioimmunoassay79, 80, 81 and 
enzyme-linked immunosorbent assay (ELISA ) . 87 High performance liquid chromatography 
with electrochemical coulometric-array detection 91 has been used to detect methadone in 
hair and liquid chromatography/ion spray-mass spectrometry 84 has been used to separate 
optical isomers of methadone and its metabolite. In most analyses of methadone in hair, 
gas chromatography-mass spectrometry has been used.
3.11 DRUG LEVELS IN HAIR
3.11.1 OPIATES
Levels found for morphine, codeine and 6 -monoacetylmorphine in head hair from heroin 
abusers have been reported as 1.0 - 21.8 ng/mg morphine, 0.1 - 4.0 ng/mg codeine and 
2.0 - 74.2 ng/mg 6 -monoacetylmorphine . 97 Other authors reported morphine levels higher 
than these along with lower 6 -monoacetylmorphine levels. In these cases sodium 
hydroxide hydrolysis was used in the method and a considerable amount of 
6 -monoacetylmorphine would have been hydrolyzed to morphine.
3.11.2 METHADONE
RIA methods found levels in the region of 0.2 - 10.63 ng/mg for methadone in head hair . 68 
Levels of methadone and EDDP detected in hair using solid phase extraction as the 
extraction method ranged from 0 - 42.0 ng/mg and 0 - 2.4 ng/mg . 30 In one case where solid 
phase microextraction (SPME) was used as the extraction method, methadone and EDDP 
levels as high as 78.1 ng/mg and 7.76 ng/mg were reported . 85 For another SPME method 
EMDP was also reported positive in two cases at concentrations 0.18 and 0.84 ng/mg . 83
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3.12 EXPERIMENTAL
3.12.1 CHEMICALS
Standard solutions of morphine-d3 , codeine, codeine-d3 , methadone, methadone-d3 were 
supplied by Sigma Chemicals Co. (St. Louis, USA). Morphine, 6 -monoacetylmorphine, 
6 -monoacetylmorphine-d3 ) methadone-d^ EDDP, and EDDP-d3 were produced by Radian 
International and obtained from Promochem Ltd. (Hertfordshire, England). Bis- 
(trimethylsilyl)trifluoroacetamide (BSTFA) with 1 % trimethylchlorosilane was obtained 
from Pierce (Illinois, USA). HPLC grade acetone, chloroform, dichloromethane, methanol 
were obtained from Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical grade 
potassium dihydrogen phosphate, sodium hydroxide and sodium bicarbonate were obtained 
from BDH Laboratory Supplies (Poole, England). Sodium dodecyl sulphate, 13- 
glucuronidase (Helix pomatia) and pentafluoropropionic anhydride (PFPA) were obtained
(R)from Sigma Chemicals Co. (U.K.) and analytical grade concentrated ammonia was 
obtained from Merck (Poole, England).
3.12.2 STANDARDS
Stock standard solutions were obtained at concentrations 1 mg/ml or 100 pg/ml in 
methanol for all standards except 6 -monoacetylmorphine and its deuterated standard which 
were dissolved in acetonitrile. Working solutions were made up at 10 pg/ml and 1 pg/ml 
by appropriate dilution of the stock standards. All standard solutions were stored at 4 °C.
3.12.3 SOLUTIONS
0.1 M Phosphate buffer, pH 6.0
Potassium dihydrogen phosphate (6.81 g) was dissolved in 450 ml of distilled water and 
the pH adjusted to 6.0 with 1.0 M potassium hydroxide solution. The solution was made up 
to the 500 ml mark with distilled water.
3.12.4 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
Two different Gas Chromatography-Mass Spectrometry (GC/MS) instruments were used 
to complete this work. The first o f these was involved solely in the method development 
stage and the second of these in the method development and validation stages.
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The first instrument used was a Hewlett-Packard model 5890 Gas Chromatograph with a 
VG Analytical VG 70-250S Mass Spectrometer. The GC was fitted with a Zebron-1, 30 m 
x 0.25 mm x 0.25 pm film thickness and the temperature programme was set from 180 to 
300 °C at 10 °C/minute. The injector temperature was 280 °C and the carrier gas was 
helium. The temperature of the source and interface were 200 °C and 250 °C respectively. 
The trap current was set at 200 pA. The injection volume was 1 pi.
The second instrument was a ThermoQuest Trace GC with a Finnigan Trace MS. The GC 
was fitted with a HP-5 column, 30 m x 0.25 mm x 0.25 pm film thickness and the 
temperature programme was set from 150 to 300 °C at 10 °C/minute. The injector 
temperature was 250 °C and the carrier gas was helium. The temperature of the source and 
interface were 200 °C and 250 °C respectively. The emission current was 350 pA. The 
injection volume was 1 pi.
3.12.5 DERIVATIZATION
Two derivatization methods were used. An unextracted standard containing 100 pi of 
morphine, morphine-d3 , codeine, codeine-d3 , 6 -monoacetylmorphine at a concentration of 
10 pg/ml and 40 pi of methadone and EDDP at a concentration of 10 pg/ml was made up 
in duplicate. Methadone-d3 , 6 -MAM-d3 and EDDP-d3 were not available at this stage. One 
standard was derivatized with PFPA and the other with BSTFA as detailed below and these 
were run on the VG-Analytical MS using full scan analysis.
3.12.5.1 Derivatization with PFPA
The standard was evaporated to dryness under nitrogen at 50 °C. 100 pi ethyl acetate and 
100 pi PFPA were added to the residue, vortex mixed and derivatized at 60 °C for 30 
minutes. The solvent was evaporated off under nitrogen at 50 °C and the residue was 
redissolved in 50 pi of ethyl acetate.
3.12.5.2 Derivatization with BSTFA
The standard was evaporated to dryness under nitrogen at 50 °C and 50 pi BSTFA with 
1 % TMCS was added, vortex mixed and derivatized at 70 °C for 15 minutes.
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3.12.5.3 Results
The following retention times and ions were observed for the derivatized analytes: 
Table 3.3: GC/MS data for opiates and methadone
Analyte Retention time (min:sec) Main Ions observed (m/z) 1
PFPA BSTFA PFPA BSTFA
EDDP* 6:52 6:52 178, 220, 277 178, 220, 277
Methadone* 7:44 7:44 72, 165,294 72, 165,294
Codeine 9:02 1 0 : 2 2 282, 304, 423, 445 178,196, 234, 371
Codeine-d3 8:59 10:19 207, 285,448 181,199, 237, 374
Morphine 8.37 10:47 414, 577 236, 371,414, 429
Morphine-d3 8.34 10:44 417,580 239,417, 432
6 -MAM 9:37 11:18 204,361,414, 473 207, 340, 399
* Analytes which do not derivatize
Symmetrical peaks were obtained for all analytes except for codeine which had been 
derivatized with PFPA. Frontal tailing was observed for this peak so derivatization by 
BSTFA was used for all further analyses. Mass spectra for the analytes and internal 
standards derivatized with BSTFA are shown in Figures 3.5 and 3.6.
3.12.6 GAS CHROMATOGRAPHY/MASS SPECTROMETRY -  SELECTED ION 
MONITORING (SIM)
A selected ion monitoring programme was set up for the analytes. Ions monitored were 
m/z 277 for EDDP, 371 for codeine, 374 for codeine-d3 , 429 for morphine, 432 for 
morphine-d3 , 399 for 6 -MAM and 402 for 6 -MAM-d3 . For methadone m/z 72 was used 
because of its higher sensitivity compared with other methadone ions. This meant that a 
separate programme had to be set up since the VG-Analytical Mass Spectrometer which 
was the only instrument available at the time could not simultaneously carry out single ion 
monitoring for the range of ions selected. Each sample was injected twice using the same 
temperature programme for methadone in the first run and the other analytes in the second 
run. Perfluorokerosene (PFK) was used to calibrate the instrument and lock ions 68.9952 
and 268.9824 a.m.u. were used for analysis of methadone and other analytes respectively. 
Switch and dwell times were set at 60 ms and 40 ms respectively for each monitored ion.
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Figure 3.5: Ion graphs for methadone, EDDP and codeine as trimethylsilyl derivative
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Figure 3.6: Ions graphs of codeine-d3 , morphine, m orph ine^  and 6 -monoacetylmorphine 
as trimethylsilyl derivatives
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3.12.7 DECONTAMINATION OF HAIR
Blank hair was obtained from a volunteer of Malay-Chinese origin. Hair was cut finely 
into 1 - 2  mm pieces with scissors and was decontaminated using several sequential wash 
procedures:
(i) One ten minute wash with sodium dodecyl sulphate solution (0.1%).
(ii) Three ten minute washes with distilled water.
(iii) Three two minute washes with methanol.
Each step was sonicated in 5 ml of solvent and then the solvent was decanted. The hair was 
allowed to dry in an oven at 40 °C.
3.12.8 SPIKING HAIR
Hair was spiked in one of two ways. Single portions of blank washed hair were weighed 
out, each at 30 mg, and the appropriate amount o f each drug was pipetted into the glass 
vial containing the weighed hair. The hair was then covered with excess methanol (if 
required) and the samples were sonicated at room temperature for 15 minutes. The 
methanol was allowed to evaporate off at room temperature. The alternative method was 
to spike blank washed hair in bulk to give standards equivalent to 10, 25, 50, 75, 100 ng/30 
mg. The method of spiking was the same as described previously. The appropriate amount 
of sample was weighed out accurately.
3.12.9 METHANOLIC TREATMENT OF HAIR SPIKED WITH OPIATES 
FOLLOWED BY LIQUID-LIQUID EXTRACTION
3.12.9.1 Methanolic Treatment
A published method42 was initially used to extract the drugs from hair. Two 50 mg samples 
of hair spiked with 25 ng and 100 ng of morphine, codeine and 6 -MAM were weighed into 
vials. Methanol (1 ml) was added to each along with 100 pi of morphine-d3 , 100 pi 
codeine-d3 and 100 pi 6 -MAM-d3 both at a concentration of 1 pg/ml. The hair was then 
incubated at 37 °C for 18 hours. After incubation, the methanol was removed using a glass 
pipette and evaporated at 50 °C under nitrogen.
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3.12.9.2 Liquid-liquid extraction
The methanolic extracts were purified further by liquid-liquid extraction. To the residue, 
2  ml of distilled water followed by 2  ml of saturated sodium bicarbonate buffer, adjusted to 
pH 8.4 with 1 M sodium hydroxide solution were added. This was vortex mixed for 15 
seconds and 7 ml of toluene-heptane-isoamylalcohol 70:20:10 were added followed by 
mixing for 15 minutes and centrifuging for 10 minutes at 2000 rev/min. The organic layer 
was transferred and evaporated at 50 °C under nitrogen. The extracts were derivatized with 
40 pi of BSTFA with 1 % TMCS at 70 °C for 15 minutes and analyzed using GC/MS with 
selected ion monitoring as described in 3.12.6.
3.12.9.3 Results
All three analytes were extracted. A blank extract showed that no extracted hair impurities 
interfered with the codeine, morphine or 6 -MAM peaks. Ratios of the analytes to internal 
standards were calculated and are displayed in Table 3.4. Methadone was now to be 
included in the procedure.
Table 3.4: Ratios of opiate analytes/internal standards
1 Sample codeine/codeine-d3 
m/z 371/374
morphine/morphine-d3  
m/z 429/432
6 -MAM/6 -MAM-d3 
m/z 399/402
1 100 ng/40 pi 
unextracted standard
0.955 0.987 0.966
100 ng/50 mg 
extracted standard
0.991 1.127 0.811
25 ng/50 mg 
extracted standard
0.309 0.208 0.171
3.12.10 METHANOLIC TREATMENT OF HAIR SPIKED WITH OPIATES, 
METHADONE AND EDDP FOLLOWED BY LIQUID-LIQUID EXTRACTION
3.12.10.1 Experimental
A method to extract morphine, codeine, 6 -MAM, methadone and EDDP simultaneously 
from hair was required. The method used previously (3.12.9) was applied to hair samples 
which had been spiked with 0, 10, 25, 50, 75, 100 ng/50 mg of each of the analytes. 
Extractions were also carried out using the same amount of each drug without the presence 
of hair. Internal standards morphine-d3 , codeine-d3 , 6 -MAM-d3 and methadone-d3 were 
added at a concentration of 50 ng/50 mg prior to the methanol incubation step.
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3.12.10.2 Results
Extracts without presence of hair showed that all analytes were successfully extracted 
using this method. However, when the hair spikes were analysed it was shown that EDDP 
coeluted with peaks resulting from the hair matrix. Quantitation of EDDP therefore was 
not possible using this extraction method. At the lower concentrations, it also became more 
difficult to quantitate codeine, morphine and 6 -MAM. This corresponds to previous reports 
using liquid-liquid extraction as a technique to extract drugs from hair where the assay was 
limited by interference . 98 Solid phase extraction is therefore a better technique to use since 
cleaner extracts are generally produced. For this reason further analyses used solid phase 
extraction as the method of extraction.
3.12.11 METHANOLIC TREATMENT OF HAIR SPIKED WITH OPIATES, 
METHADONE AND EDDP FOLLOWED BY SOLID PHASE EXTRACTION
3.12.11.1 Methanolic Treatment
Hair spiked to give concentrations 50 and 100 ng/50 mg of morphine, codeine, 6 -MAM, 
methadone and EDDP was incubated at 37 °C for 18 hours in 1 ml of methanol. After 
incubation the methanol was removed and a further 1 ml portion was added to the hair, 
sonicated briefly and combined with the first fraction. The methanol was evaporated to 
dryness at 50 °C under nitrogen.
3.12.11.2 Solid Phase Extraction
This solid phase extraction method was currently being used in the laboratory to extract 
opiates from blood and saliva.
The residues were re-dissolved in 2 ml of distilled water and 2 ml of phosphate buffer, 
pH 6.0. They were vortex mixed and centrifuged for 10 minutes at 2500 rev/min. World 
Wide Monitoring Clean Screen® columns' ( Z S D A U 0 2 0 )  were conditioned with 3 ml of 
methanol, followed by 3 ml of distilled water and then 1 ml phosphate buffer. The samples 
were applied to the columns at 2  ml/min. which were then washed with 2  ml distilled 
water, 2 ml 0.1 M hydrochloric acid and 3 ml methanol. The columns were dried under full 
vacuum for 10 minutes and the analytes were eluted with 4 ml of dichloromethane/
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isopropanol/concentrated ammonia (78:20:2). The solvent was evaporated off and the 
residue derivatized in 40 pi BSTFA with 1% TMCS.
3.12.11.3 Results
The extraction was very clean for morphine, codeine, 6-MAM and EDDP, but comparison 
of extracts containing no hair with those containing hair showed that peaks from the hair 
matrix coeluted with methadone and methadone-d3 ions m/z 72 and 75 respectively.
Several steps were attempted to improve the method for methadone. The first o f these was 
to add another clean-up step to the solid-phase extraction procedure.
3.12.12 METHANOLIC TREATMENT OF HAIR SPIKED WITH OPIATES, 
METHADONE AND EDDP FOLLOWED BY SOLID PHASE EXTRACTION 
(METHOD II)
3.12.12.1 Experimental
Blank hair samples and hair samples spiked to give 50 ng/30 mg were extracted using the 
procedure in 3.12.11 which was modified to include an additional acetone/chloroform step. 
The acetone/chloroform step involved adding 4 ml of acetone/chloroform (1:1) to the 
columns before the final elution step. Acetone/chloroform and dichloromethane/
isopropanol/ammonia fractions were collected and analyzed to find if the additional step 
removed peaks that coeluted with methadone.
3.12.12.2 Results
The acetone/chloroform fraction step cleaned up the the final extract considerably. This 
was shown by analyzing the acetone/chloroform extract obtained from blank hair which 
indicated that the peak which had previously coeluted with methadone m/z 72 eluted in this 
fraction. Analysis of the dichloromethane/isopropanol/ammonia fraction for ion m/z 72 
showed that the methadone peak was now separated. However, this was not the case for 
the methadone-d3 ion m/z 75. The blank dichloromethane/isopropanol/ammonia fraction 
still showed coelution with peaks resulting from the hair matrix.
Analysis of the two fractions for opiates and EDDP revealed that these analytes only eluted 
in the dichloromethane/isopropanol/ammonia fraction.
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These results showed that the methadone-d3 m/z 75 ion was not ideal for quantification 
using this method and two other options were considered. Alternative ions, for instance 
m/z 294 and 297 could be used for methadone and methadone-d3 respectively, however the 
intensities of these ions are greatly reduced from ions m/z 72 and 75 and therefore using 
these ions for quantitation would mean the limit of detection would be much higher. 
Alternatively a different internal standard such as methadone-d9  could be used to see if ion 
m/z 78 could be used. It was the second of these options which was considered first. Also, 
it has been suggested by other authors that methanolic treatment of hair prior to extraction 
provides less clean extracts than other methods such as acid hydrolysis. A comparison of 
these two methods using methadone-dg as the internal standard was carried out.
3.12.13 ACIDIC HYDROLYSIS VERSUS METHANOLIC TREATMENT
3.12.13.1 Sample Preparation
Blank hair samples and hair samples spiked with 50 ng/30 mg and 75 ng/30 mg of codeine, 
morphine, 6 -MAM, methadone and EDDP were weighed out in duplicate to give 30 mg 
samples. Internal standards codeine-d3 , morphine-d3 , 6 -MAM-d3 , methadone-d9  and 
EDDP-d3 were added at a concentration of 50 ng/30 mg.
3.12.13.2 Methanolic Treatment
One set of samples was treated with 1 ml of methanol and incubated in the oven at 45 °C 
for 18 hours. The samples were cooled and the methanol was drawn off and the hair rinsed 
with another 1 ml aliquot of methanol. The second methanol aliquot was combined with 
the corresponding first aliquot.
3.12.13.3 Acid Hydrolysis
The other set of hair samples was hydrolysed with 0.1M hydrochloric acid for 12 hours at 
45 °C. The samples were cooled, neutralized with 0.1M sodium hydroxide solution and 1 
ml phosphate buffer (0.1M, pH 6 ) was added. The sample was shaken, centrifuged at 
2500 rev/min. and the solution was removed from the hair. The hair was rinsed with 1 ml 
phosphate buffer, centrifuged and the phosphate buffer fractions were combined.
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3.12.13.4 Extraction
The extraction procedure used was that in 3.12.12 (including the acetone/chloroform step). 
Ions m/z 72 and 294 were monitored for methadone and m/z 78 and 303 were monitored 
for methadone-dg.
3.12.13.5 Results
All analytes were extracted by both methods and no interfering peaks were identified at 
corresponding retention times to analytes in the blank samples.
Similar ratios of analyte:internal standard were obtained for all the analytes, however it 
was noticed that the peak area of 6 -MAM and 6 -MAM-d3 were much lower for the acid 
hydrolysis method than the methanol method. This may have been due to hydrolysis of the 
6 -MAM to morphine during the acidic step, however the morphine peak areas did not 
clearly reflect this and a recovery study was required to investigate this.
3.12.14 RECOVERY STUDY OF EXTRACTION PROCEDURE
3.12.14.1 Gas Chromatography-Mass Spectrometry
At this stage in the method development a new GC/MS instrument was available in the 
laboratory which made it possible to analyze the chosen ions for methadone and opiates 
simultaneously. This instrument was a ThermoQuest Trace GC with a Finnigan Trace MS 
The GC was fitted with a HP-5 column, 30 m x 0.25 mm x 0.25 pm film thickness and the 
temperature programme was set from 150 to 300°C at 10 °C/minute. The injector 
temperature was 250°C.
All further analyses were run on this instrument since this reduced the analysis time.
3.12.14.2 Extraction
A recovery study was carried out to determine the recovery of each drug using the solid 
phase extraction procedure without the presence of hair. Ten standards containing 50 ng of 
each analyte were made up. The methanol was evaporated to dryness and five of the vials 
were redissolved in 2 ml of distilled water and 2 ml of phosphate buffer, pH 6.0. The 
remaining five were redissolved in 2 ml distilled water and 2 ml of phosphate buffer, pH 
7.0. These were then extracted using the solid phase extraction method.
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3.12.14.3 Results
The recoveries obtained using this method were high for all of the drugs using both pH's of 
buffer (Table 3.5). However, EDDP and codeine gave higher recoveries with pH 6.0 and 
the other analytes gave comparable recoveries at the two pH's.
Table 3.5: Recovery study of SPE method without presence of hair
1 Sample EDDP
%
Methadone
%
codeine
%
morphine
%
6 -MAM | 
%
pH 6.0 96.0 98.3 96.9 95.2 99.5
pH 7.0 87.7 96.6 88.4 99.8 99.4
Phosphate buffer at pH 6.0 was used for further extractions.
3.12.15 RECOVERY STUDY: METHANOLIC TREATMENT VERSUS ACID 
HYDROLYSIS VERSUS ENZYME HYDROLYSIS
Recoveries using three different pre-extraction treatments were compared. These included 
the methanolic treatment and hydrochloric acid methods (3.12.13.2 and 3.12.13.3) and also 
an enzymatic method using p-glucuronidase.
3.12.15.1 P-glucuronidase method
To 30 mg hair samples was added 1 ml phosphate buffer, pH 6.0 followed by 50 pi p- 
glucuronidase solution, p-glucuronidase solution was made up by adding 1 ml P- 
glucuronidase (Helix pomatia 132 500 units/ml) to 4 ml phosphate buffer, pH 6.0 and 
vortexing briefly. The hair samples were incubated at 40 °C for 2 hours and after cooling, 
the solution was drawn off. The hair was washed with 1 ml phosphate buffer and this 
solution was combined with the first. The combined phosphate buffer fractions were 
applied to the solid phase extraction columns.
3.12.15.2 Results
The p-glucuronidase method clearly hydrolyzed 6 -MAM to morphine, giving morphine a 
recovery of 182 % (Table 3.6). The acid hydrolysis method also hydrolyzed some of the 6 - 
MAM to morphine. Methanol treatment extracted the analytes from spiked hair with high 
recoveries and no or minimal hydrolysis of 6 -MAM to morphine.
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Table 3.6: Recoveries on spiked hair using methanol treatment, acid and enzyme 
hydrolysis
Method EDDP
%
Methadone
%
codeine
%
morphine
%
6 -MAM
%
Methanol 82.4 78.3 87.1 82.3 91.5
Hydrochloric acid 
(0.1M)
76.0 80.7 87.6 1 1 2 . 2 58.2
p-glucuronidase 76.7 67.2 90.3 182.6 3.8
...........
3.12.16 INVESTIGATION INTO HYDROLYSIS OF 6 -MAM TO MORPHINE BY 
ACID HYDROLYSIS METHOD
3.12.16.1 Experimental
Nine 30 mg portions of blank hair were weighed out into separate vials. Three were spiked 
with 6 -MAM only, three with morphine only and three with both 6 -MAM and morphine at 
a concentration of 50 ng/30 mg. These were all treated using the acid hydrolysis method 
and internal standards were added after the extraction.
3.12.16.2 Results
Recoveries were calculated for morphine and 6 -MAM in each sample and these are 
displayed below in Table 3.7. They clearly show that under these hydrolysis conditions 
6 -MAM is hydrolyzed to morphine giving a conversion of almost 45 %. Therefore this 
method cannot give a true reflection of the concentrations in hair.
Table 3.7: Recovery of morphine and 6 -MAM after acidic hydrolysis
% 6 -MAM 
recovered
% Morphine 
recovered
6 -MAM only 23.3 ± 6 . 8 43.5 + 2.8
Morphine only - 73.3 ± 6 . 6
6 -MAM and morphine 24.8 ± 7.7 111 ±0.4
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3.12.17 METHOD VALIDATION
3.12.17.1 Linearity
Since the enzyme and acidic methods caused a certain degree o f hydrolysis of 6 -MAM to 
morphine it was decided to validate the methanolic method. Linearity was determined for 
the concentration range of 10 to 100 ng/30 mg hair. A larger quantity o f hair could have 
been chosen, but since the hair case samples were to be sectioned the likelihood of 
obtaining more than 30 mg per centimetre o f hair was low. Five samples at each 
concentration were extracted. Ratios of drug to internal standard are displayed in Table 3.8 
along with the coefficient of variation in parenthesis. Values of correlation coefficient, R 
and intercept and slope values for regression equations are displayed in Table 3.9.
Table 3.8: Intra-day Variation
1 Concentration 
(ng/30 mg hair)
meth/meth- d9 
m/z 72/78
EDDP/EDDP- d3 
m/z 277/280
cod/cod-d3 
m/z 371/374
mor/mor-d3 
m/z 429/432
MAM/MAM- 
m/z 399/402
10
0.217(8.9) 0.264 (7.8) 0.188(5.4) 0.123 (9.7) 0.186 (6.7)
25
0.522 (6.4) 0.537 (5.6) 0.415(2.4) 0.386 (9.7) 0.510(7.3)
50 1 . 2 0 1  (8 .8 ) 0.963 (8.5) 0.977 (8.4) 0.820 (5.1) 1.012(6.9)
75 1.793 (8.1) 1.504 (7.6) 1.465 (8 .6 ) 1.244 (6.7) 1.473 (5.7)
1 0 0 2.266 (5.2) 2.049 (2.7) 1.932 (5.7) 1.679 (6.9) 1.887 ( 8 .8 )
Table 3.9: Linear Regression Values
Methadone EDDP Codeine Morphine 6 -MAM
R1 0.9963 0.9970 0.9983 1.0000 0.9978
Intercept -0.0138 0.0348 -0.0327 -0.0469 0.0297
| Slope 0.0233 0.0198 0.0198 0.0172 0.0189
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3.12.17.2 Inter-day variation
Inter-day variation was assessed for the same concentration range as the intra-day variation 
(Table 3.10). These values are based on ratios obtained over five days and these were less 
than 13 % for all the drugs over the concentration range.
Table 3.10: Inter-day Variation
I Concentration 
(ng/30 mg hair)
meth/meth- d9 
m/z 72/78
EDDP/EDDP- d3 
m/z 277/280
cod/cod-d3 
m/z 371/374
mor/mor-d3 
m/z 429/432
MAM/MAM-d3 
m/z 399/402
10 0.195 (9.8) 0.244 (8.2) 0.186(12.9) 0.131 (7.7) 0.183 (5.7)
25 0.485 (9.7) 0.543 (2.8) 0.415(8.4) 0.349 (6.5) 0.520 (2.5)
50 1.148 (8 .8 ) 1.152 (7.9) 1.081 (8 .8 ) 0.788 (3.5) 1.143 (9.3)
75 1.627 (8.9) 1.698 (7.6) 1.553 (5.4) 1.220 (6.7) 1.607 (7.4)
1 0 0 2.169 (4.3) 2.243 (6 .6 ) 2.028 (4.9) 1.665 (6.1) 2.201 (8.3)
3.12.17.3 Recovery
The recovery of the method from spiked hair samples has already been mentioned in 
3.12.15. However, the recovery from actual hair samples where the drug is bound within 
the hair will be lower than this. A better indicator o f the true recovery can be calculated 
using fortified hair samples but these were not available. However, even these values are 
not precise. Recoveries of drugs from hair will vary to a certain extent for each individual 
due to parameters such as hair diameter, degree o f preservation of cuticle and chemical 
changes to hair as a result of treatment.
3.12.17.4 Limit of Quantitation and Detection
Limits of detection and quantitation were determined for each of the drugs on spiked hair. 
30 mg hair samples were spiked with each drug to give concentrations 2.0, 1.0, 0.75, 0.5, 
0.4, 0.3, 0.2, and 0.1 ng/30 mg. These were extracted as previously. The limit of detection 
was defined as the concentration of drug giving a signal to noise ratio of 3 and the limit of 
quantitation was defined as the concentration of drug giving a signal to noise ratio of 5 
(Table 3.11).
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Table 3.11: Limit o f Quantitation and Detection
"  - Methadone EDDP Codeine Morphine 6 -MAM 1
ng/30 mg ng/30 mg ng/30 mg ng/30 mg ng/30 mg |
LOD 0.75 2 . 0 1 . 0 1 . 0 1 . 0
| LOQ 1 . 0 5.0 2 . 0 2 . 0 2 . 0
3.12.18 CONCLUSIONS
Comparisons of methanolic, (3-glucuronidase and hydrochloric acid methods to extract 
opiates and methadone from hair showed that there was a considerable amount of 
hydrolysis of 6 -MAM to morphine using the p-glucuronidase method and to lesser extent 
with the hydrochloric acid method. This would be accounted for using the deuterated 
internal standards, however, in cases where 6 -MAM is present in hair at a low 
concentration then a negative result could be obtained. This would affect the interpretation 
of the results since a sample found positive for 6 -MAM is indicative of heroin use. The 
methanolic extraction method did not give any significant conversion of 6 -MAM to 
morphine and for this reason was the preferred method. This method successfully extracted 
morphine, codeine, 6 -MAM, methadone and EDDP from spiked hair samples. Calibration 
curves were linear for all analytes producing correlation coefficients > 0.996. Intra-day and 
inter-day variation were assessed and coefficients of variation were shown to be < 1 0  % 
and < 1 3 %  respectively for all analytes. Limits of quantitation and detection were found to 
be suitably sensitive. This method was applied to 31 postmortem case samples to assess the 
quantities of each analyte present in hair to give an indication of the extent of drug use of 
each individual and a drug use history (Chapter 8.1).
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4 Antidepressants in blood
4.1 FLUOXETINE
Fluoxetine (Prozac®) is an antidepressant which was first introduced into the United States 
in 1988 for the treatment of depression. It is a selective serotonin reuptake inhibitor (SSRI) 
which has been found to be as effective as the traditional antidepressants, but due to its 
safer pharmacological profile has become one of the most widely prescribed 
antidepressants. It has not only been used in the treatment of depression, but has also had 
efficacy in the treatment of obsessive compulsive disorders, bulimia nervosa and obesity.
4.2 CHEMISTRY
Fluoxetine is chemically known as (±)-N-methyl-y-3-phenyl-3-[(a-a-a-trifluoro-p-tolyl)- 
oxy] propylamine and has a molecular formula C 1 7H lgF3NO and a molecular weight of
309. Norfluoxetine is produced by demethylation of fluoxetine and has a molecular weight 
of 295. The structures of fluoxetine and its metabolite are given in Figure 4.1.
o
CH-jC H jN
H
Norfluoxetine
o
Fluoxetine
Figure 4.1: Chemical structures of fluoxetine and norfluoxetine
Fluoxetine and norfluoxetine can be obtained as hydrochloride salts. The hydrochloride
salt of fluoxetine is soluble in water at 50 mg/ml and is stable at temperatures up to 50 °C 
for the duration of 2  years.
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4.3 METABOLISM AND EXCRETION
Fluoxetine is rapidly transformed to norfluoxetine which has pharmacological activity 
equivalent to the parent drug. In a study where radiolabelled fluoxetine was administered 
to healthy volunteers at a dosage of 60 mg daily for 30 days, 60 % was excreted in the 
urine over a five week period. Only 2.5 % of this was unmetabolized drug, 10 % 
norfluoxetine and the remainder other conjugated metabolites (Figure 4.2)."
Fluoxetine Urinary Excretion
f3c -
o -
CH2CH2N'
.CH,
H
Fluoxetine 2.5%
O
H
Norfluoxetine 10%
Other metabolites 
72.8%
F3C
O
OH
HO
OH
O
ch2c h 2n h
COOH
OH
HO
Fluoxetine glucuronide 5.2%
Figure 4.2: Fluoxetine metabolism and excretion
OH
Norfluoxetine glucuronide 9.5%
4.4 PHARMACOKINETICS
After oral dosing, fluoxetine is well absorbed and pharmacokinetic studies have shown that 
peak plasma concentrations are reached within 6  to 8  hours. A single oral dose of 40 mg 
produced peak plasma levels ranging from 0.015 - 0.055 mg/L within this time . 62 Daily 
doses of 20 - 60 mg have produced steady state levels ranging from 0.025 - 0.473 mg/L
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fluoxetine and 0.018 - 0.466 mg/L norfluoxetine . 100 It has also been shown that at steady 
state, the plasma concentration of norfluoxetine is greater than that of fluoxetine and that 
steady state concentrations of fluoxetine or norfluoxetine do not change when the drug is 
administered over a long period of time." The distribution of fluoxetine to tissues is 
extensive and the volume of distribution is large after single or multiple dosing. This 
combined with a low clearance rate leads to the long half-life which the drug possesses. 
Pharmacokinetic data is summarized in Table 4.1 . 62
Table 4.1: Pharmacokinetic data for fluoxetine and norfluoxetine
1 Fluoxetine Norfluoxetine
Half life 1-3 days 7-15 days
Vd (L/kg) 26 -
1 Protein Binding (%) 94 -
pKa 9.5 -
4.5 TOXICITY
Side effects o f fluoxetine treatment include nausea, anxiety, insomnia, headache and dry 
mouth. Excessive doses of fluoxetine causes symptoms such as lethargy, tachycardia and 
hypertension. Few authors have reported fluoxetine deaths where it was the sole drug 
detected in the blood. Drug concentrations in 6  fluoxetine fatalities (4 of these cases 
involving another drug) were found to range from 1.3 - 6 . 8  mg/L blood fluoxetine and 
0.9 - 5.0 mg/L blood norfluoxetine . 62
Although, fluoxetine is considered to be a much safer drug than the tricyclic 
antidepressants, the long half lives of fluoxetine and norfluoxetine can result in potentially 
serious drug interactions which are caused by substantial quantities of fluoxetine remaining 
in the plasma weeks after administration has ceased.
Fluoxetine in combination with monoamine oxidase inhibitors (MAOIs) can cause a 
serious interaction known as the Serotonin Syndrome. As a result of these interactions with 
fluoxetine, whenever treatment is changed from using fluoxetine to a MAOI, a period of 
five weeks between treatments is necessary to allow fluoxetine to be flushed from the 
system. The Serotonin Syndrome has also been observed with fluoxetine and lithium , 101 
fluoxetine and carbamazepine , 102 and the serotonin precursor L-tryptophan . 103 Symptoms
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of this interaction include euphoria, drowsiness, sustained rapid eye movement, 
overreaction of the reflexes, clumsiness, restlessness, feeling drunk and dizzy, muscle 
contraction and relaxation in the jaw, sweating, intoxication, rigidity, high body 
temperature, confusion, hypomania, shivering, diarrhea, loss of consciousness and death . 104
4.6 ANALYSIS
Many analytical methods have been published for the analysis of fluoxetine and its 
metabolite in plasma or serum. Both gas and liquid chromatographic methods have proved 
popular choices.
One of the first methods to be published involved a liquid-liquid extraction procedure 
followed by derivatization with pentafluoropropionic anhydride and analysis by gas 
chromatography with electron capture detection (GC-ECD ) . 105 Other authors used 
heptafluorobutyric anhydride as an alternative derivatizing agent and reported an increase 
in sensitivity . 106 Other GC/ECD methods used solid phase extraction prior to analysis 
using either Bond Elut Certify107 or Bond Elut C 8 108 columns. These methods1 0 7 , 108 reported 
higher recoveries than liquid-liquid extraction methods.
Both fluoxetine and norfluoxetine exist as enantiomers. GC-ECD has also been used to 
analyse these enantiomers following their extraction from plasma and urine of humans, and 
liver and brain tissue of rats . 109 (S)-(-)-N-trifluoroacetylprolyl chloride was the chiral 
derivatizing agent employed. Other authors modified this method to allow simultaneous 
determination of fluvoxamine and the enantiomers o f fluoxetine and norfluoxetine by gas 
chromatography-mass spectrometry. 110 Recoveries o f these compounds ranged from 50 to 
6 6  % and the limit of quantitation for the (R) and (S) enantiomers of fluoxetine and 
norfluoxetine was 1 ng/ml.
Methods for the analysis o f fluoxetine and norfluoxetine by gas chromatography with 
nitrogen-phosphorus detection (GC-NPD) have also been developed.111, 112 The nitrogen 
containing structure of fluoxetine is compatible with a high sensitivity by NPD and has 
proved to be a good method for analysing low concentrations of the drug in plasma. 
Detection limits of 0.3 ng/ml for fluoxetine and 2 ng/ml for norfluoxetine have been 
obtained using NPD detection . 112 Other authors used GC-NPD to simultaneously analyse
Chapter 4: Antidepressants in Blood Page 45
fluoxetine and desipramine which can be coadministered . 111 Limits of detection were not 
reported in this paper.
High performance liquid chromatography (HPLC) analysis for the determination of 
fluoxetine has been the most common method used for the identification and quantitation 
of the drug and its metabolite. These methods have involved the use of solid phase or 
liquid-liquid extraction with ultra violet (UV) or fluorescence detection.
One of the first methods developed to determine fluoxetine and norfluoxetine in serum 
used reversed phase HPLC with UV detection . 100 A multi-step extraction was used to 
isolate the drug and metabolite from the serum followed by reversed phase 
chromatography using a phenyl column. Recoveries of 80 % were achieved and the limit 
of detection was 15 ng/ml. A number of regularly administered drugs given to psychiatric 
patients were evaluated for their ability to interfere in the assay. Imipramine, desipramine, 
protriptyline and loxapine all coeluted with one of the analytes.
Another reversed phase HPLC assay using a cyano column and UV detection was 
established for the purpose of correlating serum fluoxetine and norfluoxetine 
concentrations to clinical response . 113 From results on thirteen patients receiving doses of 
20 - 60 mg/day the fluoxetine and norfluoxetine serum concentrations were 73 - 453 ng/ml 
and 54 - 362 ng/ml respectively and it was found that antidepressant response and serum 
concentration were not correlated.
Other HPLC methods have involved pre-derivatization of fluoxetine and norfluoxetine 
with fluorescent detection providing more sensitive and selective assays . 114 Fluoxetine and 
its metabolite were extracted from plasma by liquid-liquid extraction and derivatized at 
room temperature with dansyl chloride. The fluorescent derivatives were chromatographed 
using a reversed phase C-18 column. Advantages of this method over UV methods are that 
the derivatizing agent is specific for primary and secondary amines and so no major 
antidepressants interfere in the assay. Therefore, the problem of co-elution of tricyclic 
antidepressants and secondary amines is resolved.
Another more recent method involved pre-column derivatization with dansyl chloride . 1' 5 
Simultaneous determination of fluoxetine, D-fenfluramine and D-norfenfluramine in
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plasma, brain tissue and brain microdialysate was carried out using fluoxetine as the 
internal standard. The limit of quantitation for fluoxetine in plasma was 3.1 ng/ml. 
Although fluoxetine was used as an internal standard it was reported that this technique can 
be used for the analysis of fluoxetine using fenfluramine as the internal standard. Although 
these procedures involving a pre-derivatization step increase sensitivity and selectivity, the 
time taken to prepare the sample is extended.
Many of the reported assays require multi-step extraction methods to provide a sufficiently 
pure sample to be analysed by HPLC. A rapid, sensitive micromethod using a reversed 
phase liquid chromatographic procedure to separate and quantify fluoxetine and 
norfluoxetine in plasma after a single extraction step using mefloquine as an internal 
standard has been developed . 116 The method used a reversed phase C - 8  column and 
detection at 226 nm, and was found to give an improved detection limit ( 2  ng/ml for both 
fluoxetine and norfluoxetine) over other UV methods, whilst determining the same 
specificity. A selection of drugs which are commonly co-administered with fluoxetine 
were extracted using the method and were shown not to interfere.
An HPLC assay with automated extraction was developed to quantitate fluoxetine and 
norfluoxetine in serum . 117 This method combined both solid phase and liquid-liquid 
extractions with a back extraction followed by reversed phase chromatography with a C - 8  
column and UV detection. Clean chromatograms with few interferences were obtained and 
the sample preparation time was significantly reduced from that of non-automated 
methods. However, automated machines are not available in many laboratories.
Few authors reported solid phase extraction with HPLC analysis. A method using solid 
phase extraction with Bond Elut C l 8  columns followed by a reversed phase liquid 
chromatographic procedure with fluorescence detection was developed . 118 A recovery of 
85 % was obtained and the method allowed the detection of 20 ng/ml of fluoxetine and 
norfluoxetine. Protriptyline, maprotiline and its desmethyl metabolite were the only 
compounds among traditional antidepressants and benzodiazepines which showed 
fluorescence under the conditions selected for fluoxetine detection.
The most recently reported method on the detection of fluoxetine in plasma has used liquid 
chromatography with tandem mass spectrometric detection. The analytes were extracted
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from plasma by liquid-liquid extraction, separated on a C18 column and ionised by 
TurboIonSpray ionisation. Recoveries were greater than 97 % and the lower limit of 
quantification was 0.15 ng/ml.
All o f the methods mentioned so far have extracted fluoxetine from serum, plasma or brain 
tissue. However, in forensic toxicology it is important to have methods capable of 
measuring substances in whole blood. None of the previously mentioned methods were 
validated to analyze whole blood samples. Such samples can prove difficult to analyze by 
HPLC-UV due to the decomposition of the sample and more specific techniques are 
required.
One of two methods to analyze fluoxetine in whole blood used liquid-liquid extraction 
followed by derivatization with PFPA and analysis by gas chromatography-mass 
spectrometry (GC/MS) . 119 The limit of detection for this method was 12.5 ng/ml and this 
was the only reported method to use a deuterated internal standard for identification and 
quantitation of fluoxetine and its metabolite.
One other method which reported the extraction of fluoxetine from whole blood used 
HPLC with fluorescence detection following SPE . 120 This method simultaneously extracted 
citalopram, paroxetine, fluoxetine and metabolites in plasma or whole blood. The limits of 
detection of these were 8.1 ng/ml, 8.2 ng/ml, and 30 ng/ml respectively.
4.7 PAROXETINE
Paroxetine (Seroxat®) was first introduced into the United Kingdom in 1991 as a treatment 
for depression . 121 Since then it has also been prescribed to treat obsessive compulsive 
disorder, panic disorder and several other psychiatric and physical disorders. It has been 
found to be as effective as the tricyclic antidepressants such as imipramine122 but with 
fewer side effects.
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4.8 CHEMISTRY
Paroxetine is chemically known as (-)-trans-4-(p-fluorophenyl)-3-[(3,4-(methylenedioxy)- 
phenoxy)methyl]piperidine and has molecular formula C 1 9H2 Q0 3NF and molecular weight
329.4. It has a phenylpiperidine structure as shown in Figure 4.3. Paroxetine is 
administered as its hydrochloride salt in doses of 30 mg.
F
Paroxetine
H
Figure 4.3: Chemical structure of paroxetine
4.9 METABOLISM AND EXCRETION
Paroxetine undergoes first pass metabolism and is metabolized to several inactive 
compounds as shown in Figure 4.4. The principal metabolic pathway is thought to be 
through oxidation to an unstable catechol intermediate which is in turn methylated and 
conjugated to a glucuronide or sulphate. Less than 2 % of the paroxetine dose remains 
unchanged in the urine . 123
4.10 PHARMACOKINETICS
After oral dosing, paroxetine is almost completely absorbed and peak plasma 
concentrations are reached within 3 to 8  hours after administration. Steady state 
concentrations are reached within seven to fourteen days after multiple dosing of 2 0  or 
30 mg daily. A single oral dose of 20 mg produced peak plasma levels ranging from 
0.008 - 0.033 mg/L within 3 to 8  hours. Daily doses of 30 mg produced an average steady 
state level of 0.062 mg/L at 5.2 hours . 123 The distribution of paroxetine to tissues is 
extensive and the volume of distribution is large. Pharmacokinetic data is summarized in 
Table 4.2 . 62
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Figure 4.4: Paroxetine metabolism and excretion
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Table 4.2: Pharmacokinetic data for paroxetine
Paroxetine
Half life 1-3 days
Vd (L/kg) 3-28
Protein Binding (%) 95
pKa 9.9
4.11 TOXICITY
Side effects of paroxetine have included nausea, somnolence, tremor, insomnia, headache 
and dry mouth. Excessive doses of paroxetine cause symptoms such as lethargy, 
tachycardia and hypertension. Drug concentrations detected in blood in 4 paroxetine 
fatalities ranged from 1.4 - 4.0 (mean 2.7) mg/L . 62 In two of these cases imipramine or 
moclobemide were detected in significant quantities.
Paroxetine, like fluoxetine should not be taken concurrently with monoamine oxidase 
inhibitors or L-Tryptophan since this can cause the potentially fatal Serotonin Syndrome.
4.12 ANALYSIS
Several methods for the analysis of paroxetine in human plasma or serum have been 
published. The most common method of analysis has been by HPLC either with ultra­
violet detection1 2 4 , 1 2 5 , 126 or fluorescence detection.120,127, l28> 129, l30) 13! Fluorescence detection 
methods all produced limits of detection lower than those of the ultra-violet detection. One 
of the ultra-violet methods used fluoxetine as the internal standard, however for this 
method the limit of quantitation was only 5 ng/ml. Another method which used fluoxetine 
as the internal standard used GC-ECD . 132 The extraction method was a simple liquid-liquid 
extraction method followed by derivatization with heptafluorobutyric anhydride. The limit 
of detection for this method was 8.5 ng/ml. A lower limit of detection of 3 ng/ml was 
obtained using GC-NPD to detect paroxetine in monkey plasma, but this method involved 
a multi-step extraction.
Most extraction methods for paroxetine used LLE, but SPE and automated column 
switching methods have also been employed. SPE methods have several advantages over 
LLE methods. Higher selectivity can be obtained since there is now a wide choice of
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sorbents and solvents which can be selected depending on the application. Cleaner extracts 
can be produced since analytes can be selectively retained on and eluted from the column. 
Extraction can be less time consuming and since samples can be processed simultaneously, 
the system can be automated. SPE avoids the problem of emulsions forming which can 
reduce recoveries. Reproducibility is usually good since specific molecular interactions are 
involved. Previous SPE methods used either Bond Elut C l 8  1 2 8 , 131 or 1ST C8  120 columns for 
analysis and gave recoveries greater than 90 %.
The only method which has reported the extraction of paroxetine from whole blood used 
HPLC with fluorescence detection following SPE . 120 The limit of detection for this method 
was 8  ng/ml. This method has already been mentioned previously since it simultaneously 
extracted fluoxetine, paroxetine, citalopram and metabolites in plasma or whole blood.
As a result of an increase in the number of whole blood samples containing fluoxetine into 
our department it was necessary to develop an improved method to extract fluoxetine from 
whole blood and to apply this method to postmortem blood samples. Solid phase extraction 
was used to extract the analytes from whole blood since this technique can often provide 
cleaner extracts than liquid-liquid extraction and produce high recoveries. Previous 
methods used Bond Elut C 8  or Bond Elut C l 8  columns. Since cyanopropyl columns had 
previously been successful in separating the analytes by HPLC, it was decided to try solid 
phase columns of this nature to extract the analytes from whole blood. Initially, HPLC with 
UV detection was used to validate the method, but in order to obtain lower limits of 
detection and the required selectivity a GC/MS method was later validated.
Further to this, an increase in the number of paroxetine samples received into the 
laboratory was recognized and the method originally developed for fluoxetine was later 
applied to paroxetine. The method was evaluated using postmortem and clinical samples 
obtained from patients receiving treatment for depression. The developed method can 
simultaneously analyze fluoxetine, norfluoxetine and paroxetine in whole blood using solid 
phase extraction followed by gas chromatography-mass spectrometry with selected ion 
monitoring.
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4.13 EXPERIMENTAL
4.13.1 CHEMICALS
Fluoxetine, norfluoxetine and tumoxetine were obtained as hydrochloride salts from Eli 
Lilly (Windlesham, England). Paroxetine hydrochloride was obtained from SmithKline 
Beechams (Herts, England) and maprotiline from Promochem (Herts, England). 
Clomipramine was supplied by Geigy Pharmaceuticals (Macclesfield, England). HPLC 
grade methanol, acetonitrile, acetone, chloroform and dichloromethane were obtained from 
Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical grade potassium dihydrogen 
phosphate, sodium hydroxide, HPLC grade w-amyl alcohol, toluene and triethylamine were 
obtained from BDH laboratory supplies (Poole, England). HPLC grade isopropanol was 
obtained from Fisher Scientific U.K. Ltd. (Leicestershire, England) and HPLC grade 
hexane from Rathbum Chemicals Ltd. (Walkerbum, Scotland). Analytical grade 
concentrated ammonia and glacial acetic acid were obtained from Merck (Poole, England). 
Heptafluorobutyric anhydride was obtained from Sigma® Chemicals Co. (U.K.).
4.13.2 STANDARDS
Stock standard solutions of fluoxetine, norfluoxetine, tumoxetine, paroxetine, maprotiline 
and clomipramine were prepared in methanol at a concentration o f 1 mg/ml and stored at 
- 20 °C. Each of these stock solutions was diluted with methanol to give working standard 
solutions at 1 pg/ml and 10 pg/ml and these were refrigerated at 4 °C.
4.13.3 SOLUTIONS AND BUFFERS 
1 M Sodium carbonate buffer, pH 10
10.6 g of sodium carbonate (FW = 105.99) was weighed out into a 100 ml volumetric flask 
and made up to the mark with distilled water. 8.4 g of sodium hydrogen carbonate was 
weighed out into a 1 0 0  ml volumetric flask and made up to the mark with distilled water. 
These two solutions were combined, mixed well and stored in a bottle at room temperature.
0.5 M Sodium phosphate buffer, pH 10
7.8 g of sodium phosphate monobasic dihydrate (FW = 119.98) was weighed out into a 
100 ml volumetric flask and made up to the mark with distilled water. The pH was 
adjusted to pH 10 using 10 M sodium hydroxide solution followed by 0.1 M hydrochloric 
acid while mixing on a magnetic stirrer. The buffer was stored at room temperature.
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0.1 M Potassium Phosphate buffer, pH 6.0
6 .8 lg  of potassium dihydrogen phosphate (FW = 136.09) was weighed out into a 0.5 1 
volumetric flask and approximately 450 ml of distilled water were added. The pH was 
adjusted to 6.0 with 1.0 M potassium hydroxide solution while stirring. The solution was 
then made up to 0.5 1 with distilled water.
4.13.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
HPLC conditions were set-up using a cyano column to separate fluoxetine and 
norfluoxetine . 113 This method avoided using the odourous solvent triethylamine which is 
often used to reduce peak tailing when separating basic drugs such as fluoxetine. This 
analytical technique was used to validate current liquid-liquid extraction techniques and a 
new solid phase extraction method for analysis o f fluoxetine and norfluoxetine in whole 
blood.
Analysis of fluoxetine and norfluoxetine was carried out using a Gilson system consisting 
of a 307 pump with 5SC pumphead and a 118UV detector. The column selected was a 
Supelcosil LC-PCN 25 cm x 4.6 mm i.d., 5 pm particle size. The mobile phase was an 
acetonitrile/methanolic buffer mixture which was prepared by buffering 0.01M potassium 
dihydrogen phosphate to pH 7 using 1M potassium hydroxide solution and mixing it with 
HPLC grade methanol in the ratio 5:4. 167 ml of acetonitrile was added to 90 ml of the 
methanol buffer and this was degassed under helium for 15 minutes and pumped at a flow 
rate of 2 ml/min. The mobile phase was allowed to equilibrate for 30 - 60 minutes and a 
detection wavelength of 226 nm was used.
A mixed standard solution containing 100 pi of fluoxetine, norfluoxetine and tumoxetine 
each at a concentration of 1 pg/ml and three standard solutions containing each drug 
separately were evaporated to dryness at 40 °C under nitrogen. The residues were 
redissolved in 200 pi of mobile phase and sonicated at room temperature for 5 minutes. 
20 pi of each standard was injected into the HPLC system.
The chromatographic conditions described produced good separation of the analytes and 
internal standard. The order of elution was norfluoxetine, fluoxetine then tumoxetine and 
retention times were found to be 4.9, 6 . 8  and 7.4 minutes respectively.
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4.13.5 CURRENT METHODOLOGY
Liquid-liquid extraction has been the preferred extraction method for fluoxetine and 
norfluoxetine from whole blood. Two methods from the literature were chosen and 
compared with solid phase extraction.
4.13.6 LIQUID-LIQUID EXTRACTION METHOD 11 0 6
4.13.6.1 Sample Preparation
Packed red blood cells from the blood bank which was time expired was used as blank 
blood. These were suspended in a ratio of 1:1 with isotonic saline solution which was made 
up by dissolving 9.5 g of sodium chloride in 1 litre of distilled water.
Blood samples were prepared by spiking 1 ml of blank blood with fluoxetine and 
norfluoxetine to give concentrations 100, 200, 400, 1000, 1400, 2000 ng/ml. A 1 ml blank 
blood sample containing no drug was also pipetted into a centrifuge tube. Unextracted 
standards at equivalent concentrations were also prepared. Each concentration was 
prepared in triplicate.
4.13.6.2 Extraction
Carbonate buffer (2 ml, 1 M, pH 10) was added to each blood sample followed by 6  ml of 
chlorobutane. This was mixed on a rocking and rolling mixer for 10 minutes and 
centrifuged at 3000 rev/min. for 10 minutes. The upper chlorobutane layer was transferred 
to a clean test tube and 2 ml of 0.2 M hydrochloric acid was added. Mixing and 
centrifuging were carried out as previously and the chlorobutane layer was removed and 
discarded. The acidic layer was basified using 2 ml of pH 10 carbonate buffer and 5 ml 
toluene were added. After mixing and centrifuging, the toluene layer was removed and 
evaporated to dryness at 50 °C under nitrogen. 200 ng of clomipramine was added to each 
vial as internal standard, evaporated to dryness and redissolved in 2 0 0  pi of mobile phase. 
20 pi of each extracted and unextracted standard was injected into the HPLC system.
4.13.6.3 Results
Relative recoveries of fluoxetine and norfluoxetine from whole blood were determined by 
comparing the peak heights obtained from spiked whole blood extracts with unextracted 
standards at equivalent concentrations. The mean percentage recoveries were calculated at 
each concentration and it was found that the recoveries of fluoxetine were higher than
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those of its metabolite by approximately 20 % (Table 4.3). Recoveries of the metabolite 
were less than 50 %.
Table 4.3: Recoveries using liquid-liquid extraction method 1
Concentration in blood 
(ng/ml)
Mean % Recovery 
Norfluoxetine
Mean % Recovery 
Fluoxetine
1 0 0 49.4 73.2
2 0 0 50.0 6 8 . 0
400 43.2 68.3
1 0 0 0 37.5 60.7
1400 33.0 58.4
2 0 0 0 38.4 52.0
Since the recoveries were relatively low for this liquid-liquid extraction method, a different 
method was used and the recoveries compared.
4.13.7 LIQUID-LIQUID EXTRACTION METHOD 2 100
4.13.7.1 Sample Preparation
Standards were prepared as in 4.13.6.1.
4.13.7.2 Extraction
To the spiked blood sample, 2 ml of sodium phosphate buffer (0.5 mol/L, pH 10) were 
added and vortex mixed for 5 seconds. 5 ml of hexane:«-amyl alcohol 97:3 (v/v) were then 
added, shaken for 20 minutes and centrifuged for 10 minutes at 3000 rev/min. The organic 
phase was transferred and 1 ml of 0.1 M hydrochloric acid added, shaken for 20 minutes 
and centrifuged for 10 minutes at 3000 rev/min. The organic phase was removed and 
discarded. To the aqueous phase, 1 ml of sodium hydroxide was added followed by 
hexane:«-amyl alcohol 97:3 (v/v). This was shaken for 20 minutes and centrifuged for 
10 minutes at 3000 rev/min. The organic layer was transferred and one drop of methanolic 
hydrochloric acid added. The solvent was evaporated to dryness and reconstituted in 
200 pi o f mobile phase for HPLC analysis or derivatized for GC/MS analysis.
4.13.7.3 Results
Relative recoveries of fluoxetine and norfluoxetine from whole blood were determined and 
the mean percentage recoveries are given in Table 4.4. The recoveries using this method
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were similar for fluoxetine and norfluoxetine and also much higher than the previous 
liquid-liquid method.
Table 4.4: Recoveries using liquid-liquid extraction method 2
Concentration
(ng/ml)
Mean % Recovery 
Norfluoxetine
Mean % Recovery 
Fluoxetine
1 0 0 79.2 79.2
2 0 0 8 6 . 0 92.9
400 81.4 82.1
1 0 0 0 87.7 88.4
1400 95.9 91.0
2 0 0 0 89.5 93.6
4.13.8 SOLID PHASE EXTRACTION
The solid phase extraction columns chosen for this analysis consisted of a cyanopropyl 
bonded phase. This type of phase has the potential to extract a wide variety of drugs under 
the correct analytical conditions. Therefore, this type of sorbent can be used for solid phase 
extraction provided the correct conditions are applied to achieve retention or elution of 
analytes when required. The cyanopropyl bonded phase possesses an intermediate polarity 
which allows analytes to be separated from an aqueous matrix or a non-polar medium and 
should also allow elution to be easier than that obtained with non-polar sorbents such as 
C l 8 . The primary interactions of the sorbent in polar solvent surroundings are due to 
hydrophobicity and the retention of analytes is largely due to non polar Van der Waals 
binding forces. Secondary interactions which play a role are electrostatic interactions at 
residual silanol groups and in aqueous solutions there is the possibility of ionic interactions 
with protonated bases. Also dipole-dipole interactions may occur at the cyano functional 
group. Fluoxetine could potentially interact with the phase by all of these mechanisms.
4.13.8.1 Sample Preparation
Four blood samples were prepared by addition of 20 pi of fluoxetine and 20 pi of 
norfluoxetine, both at a concentration of 10 pg/ml to centrifuge tubes. The samples were 
evaporated to dryness, reconstituted in 1 ml of blank blood and sonicated for 5 minutes. 
Phosphate buffer, pH 7.92 ( 6  ml, 0.1M) was added to two of the tubes and phosphate
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buffer, pH 6.5 was added to the other two tubes. These were vortex mixed for 30 seconds 
and then centrifuged at 3500 rev/min. for 15 minutes.
4.13.8.2 Solid Phase Extraction
Bond Elut cyanopropyl columns (100 mg, 10 ml reservoir) were conditioned with 2 ml of 
methanol followed by 2 ml of potassium dihydrogen phosphate buffer (0.1 M, pH 7.92 or
6.5 corresponding to pH of phosphate buffer used to dilute blood sample). The diluted 
blood samples were applied to the columns and the vacuum was applied to give a flowrate 
o f 1.5 ml/min. The column was washed with 1 ml deionized water followed by 0.5 ml 
acetic acid (0.01M, pH 3.3) at a flowrate of 1.5 ml/min. The sorbent was dried for 
5 minutes under a full vacuum followed by addition of 50 pi methanol and a further 
1 minute with the vaccuum on full. A further wash was carried out using 4 ml of acetone- 
chloroform (1:1) at a flowrate of 0.8 ml/min. This fraction was collected, evaporated to 
dryness at 40 °C. The drugs were eluted with 2 ml of ethyl acetate containing 2 % 
concentrated ammonia at a flowrate of 0.5 ml/min. A further 1 ml of ethyl acetate 
containing 2  % concentrated ammonia was added to the columns and these samples were 
collected separately. Samples were evaporated to dryness at 40 °C. To all fractions, 20 pi 
of clomipramine at 1 0  pg/ml was added and this was evaporated to dryness under nitrogen 
and the residue was reconstituted in 200 pi of mobile phase for HPLC analysis.
4.13.8.3 Results
The acetone-chloroform extracts were analysed and showed that no significant amount of 
fluoxetine or norfluoxetine was eluted in this step. Peak height ratios were calculated for 
fluoxetine and norfluoxetine to internal standard and the recoveries calculated for the 
extraction using phosphate buffer at two different pH's. The extraction using phosphate 
buffer pH 6.5 gave higher recoveries than at pH 7.92 for the ethyl acetate extracts (Table 
4.5). Recoveries were much lower for norfluoxetine than fluoxetine at both pH's which 
suggested that either the pH of buffer should be altered or an alternative elution solvent 
should be used. The third millilitre of ethyl acetate with 2 % concentrated ammonia used to 
elute any remaining drugs was analysed, but no fluoxetine or norfluoxetine was identified.
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Table 4.5: Recoveries using phosphate buffer, pH 6.5 and pH 7.9.
pH of phosphate buffer Mean % Recovery Mean % Recovery
Norfluoxetine Fluoxetine
6.5 25.9 67.1
7.92 5.3 50.4
The experiment was repeated using different pH's of phosphate buffer.
4.13.9 METHOD DEVELOPMENT: ALTERING PH OF PHOSPHATE BUFFER 
Phosphate buffer was prepared as described in 4.13.3 and the pH was adjusted to 5.0, 6.0 
and 7.0 with potassium hydroxide solution. Blood was spiked and extracted as before and 
the recoveries were calculated.
Table 4.6: Recoveries using phosphate buffer, pH 5.0, pH 6.0 and pH 7.0.
pH of phosphate buffer Mean % Recovery Mean % Recovery
Norfluoxetine Fluoxetine
5.0 36.0 (7.1) 63.6 (6.4)
6 . 0 53.0(10.9) 89.4 (6.1)
7.0 14.8 (4.6) 37.9 (5.7)
The acetone-chloroform fractions showed no presence of fluoxetine or norfluoxetine. 
Recoveries were highest using phosphate buffer pH 6.0. These were 53.0 % and 89.4 % 
for norfluoxetine and fluoxetine respectively. Since the recovery obtained for norfluoxetine 
was still low, the elution solvent was changed to try and elute a higher percentage of drug.
4.13.10 METHOD DEVELOPMENT: CHANGING THE ELUTION SOLVENT
The elution solvent was changed to dichloromethane:isopropanol 8:2 with 2 % 
concentrated ammonia. This elution mixture was used as an alternative to ethyl acetate.
The recoveries were 78.6 and 88.2 % for norfluoxetine and fluoxetine respectively. The 
fluoxetine recovery was similar to that in the previous experiment, however, the 
norfluoxetine recovery increased by more than 2 0  %.
4.13.11 RECOVERY OF INTERNAL STANDARD
Three 1 ml samples of blank blood were spiked with 20 pi of clomipramine at 10 pg/ml. 
This was extracted as in 4.13.8.2 except using the new elution mixture and fluoxetine in
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this case was added after the extraction procedure. 2 0  pi of each extract was injected into 
the HPLC system and unextracted standards at the same concentration were injected. The 
recovery of the internal standard was 80 %.
4.13.12 METHOD VALIDATION
4.13.12.1 Linearity
Fluoxetine and norfluoxetine were added to centrifuge tubes to give concentrations of 25, 
50, 100, 200, 400, 1000, 2000 ng/ml blood. Internal standard, clomipramine was added to 
give a concentration of 200 ng/ml blood. Each concentration was extracted in triplicate. 
Unextracted standards and solid phase extracted standards containing equivalent 
concentrations of fluoxetine and norfluoxetine were analyzed. Calibration graphs were 
constructed for the compounds using the values displayed in Table 4.7. These were linear 
producing regression coefficients of 0.999 and 0.998 and intercepts - 0.0096 and - 0.0024 
for fluoxetine and norfluoxetine respectively.
Table 4.7: Intra-day Variation
Extracted standards Unextracted standards
Concentration PH ratio PH ratio PH ratio PH ratio 1
(ng/ml blood) NFLU/CLO FLU/CLO NFLU/CLO FLU/CLO
(RSD %) (RSD %) (RSD %) (RSD %)
25 0.099 (8.4) 0.099 (9.6) 0.094 (13.6) 0.092 (14.7)
50 0.189 (5.6) 0.193 (4.2) 0.203 (7.1) 0.183 (8.7)
1 0 0 0.381 (4.0) 0.395 (9.2) 0.370 (7.1) 0.336 (5.0)
2 0 0 0.655 (7.1) 0.735 (4.3) 0.752 (3.9) 0.667 (7.7)
400 1.563 (2.1) 1.474 (3.1) 1.526 (6.4) 1.312 (8.3)
1 0 0 0 3.694 (3.2) 3.595 (9.1) 4.10(5.2) 3.650 (4.1)
2 0 0 0 7.332 (3.4) 6.967 (5.7) 7.910 (3.9) 7.067(4.1)
*PH = Peak Height, RSD = Relative standard deviation as a percent 
NFLU = norfluoxetine, FLU = fluoxetine, CLO = clomipramine
4.13.12.2 Recovery
Relative recoveries of fluoxetine and norfluoxetine were obtained by extracting the 
compounds at three different concentrations (100, 200, 400 ng/ml) and extractions at each 
concentration were carried out in triplicate. 2 0  pi clomipramine at 1 0  pg/ml was added
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after the extraction process. Mean recoveries were determined by comparing the ratio of 
peak heights obtained from spiked whole blood extracts with the ratio of peak heights 
obtained from unextracted standards at equivalent concentrations and were found to be 
approximately 95 % and 85 % for fluoxetine and norfluoxetine respectively (Table 4.8).
Table 4.8: Recoveries of fluoxetine and norfluoxetine
Concentration Mean % Recovery Mean % Recovery 1
(ng/ml blood) NFLU (RSD %) FLU (RSD %)
1 0 0 84.3 (4.0) 95.3 (2.7)
2 0 0 85.2 (4.1) 93.2(4.1)
400 86.3 (4.2) 97.4 (5.4)
4.13.12.3 Limit of Detection
Blank blood was spiked to give concentrations 10, 15, 20 ng/ml of fluoxetine and 
norfluoxetine. The limit of detection was taken to be the concentration of drug giving a 
signal to noise ratio of 3 and this was found to be 10 ng/ml for both analytes using this 
method.
4.13.13 EXTRACTION OF POSTMORTEM BLOOD
4.13.13.1 Experimental
The method was tested using two postmortem blood samples known to contain fluoxetine. 
These were extracted using the SPE method. Spiked blood standards at 50 ng/ml and 200 
ng/ml and a blank blood sample were extracted at the same time.
4.13.13.2 Results
The blank blood extract gave a small peak at 6 . 6  minutes which in previous blank samples 
was not present. This peak was also present in the spiked blood extracts. However, it did 
not interfere with internal standard, norfluoxetine or fluoxetine which eluted at 4.5, 5.3 and
7.3 minutes respectively.
Analysis of the two postmortem blood samples showed peaks which interfered with 
fluoxetine, norfluoxetine and clomipramine. Since one of these case samples was known to 
contain only fluoxetine and norfluoxetine, interference resulting from the presence of other 
drugs was ruled out. These other peaks were caused by the degradation o f the blood
Chapter 4: Antidepressants in Blood Page 61
samples which is a problem with postmortem blood samples. The method would therefore 
need to be improved to avoid this problem. Initially, protein precipitation with acetonitrile 
was investigated to clean up these samples.
S o l v e n t  S o l v e n t
8.0 6.0 2.0
T i m e  ( m i n u t e s )
CLO
FLU NFLU
7.4 5.5 4.6
T i m e  ( m i n u t e s )
(A) (B)
Figure 4.5: High performance liquid chromatograms of a blank blood extract (A) and a 
blood extract containing 100 ng/ml of fluoxetine (FLU) and norfluoxetine (NFLU) and 200 
ng/ml clomipramine (CLO) (B).
4.13.14 PROTEIN PRECIPITATION
4.13.14.1 Experimental
A blank blood sample, a 200 ng/ml spiked blood sample, a blank methanol sample, a 200 
ng/ml methanol standard, a postmortem blood sample which was known to be negative for 
fluoxetine and two case samples which were positive for fluoxetine and norfluoxetine were 
extracted using freshly made up phosphate buffer and solvents.
Chapter 4: Antidepressants in Blood Page 62
Another set of the above samples was extracted similarly, but an extra acetonitrile step was 
included in the sample preparation to see if this made a difference to the chromatograms. 
Acetonitrile is sometimes used in methods prior to extraction to precipitate proteins from 
blood.
1 ml of blood (case sample or spiked sample) was vortex mixed with 1 ml phosphate 
buffer, pH 6.0 whilst 4 ml of acetonitrile were added gradually. This was centrifuged for 
15 minutes at 3500 rev/min, evaporated down to 1 ml and 6 ml phosphate buffer, pH 6.0 
was added. SPE was carried out.
4.13.14.2 Results
Methanol extracts where no blood was present and the blood spikes produced no 
interferences which would affect quantitation of fluoxetine and norfluoxetine with or 
without the acetonitrile step. The postmortem case sample which was negative for 
fluoxetine also produced no interfering peaks. Out of the two other postmortem samples 
which were known to be positive for fluoxetine it was only possible to quantify one. The 
sample which produced many interfering peaks previously still showed these even when 
the acetonitrile step was included in the method, although it did reduce some of these 
interferences. This experiment showed that although it would be possible to quantify some 
postmortem samples by this method others could present a problem and therefore the 
method was not satisfactory for postmortem cases.
4.13.15 COMPARISON WITH LIQUID-LIQUID EXTRACTION METHOD 2
4.13.15.1 Experimental
The postmortem case samples were extracted using liquid-liquid extraction method 2 which 
was previously investigated.
4.13.15.2 Results
The liquid-liquid extraction method gave similar interferences on analysis by HPLC and 
fluoxetine and norfluoxetine were masked or only partially separated from other peaks. At 
this stage it was decided that the HPLC method was not selective enough for analysing 
postmortem samples. Analysis by GC/MS was carried out.
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4.13.16 GAS CHROMATOGRAPHY MASS SPECTROMETRY
4.13.16.1 Equipment
A Hewlett-Packard model 5890 Gas Chromatograph with a VG Analytical VG 70-250S 
Mass Spectrometer was used. The GC was fitted with a HP-5 X-link 5% PH Me silicone 
column, 30 m x 0.32 mm x 0.25 pm film thickness. The temperature programme was 
increased from 150 to 300 °C at 10 °C/min and the injector temperature was 225 °C. The 
temperature of the source and interface were 200 °C and 250 °C respectively. The trap 
current was 200 pA. The injection volume was 1 pi.
4.13.16.2 Derivatization
To the extracted residue, 500 pi toluene, 100 pi of triethylamine (0.05M) and 10 pi of 
heptafluorobutyric anhydride (HFBA) were added. The vial was sealed and heated at 50 °C 
for 15 minutes. After heating, the solvent was evaporated off at 37 °C under nitrogen and 
1 ml distilled water and 500 pi toluene were added to the vial and shaken for one minute. 
The toluene layer was removed and evaporated to dryness and the residue reconstituted in 
50 pi toluene.
4.13.16.3 Results
The following retention times and ions were observed for the derivatized analytes using 
full scan analysis:
Table 4.9: Retention times and ions observed after GC/MS analysis
Drug Retention time (min.) 
150-300 °C
Retention time (min.) 
180-280 °C
Main ions observed 
(m/z)
Fluoxetine 6.43 4.50 344
Norfluoxetine 6.08 4.08 330
Tumoxetine 7.24 5.17 344
The temperature programme was altered to reduce the analysis time. The initial 
temperature was 180 °C and this was increased at 10 °C/min to 280 °C. Retention times 
using this temperature programme are also displayed in Table 4.9. Mass spectra for the 
derivatized samples are shown in Figure 4.6. From these it was decided to monitor ions 
m/z 344 for FLU and tumoxetine (TUM) and m/z 330 for NFLU and use these for 
quantification. Figure 4.7 shows how these drugs fragment to produce these ions.
Chapter 4: Antidepressants in Blood Page 64
100 1  
90 
80 
70 
60 
50 
40 
30 -  
20 “  
10  -
117
252
r t " r ^ ^ r i“ f. r p , r ^ ,P,r l . |  ■ ‘| ‘ ■ ‘f“« m  ■“ r ‘ | 1 ■ r ■ i1 ' r *  |
200 250
Low Resolution M/z
300 400
Fluoxetine-HFB derivative.
100 -1 104
90 ~
80 ~
70 -
60  -
50 "
32940 “
30 - 160132
20  - 226
10 -
300 350 400200 25050 100 150
Low Resolution M/z
Norfluoxetine-HFB derivative.
1 0 0 1 174117
90 ~
80 -
252
44
60 -
50 "
40 ~ 344
30 -
146
20  "
I 21 °..
■|ln* 1“ ‘Tly l‘
200
10  -
350 400250 300100 15050
Low Resolution M/z
Tumoxetine-HFB derivative.
Figure 4.6: Ion graphs of HFB derivatives
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Fluoxetine-HFB
Norfluoxetine-HFB
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Figure 4.7: Derivatization of fluoxetine, norfluoxetine and tumoxetine with
heptafluorobutyric anhydride.
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4.13.17 GAS CHROMATOGRAPHY MASS SPECTROMETRY - SELECTED ION 
MONITORING (SIM)
A selected ion monitoring programme was set up for the analytes. Ions monitored were 
344 for fluoxetine and tumoxetine and 330 for norfluoxetine. Perfluorokerosene (PFK) was 
used to calibrate the instrument and lock ion 318.9792 a.m.u. was used. The initial magnet 
position was 317 a.m.u. and switch and dwell times were set at 20 ms and 50 ms 
respectively for each monitored ion. Selected ions were monitored in the electron 
ionization mode at 70 eV and the trap current was set at 200 pA.
4.13.18 METHOD VALIDATION USING GC/MS
The developed solid phase extraction method including the acetone-chloroform step was 
fully validated.
4.13.18.1 Linearity
Fluoxetine and norfluoxetine were added to centrifuge tubes to give concentrations of 10, 
25, 50, 75, 100, 200, 400 ng/ml blood. Internal standard, tumoxetine was added to give a 
concentration of 100 ng/ml blood. Each concentration was extracted in triplicate.
Table 4.10: Intra-day Variation
Extracted standards Unextracted standards
Concentration m/z 330/344 m/z 344/344 m/z 330/344 m/z 344/344
(ng/ml blood) NFLU/TUM FLU/TUM NFLU/TUM FLU/TUM
(RSD %) (RSD %) (RSD %) (RSD %)
10 0.056(15.0) 0.052(16.0) 0.058(12.9) 0.053 (16.8)
25 0.178 (5.2) 0.165 (3.6) 0.224 (2.8) 0.202 (3.4)
50 0.387 (5.2) 0.368 (5.8) 0.530 (5.9) 0.476 (2.8)
75 0.560 (6.6) 0.586 (3.5) 0.774 (5.7) 0.694 (3.3)
100 0.893 (7.9) 0.891 (3.8) 1.217(5.8) 0.988 (4.0)
200 1.785 (3.5) 1.720 (2.9) 2.051 (4.8) 2.179 (4.8)
400 3.225 (3.1) 3.423 (4.6) 4.402(1.6) 4.437 (5.9)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
Coefficients of correlation for fluoxetine and norfluoxetine extracted standards were 
> 0.999 and > 0.998 and x-axis intercepts were -0.03884 and -0.03824 respectively.
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Coefficients of correlation for fluoxetine and norfluoxetine unextracted standards were 
> 0.999 and > 0.997 and x-axis intercepts were -0.09551 and -0.03038 respectively.
4.13.18.2 Inter-day variation
Inter-day variation was assessed for the same concentration range as the intra-day 
variation. These ratios are based on ratios obtained over five days and were less than 15 % 
for both drugs over the concentration range (Table 4.11).
Table 4.11: Inter-day variation
Extracted standards Unextracted standards
Concentration m/z 330/344 m/z 344/344 m/z 330/344 m/z 344/344
(ng/ml blood) NFLU/TUM FLU/TUM NFLU/TUM FLU/TUM
(RSD %) (RSD %) (RSD %) (RSD %)
10 0.055 (4.8) 0.054 (5.2) 0.060(10.4) 0.055 (9.6)
25 0.192(14.3) 0.142(15.0) 0.218(5.7) 0.211 (7.3)
50 0.344(12.5) 0.340 (8.2) 0.524 (9.2) 0.456 (5.0)
75 0.522 (13.0) 0.550 (6.4) 0.804 (6.1) 0.725 (6.0)
100 0.888 (4.8) 0.848 (4.1) 1.229 (5.3) 1.034 (3.7)
200 1.614(6.3) 1.646 (6.8) 2.288 (9.1) 2.006 (5.3)
400 3.442 (5.6) 3.373 (2.2) 4.534 (5.1) 4.516(4.8)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
4.13.18.3 Recovery
The recovery of the method was assessed at three concentrations, 25, 50 and 75 ng/ml. The 
recoveries were higher than previously seen for the HPLC method and also higher than 
either of the liquid-liquid methods which were initially investigated.
Chapter 4: Antidepressants in Blood Page 68
Table 4.12: Recovery
1 Concentration Mean % Recovery Mean % Recovery
(ng/ml blood) Norfluoxetine (RSD %) Fluoxetine (RSD%)
25 98.2 (2.3) 95.2 (7.8)
50 97.0 (8.9) 95.9(11.6)
75 92.2(10.8) 97.1 (9.4)
RSD = relative standard deviation as a percent
4.13.18.4 Limit of detection
The limit of detection was determined as the concentration of drug giving a signal to noise 
ratio of 3. These were found to be 1 ng/ml for fluoxetine and norfluoxetine. This method 
therefore has the advantage of a lower limit of detection than the HPLC method by a factor 
of 10.
4.13.18.5 Interference
Analysis using GC/MS eliminated interference from postmortem blood samples. In papers 
reporting the analysis of tricyclic antidepressants by HPLC there were often reports of other 
antidepressants or other types of drugs interfering with the analysis.133 The use of GC/MS 
produces a higher specificity and therefore will significantly reduce the incidence of 
interference from other drugs which extract using this method. Selective ion monitoring 
means that ions can be chosen which are specific for a certain drug. The combination of 
this and the resultant retention time decrease the likelihood of interference from other 
drugs. However, if this was a problem the method could easily be carried out using fullscan 
analysis to allow the possibility of alternative quantitative ions to be chosen.
4.14 PAROXETINE EXPERIMENTAL
4.14.1 DERIVATIZATION
Paroxetine (500 ng) was derivatized using heptafluorobutyric anhydride as described in 
4.13.16.2. This derivative was injected into the GC/MS using the same temperature 
programme used for fluoxetine, 180 - 300 °C at 10 °C/min. The mass spectrum of the 
derivatized sample is shown in Figure 4.8. From this it was decided to monitor m/z 525 for 
quantification and use m/z 388 as a qualifier ion. Figure 4.9 shows the derivatized 
molecule.
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Figure 4.8: Mass spectrum of paroxetine-HFB derivative
Figure 4.9: Structure of paroxetine-HFB derivative
4.14.2 METHOD VALIDATION FOR PAROXETINE BY GC/MS
The developed method for fluoxetine was carried out on paroxetine and the method was
validated for this drug.
4.14.2.1 Linearity
Linearity for paroxetine was evaluated by extracting blood samples spiked to give 
concentrations 10, 25, 50, 75, 100, 200, 400 ng/ml blood. Internal standard, maprotiline
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was added to give a concentration of 50 ng/ml blood. Each concentration was extracted in 
triplicate.
Table 4.13: Intra-day Variation for Paroxetine
Concentration 
(ng/ml blood)
Extracted Unextracted
m/z 525/445 
PAR/MAP (RSD %)
m/z 525/445 
PAR/MAP (RSD %)
10 0.038 (12.8) 0.035 (6.9)
25 0.077 (5.1) 0.078 (5.8)
50 0.161 (4.0) 0.160 (4.5)
75 0.215(2.4) 0.218(5.8)
100 0.291 (7.5) 0.307 (7.2)
200 0.669 (3.6) 0.649 (3.4)
400 1.420 (6.3) 1.420 (4.8)
PAR = paroxetine, MAP = maprotiline, RSD = relative standard deviation as a percent
Coefficient of correlation for paroxetine extracted standards was > 0.997 and x-axis
intercept was -0.02906.
4.14.2.2 Inter-day variation
Inter-day variation was assessed for the same concentration range as the intra-day 
variation. The coefficient of variation were determined over five days and were less than 
15 % across the concentration range (Table 4.14).
Table 4.14: Inter-day variation for Paroxetine
Concentration 
(ng/ml blood)
m/z 525/445 
PAR/MAP (RSD %)
10 0.033 (14.1)
25 0.080 (7.8)
50 0.154 (9.2)
75 0.221 (7.4)
100 0.326(11.5)
200 0.722(11.7)
400 1.553 (7.4)
PAR = paroxetine, MAP = maprotiline, RSD = relative standard deviation as a percent
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4.14.2.3 Recovery
The recovery of the method was assessed at three concentrations, 25, 50 and 75 ng/ml and 
the results are displayed in Table 4.15.
Table 4.15: Recovery of Paroxetine
Concentration Mean % Recovery 1
(ng/ml blood) Paroxetine (RSD %)
25 84.2 (5.4)
50 83.2 (6.2)
1 75 81.5(3.7) 1
RSD = relative standard deviation as a percent
4.14.2.4 Limit of detection
The limit of detection was determined as the concentration of drug giving a signal to noise 
ratio of 3. This was found to be 1 ng/ml.
4.15 CONCLUSIONS
The developed method successfully extracted fluoxetine, norfluoxetine and paroxetine 
simultaneously from spiked whole blood samples using cyanopropyl columns. Calibration 
curves were linear for all the analytes. Intra-day variation gave coefficients of variation 
< 12 % at higher concentrations and < 17 % at lowest concentration and inter-day variation 
< 1 5 %  in all cases. The limit of detection was found to be lower than previous methods 
which simultaneously analyzed these compounds in plasma or whole blood.
The method was applied to postmortem case samples and clinical samples to assess the 
quantities of these drugs in whole blood samples (see Chapter 8.3).
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5 Antidepressants in Saliva
5.1 INTRODUCTION
Saliva testing for drugs was first used about 30 years ago to identify and quantitate lithium 
and anticonvulsant drugs for the purpose of pharmacokinetic studies and therapeutic drug 
monitoring. Therapeutic drug monitoring is useful for drugs which have a narrow 
therapeutic concentration margin. However, to be able to use saliva for such a purpose a 
correlation between plasma and salivary drug concentrations must exist.
In more recent years there has been growing interest into the measurement of drugs of 
abuse in saliva134 and as a result saliva testing has become of interest to law enforcement 
agencies for road-side testing of potentially intoxicated drivers.135, 136 Most o f the 
commonly used drugs of abuse, cannabinoids, cocaine, opioids, benzodiazepines, 
amphetamines, barbiturates have been measured in saliva by various techniques.
A European project called the Roadside Testing Assessment (ROSITA) project was set up 
in 1999 to investigate oral fluid in road side testing. Eight countries took part in assessing 
12 urine tests, 3 saliva tests and 1 sweat test. During this project a survey was conducted 
into the preferences of police officers involved in collecting samples. The outcome o f this 
was that oral fluid was the preferred sample to be tested at the roadside. Drug classes 
which were tested were cannabinoids, amphetamines, benzodiazepines, opiates and 
cocaine. The onsite tests were confirmed by gas chromatography-mass spectrometry, high 
performance liquid chromatography-diode array detection or gas chromatography-electron 
capture detection.
However, it is not only illicit drugs which can cause driving impairment. Many widely 
prescribed drugs have the ability to impair driving performance. Also, combinations of 
drugs or drugs and alcohol can enhance driving impairment. Therefore, to assess the 
implications a drug or a combination of drugs has on the driving population and especially 
those who are impaired, it is important to be able to measure all prescription and over the 
counter drugs as well as illicit drugs in saliva. Until recently, the importance of saliva 
analysis of prescription drugs has been in therapeutic drug monitoring, but now saliva 
testing of these drugs is relevant in a forensic context.
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The interest in saliva testing has stemmed from the fact that the collection of saliva is much 
easier than that of blood. Collection is non-invasive and spares the patient from the 
discomfort of repeated venipuncture and avoids the privacy issues involved with urine 
collection. Samples can be stored at room temperature and transportation of samples 
requires no special needs such as refrigeration. Direct observation of the sample collection 
can prevent adulteration or possible swapping of samples, a problem sometimes 
encountered with urine collection. No training requirements are necessary by staff 
collecting samples and the risk of infection is low. This contrasts with blood collection 
which requires a medically qualified person to take the sample, and the risk of infection is 
always present. Saliva has a low protein content compared to blood so binding o f drugs 
will be less and it will have the advantage of giving an improved indication of the degree 
of intoxication of an individual compared with urine.
However, the disadvantages of using such a matrix are that the mucopolysaccharides and 
mucoproteins in saliva can cause it to have a viscous, sticky consistency which make 
handling more difficult. Sufficient volume of sample for analysis can be a problem with 
the elderly and with patients who have been administered certain drugs or who have an 
illness that can cause dry mouth. Drugs can cause contamination of the oral cavity if  they 
are administered orally, intranasally or smoked. The method of saliva collection and 
variability of saliva pH between individuals can both have a large influence on the 
concentrations of drugs detected in the saliva sample.
5.2 COMPOSITION OF SALIVA
Saliva is a filtrate of blood and a combination of several oral fluids secreted by three 
principal glands known as the parotid, submandibular and sublingual glands. Parotid gland 
secretions are watery and contain the enzyme, amylase, which catalyzes starch breakdown. 
In comparison, the sublingual and submandibular secretions contain mucoid and serous 
because of the presence of mucous and serous cells in these glands.137
Whole saliva is 99 % water, but also contains sodium, potassium, calcium and magnesium 
cations, chloride, phosphate and bicarbonate anions, urea, proteins and traces of ammonia, 
uric acid, lipid, cholesterol, fatty acids, amino acids, sialic acid, mucins and enzymes for 
digestion. The total protein content in saliva is less than 1 % that of blood. Each type of
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salivary gland produces saliva with a different composition of these constituents and 
compositions vary between individuals depending on several factors including age, sex, 
time of day, diet and changes in flow rate.138
Under resting conditions, 65, 23 and 4 % of mixed saliva is produced by the 
submandibular, parotid and sublingual glands with the further 8 % produced by the minor 
mucous glands.139, 140 Under stimulated conditions, saliva flow is increased mainly from 
the parotid glands and this saliva makes up about 50 % of the mixed saliva which will now 
be more watery than before stimulation.139
5.3 SALIVA FLOW RATE
Humans produce between 0.5 and 1.5 litres of saliva per day.141 The rate of secretion 
varies throughout the day, it being lowest during sleep and highest in mid-afternoon.142 It 
also varies with season, with flow being higher in winter than in summer.143 Saliva flow 
has been shown to change with age, younger people producing greater rates than the 
elderly. 144
Saliva flow rate can be increased by ingestion of food and using stimuli which will be 
mentioned in 5.9. This increase in flow rate causes a change in salivary composition which 
is independent of the stimulus used. An increase in salivary flow will increase the 
concentrations of sodium cations, chloride and bicarbonate anions, but decrease potassium 
cations. In general, an increase in flow rate will cause a decrease in the viscosity.
Some diseases such as congenital xerostomia or Sjogren's syndrome145 directly affect the 
salivary glands causing decreased salivation. Changes in saliva flow may also result from 
illnesses such as chronic rheumatoid arthritis146, alcoholic cirrhosis147, cystic fibrosis and 
conditions such as pregnancy.148 Certain types of drugs: anticholinergic149, antidepressant150 
and anticonvulsant151 have also proven to have a side effect in decreasing saliva secretion.
5.4 SALIVA pH
In humans, saliva pH can range from 6.2 to 7.4.152 Parotid saliva pH is between 5.45-6.06 
and submandibular pH between 6.02-7.14 under resting conditions.153 After stimulation, 
the acidity of the saliva can decrease by up to 2 pH units because of the increase of 
bicarbonate anions. Changes in salivary pH are entirely dependent on changes in flow rate.
Chapter 5: Antidepressants in Saliva Page 75
A decrease in salivary pH is the result of a decrease in flowrate and an increase in salivary 
pH is the result of an increase in flowrate.
5.5 SECRETION OF DRUGS INTO SALIVA
Drugs are transferred from the blood into the salivary duct by transportation through the 
capillary wall, the basement membrane and the membrane of the glandular epithelial cells. 
However, it is the transportation of drugs across the epithelial membrane which is the rate 
determining step for the process. The principal method of transportation of drugs across 
this membrane is believed to be by passive diffusion, a process which depends on the drug 
existing in a non-ionized state. However, active transport and ultrafiltration may also play 
a role.
Many drugs are weak electrolytes which are only partially dissociated at physiological pH. 
The non-ionized form of drug is lipid soluble and will therefore cross the phospholipid 
bilayer which separates blood and saliva. An equilibrium will form between the blood and 
saliva for the non-ionized form and equilibria between the ionized and non-ionized forms 
will exist in both blood and saliva. The extent of ionization in the blood and saliva will 
depend on the pH on each side of the membrane. Figure 5.1 shows the transfer of an acidic 
drug across the epithelial membrane.
HA HA
/ /
/ /
H + + A- H + + A-
BLOOD S ALIYA
Figure 5.1: Equilibria between ionized and unionized forms of an acidic drug partitioning 
between blood and saliva by passive diffusion.
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The saliva:plasma concentration ratio of acidic and basic drugs can be derived by 
considering the following nine equations. The derivation is for an acidic drug, but the 
derivation for basic drugs is obtained in a similar manner.
The ionization of an acidic drug can be given by the following equation:
[H+][A“]
Ka =
[HA]
Equation 1
where Ka is the dissociation constant o f the drug
[H+] is the hydrogen ion conentration 
[A‘] is the concentration of ionized species 
[HA] is the concentration of unionized species
Taking logarithms of both sides of the equation forms the Henderson-Hasselbalch 
equation:
pH = pKa + log ~  —
[HA]
Equation 2
where pKa is the pH at which the drug is 50 % ionized
From equation 2, taking exponentials of both sides yields equation 3:
]  = l Q ( PH - p K a )
[HA]
Equation 3
It is known that the amount of ionized drug and the amount of unionized drug are 
equivalent to the total concentration of the acidic drug :
[A-] + [HA] = [A]
Equation 4
where [A] is the total concentration of the acidic drug (assuming no binding to protein).
Solving simultaneous equations 3 and 4 yields equation 5:
Chapter 5: Antidepressants in Saliva Page 77
[A] = l + 10(pH_pKa)
Equation 5
The saliva/plasma drug concentration ratio of an acidic drug for paired saliva and plasma 
samples can therefore be expressed as:
s . p _  [A > _ 1 +1 Q(pHs~pKa)
~~ [A]p 1 + 10(pHp" pKa)
Equation 6
The saliva/plasma drug concentration ratio of a basic drug for paired saliva and plasma 
samples can be calculated in a similar manner and can be expressed as:
S . P _  T O  _  i +  i o (pKa- pHs)
~~ [B]P ~ l + lO(pKa- pHp)
Equation 7
Equations 6 and 7 do not take into account that many drugs are highly protein bound in 
plasma and that some may also bind to protein in saliva. Correcting for protein binding 
gives equation 8 for acidic drugs and equation 9 for basic drugs.
g . p _ [A> _ 1 + 10(pHs~pKa)x fP 
~ [A]P “  i + io(PHp-PKa) Xfs
Equation 8
g . p _  [ B >  _  i  +  i o (pKa- pHs) fp 
~ [B]P ~ l + 10(pKa- pHp)Xfs
Equation 9
where fp is the non protein bound fraction of the total drug in plasma 
fs is the non protein bound fraction of the total drug in saliva 
Protein binding in saliva is usually negligible and it is assumed that fs is equivalent to 1.
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It has been established from these equations and other calculations154 that for acidic drugs 
with pKa values greater than 8.5 and for basic drugs with pKa values less than 5.5, the 
value of unbound saliva/plasma ratio remains the same even with a change in saliva pH. 
The saliva/plasma ratio for acidic drugs with pKa values less than 8.5 and basic drugs with 
pKa values greater than 5.5 will vary when there is an alteration in saliva pH. This is 
summarized in Table 5.1.
Table 5.1: Summary of how saliva/plasma ratios are affected by change in saliva pH 
for acidic and basic drugs
Acidic Drugs I pKa > 8.5
Change in saliva pH does not 
affect saliva/plasma ratio
pKa < 8.5
Change in saliva pH does 
affect saliva/plasma ratio
1 Basic Drugs pKa < 5.5
Change in saliva pH does not 
affect saliva/plasma ratio
pKa > 5.5
Change in saliva pH does 
affect saliva/plasma ratio
5.6 DRUG PROPERTIES AFFECTING SECRETION INTO SALIVA
The saliva/plasma ratio is determined by the mechanism which transfers drugs from the 
blood into saliva. It has already been mentioned that for most drugs simple diffusion is the 
mode of transport. In order that the drugs can cross the epithelial membrane, the drugs 
must be lipid-soluble, non-ionized and not bound to proteins. However, this is a simplified 
version and other factors must also be taken into consideration. These include molecular 
weight and stereochemistry, lipid solubility, pKa of ionized compounds and protein 
binding in plasma and saliva.
5.6.1 MOLECULAR WEIGHT
In theory, smaller molecules diffuse more easily than larger ones. For highly water soluble 
drugs, a molecular weight of 100 has been shown to be a critical size.139
5.6.2 SOLUBILITY
The diffusion of a drug from blood to saliva is dependent on the lipophilicity of the drug. 
Lipophilic drugs tend to diffuse more easily than lipophobic drugs.
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5.6.3 pKa OF IONIZED COMPOUNDS
Partition theory states that the pKa value of a particular drug and the pH of the medium in 
which the drug exists dictate the relative amounts of ionized and unionized forms on both 
sides of the separating membrane. With acidic drugs, the saliva/plasma ratio decreases with 
decreasing saliva pH and with basic drugs, the saliva/plasma ratio decreases with 
increasing saliva pH.
In humans, saliva is usually more acidic than blood and physiological pH of blood is 7.4. 
Therefore:
for acidic drugs, more drug is in the non-ionized form in the acidic saliva matrix which 
causes diffusion across the membrane into blood. As a result of the higher pH on the blood 
side of the membrane, more of the drug is present in an ionized form (Figure 5.2). It 
follows that unbound acidic drugs have a saliva/plasma ratio < 1.
for basic drugs, more drug is in the ionized form in the acidic saliva matrix. This means 
that non-ionized drug can diffuse from the blood compartment to the saliva compartment 
(Figure 5.3). It follows that unbound basic drugs have a saliva/plasma ratio > 1.
HA HA BOH
H+ + A-
SALIVA 
(acidic pH)
H+ + A- B+ + OH-
BLOOD 
(pH 7.4)
SALIVA 
(acidic pH)
-  BOH
/
V
B+ + OH-
BLOOD 
(pH 7.4)
Figure 5.2: Diffusion of non-ionized 
acidic drug from saliva to blood.
Figure 5.3: Diffusion of non-ionized 
basic drug from blood to saliva.
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5.6.4 PROTEIN BINDING
Drugs can bind to proteins to different extents and are often bound to either albumin or oti- 
acid glycoprotein, the concentrations of which can vary between individuals. When more 
than one protein-binding drug is present in the system these can compete for the protein 
binding sites. This explains why drugs with the same pKa values can have completely 
different saliva/plasma ratios. Alterations in the binding of a drug to saliva or blood 
proteins will affect the concentrations of unbound drug found in saliva and blood.
5.7 CONTAMINATION
Different routes of administration will have an effect on the saliva/plasma ratios observed 
for the same drug. This was observed for cocaine which was administered intravenously, 
intranasally and smoked. High saliva/plasma ratios were seen for intranasal administration 
and for smoking as a result of contamination of the nasal and oral cavities. However, 
contamination by these methods was shown to clear rapidly and saliva/plasma ratios were 
comparable with those obtained for intravenous administration two hours after snorting or 
smoking.155
Also, there is the possibility of external contamination from the surrounding environment 
due to passive inhalation of drugs which can be smoked. However, to date no studies have 
been carried out to prove or disprove this.
5.8 PHARMACOKINETIC PARAMETERS
Since the mode of transfer of drugs into saliva is mainly by passive diffusion of drugs from 
the blood into saliva then the amount of a drug present in blood will have an effect on the 
amount in saliva. For cocaine the shape of saliva drug concentration curves corresponded 
with the plasma drug concentration curves. Half-life values could be estimated for cocaine 
in saliva and these were generally found to be lower than the corresponding half-lives in 
plasma after intravenous injection. After smoking or intranasal administration, the half- 
lives were comparable.155
Chapter 5: Antidepressants in Saliva Page 81
5.9 COLLECTION OF SALIVA
5.9.1 METHODS
Collection of saliva is non-invasive and it is largely due to this that the analysis of this 
biological fluid for drugs has become popular. Special collection methods have been 
designed to improve sampling and make handling easier. To be of general clinical value, 
whole saliva is required to measure drug levels and it can be collected by a number of 
methods, either by stimulatory or non-stimulatory techniques. Stimulatory techniques are 
used to increase the flow of saliva and reduce the collection time.
Non-stimulated methods include allowing saliva to accumulate in the mouth and spitting it 
into a container or using the draining method which simply involves allowing the saliva to 
drip from the mouth. Repeated expectoration causes bubbles in the saliva which may affect 
the pH and collection by this method also has the disadvantage o f collecting mucoid 
proteins and mouth debris. Saliva can also be collected by a suction method which 
aspirates saliva from the floor of the mouth as it is produced. Other methods involve using 
absorbent pads to soak up saliva as it is produced.156 The pH of non-stimulated saliva has 
been reported to be more variable than that of stimulated saliva.157
Stimulated methods have included using citric acid, chewing paraffin wax, parafilm, 
washed rubber bands, chewing gum or sucking on teflon or a glass marble to stimulate 
saliva flow. Stimulated methods have been found not only to increase the volume of saliva, 
but also reduce the variability in pH and therefore less change in S/P ratio is observed. The 
use of parafilm, however, can cause some absorption to the stimulus and hence loss of 
drug158 and chewing gum can contain ingredients which may interfere with the assay.
Saliva samples from six cocaine users collected by stimulated and non-stimulated 
conditions were analyzed for cocaine and its metabolites. These samples showed that 
nonstimulated saliva contained more cocaine than stimulated samples most likely due to an 
increase in saliva pH as a result of the increased saliva flow rate.159
Codeine concentrations using different collection techniques were found to be highest for 
spitting. Saliva collected after chewing on gum gave the next highest concentrations and 
lower concentrations were detected after acidic stimulation.160
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A number of collection devices have been designed to facilitate collection using an 
absorbent pad or swab, such devices include Omni-Sal®, Salivette®, OraSure®, Accu- 
Sorb™. These collection devices have been found to have an influence on the amount of 
drug detected compared with saliva collected by spitting. Concentrations of 
tetrahydrocannabinol in a study in Belgium were higher in the salivette sample in 
comparison with the spitting saliva sample due to the presence of solid 
tetrahydrocannabinol in the mouth which was collected on the salivette.161 On the other 
hand codeine concentrations detected on the salivette were lower than that obtained by 
spitting.160
The method of saliva collection is therefore very important and must be taken into 
consideration when organizing saliva tests.
5.9.2 VOLUME
It has already been mentioned that the volume of saliva which an individual can produce 
will be affected by certain diseases or the administration of certain drugs. Alcohol is 
another factor that acts to reduce salivary flow.135
5.10 PRE-ANALYTICAL AND ANALYTICAL CONSIDERATIONS
5.10.1 FREEZING AND THAWING
A newly taken sample of saliva can be difficult to pipette due to the mucoproteins and 
mucopolysaccharides. However, after freezing and thawing, the sample is easier to handle 
due to the denaturation of such constituents.
5.10.2 CENTRIFUGATION
Centrifugation can help to separate protein. Also, studies have shown that the stability of 
tetrahydrocannabinol in centrifuged blank saliva is excellent but in non-centrifuged saliva 
stability was poor.
5.10.3 COLLECTION DEVICES
If collection devices are used then it is important to assess the use of these for a specific 
drug. In a study it was found that after centrifugation of the salivette, less than 1 % of 
tetrahydracannabinol was recovered from the cotton role. Therefore, an assessment of in 
vitro recovery of the drug is important.
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5.11 INTERPRETATION
5.11.1 DOSE-CONCENTRATION CORRELATIONS
A significant correlation was observed between saliva and plasma concentrations for 
codeine within an individual, but between individuals there was considerable variation.160
Early studies showed that the concentration of drugs in saliva was proportional to the 
concentration in plasma for some drugs including paracetamol,162 theophylline,163 
digoxin,164 amobarbital,165 phenytoin and phenobarbital,166 antipyrine, aminopyrine and 
phenacetin.167 A correlation was indicated for cocaine and phencyclidine168 concentrations 
in blood and saliva. However, poor correlations have been observed for 
tetrahydrocannabinol because it would appear that THC does not pass from plasma to 
saliva169 but is sequestered in the buccal cavity after smoking.
Candidates for salivary therapeutic drug monitoring are phenytoin, carbamazepine, 
theophylline, digoxin, cyclosporin.1
5.12 ANTIDEPRESSANTS IN SALIVA
The first reports into the analysis of tricyclic antidepressants in saliva involved the 
detection of amitriptyline, desipramine and nortriptyline for the purposes of therapeutic 
drug monitoring.
Correlations between blood and saliva concentrations of individuals who were 
administered desipramine were found to be good. However, correlations of saliva/blood 
ratios between individuals were poor. The authors concluded that if saliva/plasma ratios 
were determined for each patient then drug concentrations could be monitored using 
saliva.170
Other authors reported poor correlations between total plasma and saliva concentrations of 
amitriptyline and nortriptyline. However, saliva pH was not taken into account. The 
authors concluded that the plasma concentration may be predicted from those detected in 
saliva if saliva pH was taken into account.171,172
To date, there have been no other papers on the detection of antidepressants in saliva, 
including the newer, safer types which were developed after the tricyclic antidepressants.
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5.13 AIMS
The aim of this study was to validate the blood method for antidepressants in saliva and to 
apply it to samples obtained from single and chronic users of fluoxetine and paroxetine. 
Saliva collection was to be carried out using Omni-Sal® collection devices and by spitting 
in order to assess the relative merits of each technique.
5.14 EXPERIMENTAL
5.14.1 SALIVA COLLECTION
Saliva samples were collected using two methods. The first of these methods involved 
using Omni-Sal® collection devices. These consisted of an absorbent pad which was placed 
under the tongue until an indicator turned from white to blue, signifying that 1 ml of saliva 
had been collected. The collection device was then inserted into a tube containing 1 ml of 
buffer with 0.2 % sodium azide as preservative. The second collection method involved 
allowing the saliva to collect in the mouth and this was collected by spitting.
Blank saliva samples were collected from volunteers who were known not to have taken 
fluoxetine, paroxetine or other antidepressant treatment. Both methods were used to collect 
these samples.
Samples were refrigerated at - 4 °C until analysis was carried out.
5.14.2 SPIKING SALIVA
5.14.2.1 Omni-Sal® method
Blank saliva was squeezed from the absorbent pad which was in buffer using a plunger 
fitted with a filter so that as much of the liquid was removed from the pad as possible. 100 
pi of fluoxetine, norfluoxetine and paroxetine all at a concentration of 1 pg/ml in methanol 
were added to a clean test tube. The methanol was evaporated off under nitrogen at 40 °C 
and the blank saliva was poured into the test tube. This gave a spiked saliva sample with a 
concentration of 100 ng/ml of each drug. The sample was sonicated in an ultrasonic bath 
for 5 minutes. Saliva was spiked in a similar manner to give concentrations in the range of 
5 - 1 0 0  ng/ml.
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5.14.2.2 Spitting method
1 ml of saliva was pipetted into a test tube and fluoxetine, norfluoxetine and paroxetine 
were added at concentrations ranging from 5 - 1 0 0  ng/ml saliva. The samples were briefly 
vortex mixed.
Initially, the saliva was used without centrifugation or freezing and thawing and it was 
found to be difficult to handle. The viscosity and "stringy” nature of some samples made it 
difficult to pipette and also caused blockage o f solid phase extraction cartridges. After 
collection, the samples were frozen and thawed and then centrifuged to separate the 
"stringy" substance and oral debris from the rest o f the sample. This made it easier for the 
sample to be taken up by the pipette and also prevented further blockage of solid phase 
extraction columns.
5.14.3 RECOVERY STUDY OF EXTRACTION PROCEDURE FOR SALIVA
5.14.3.1 Extraction
The solid phase extraction method which was developed in Chapter 4 was used to extract 
the drugs from saliva. Initially five samples spiked to give a concentration of 100 ng/ml 
fluoxetine, norfluoxetine and paroxetine were extracted and the recovery of each was 
calculated using tumoxetine as the internal standard for fluoxetine and norfluoxetine and 
maprotiline as internal standard for paroxetine.
5.14.3.2 Results
The recoveries for norfluoxetine, fluoxetine and paroxetine were found to be 86.5, 98.4 
and 90.0 % respectively. The acetone-chloroform fractions were also analyzed and were 
shown to only contain a small percentage of the drugs, 1.7 % norfluoxetine, 0.5 % 
fluoxetine and 0 % paroxetine.
Since the blood extraction method also gave high recoveries for saliva samples this method 
was fully validated for these drugs in saliva using both the Omni-Sal® devices and the 
spitting collection methods.
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5.14.4 VALIDATION OF OMNI-SAL® METHOD
5.14.4.1 Linearity
Seven point calibration curves were produced with concentrations 5, 10, 15, 25, 50, 75, 
100 ng/ml saliva. Internal standards, tumoxetine and maprotiline were added to give 
concentrations 50 ng/ml and 25 ng/ml saliva. Each concentration was extracted five times. 
The mean ratios and correlation coefficients were calculated and displayed in Table 5.2.
Linear calibration graphs were obtained and coefficients of correlation for fluoxetine, 
norfluoxetine and paroxetine extracted standards were 0.998, 0.999 and 0.999 and x-axis 
intercepts were - 0.22382, - 0.01101 and - 0.0093 respectively.
Table 5.2: Intra-day Variation (Omni-Sal®)
Concentration 
(ng/ml saliva)
m/z 330/344 
NFLU/TUM (RSD %)
m/z 344/344 
FLU/TUM (RSD %)
m/z 525/445 
PAR/MAP (RSD %)
5 0.085 (8.9) 0.083 (10.9) 0.046 (7.9)
10 0.134 (6.2) 0.164 (2.7) 0.095 (6.8)
15 0.255 (3.9) 0.270 (8.3) 0.126 (5.8)
25 0.428 (5.8) 0.472 (5.1) 0.236 (4.9)
50 0.782 (1.4) 0.980 (5.1) 0.472 (6.6)
75 1.217(1.7) 1.409 (3.8) 0.752 <6.5)
100 1.680(1.2) 1.959 (6.5) 0.965 (3.7)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
5.14.4.2 Inter-day variation
The between-day variation was monitored by extracting the linearity curve on five different 
days over a period of two months. The relative standard deviation values were less than 
12 % for all cases (Table 5.3).
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Table 5.3: Inter-day Variation (Omni-Sal®)
Concentration 
(ng/ml saliva)
m/z 330/344 
NFLU/TUM (RSD %)
m/z 344/344 
FLU/TUM (RSD %)
m/z 525/445 
PAR/MAP (RSD %)
5 0.079(11.8) 0.087 (6.7) 0.050 (7.5)
10 0.127 (8.7) 0.172 (5.3) 0.096 (4.2)
15 0.241 (7.8) 0.272 (6.6) 0.136(9.2)
25 0.409 (5.6) 0.461 (6.9) 0.221 (7.0)
50 0.773 (8.1) 0.928 (7.3) 0.461 (10.8)
75 1.213(8.8) 1.434(1.9) 0.696 (9.5)
100 1.613(6.2) 2.026 (3.0) 0.947 (2.7)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
5.14.4.3 Recovery
A more extensive recovery study was carried out to cover the range of the calibration 
curve. Blank saliva was squeezed from the absorbent pad and spiked to give concentrations 
5 - 1 0 0  ng/ml. Each concentration was extracted five times and 50 pi o f tumoxetine and 
25 pi of maprotiline at 1 pg/ml was added after the extraction.
Table 5.4: Recovery of fluoxetine, norfluoxetine and paroxetine from spiked saliva
Concentration 
(ng/ml saliva)
% Recovery 
Norfluoxetine (RSD %)
% Recovery 
Fluoxetine (RSD %)
% Recovery 
Paroxetine (RSD %)
5 86.0 (8.6) 89.5 (9.3) 91.3 (4.8)
10 89.9 (4.5) 99.9(10.8) 92.4(10.3)
15 90.3 (7.2) 90.0 (6.6) 92.6 (6.4)
25 90.5 (5.5) 94.8 (3.3) 90.5 (5.4)
50 96.1 (4.9) 97.7 (2.8) 94.3 (3.4)
75 92.8(11.8) 94.5 (4.0) 90.9 (6.3)
100 91.9 (3.7) 97.1 (1.7) 92.8 (3.3)
RSD = relative standard deviation as a percent
Recoveries greater than 86 % for norfluoxetine, 89 % for fluoxetine and 90 % for 
paroxetine were achieved for all points on the linear calibration curve and the relative 
standard deviations were no higher than 12 %.
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5.14.4.4 Recovery of analytes from Omni-Sal swab
The method of collection of saliva can have an influence on the amount of drug detected in 
an individual at a specific time. As a result it is necessary to know the limitations of a 
device and the in vitro recovery of the drug is very important. The following experiment 
was carried out to test the recovery of the drugs from the device.
Blank saliva was collected from volunteers who were not receiving Prozac® or Seroxat® 
treatment. The saliva was collected by spitting into a plastic container. These samples were 
freezed and thawed and 6 ml samples were pipetted into plastic universals and spiked to 
give concentrations equivalent to 10, 50 and 100 ng/ml. The Omni-Sal® cotton swab was 
dipped into the saliva and removed when the indicator turned blue. The swab was placed in 
the buffer solution and the swab squeezed to give the saliva sample in buffer. These were 
then extracted and derivatized.
The results o f this experiment showed that the recovery from the swab was reproducible, 
but much lower than the recovery obtained from saliva spiked after being squeezed from 
the pad.
Table 5.5: Recoveries from Omni-Sal swab
Concentration % Recovery % Recovery % Recovery
(ng/ml saliva) Norfluoxetine (RSD %) Fluoxetine (RSD %) Paroxetine (RSD %)
10 25.6 (6.4) 29.7 (7.3) 23.2 (7.6)
50 24.2 (2.4) 29.1 (3.5) 23.3 (4.5)
100 25.1 (7.2) 30.4 (6.5) 26.3 (8.7)
RSD = relative standard deviation as a percent
The mean recovery of norfluoxetine, fluoxetine and paroxetine from the swab was found to 
be 25.0 %, 29.7 % and 24.3 % respectively. These recoveries were taken into account when 
case samples were analyzed and adjusted accordingly.
(lb5.14.4.5 Recovery of analytes from Omni-Sal swab after sonication in methanol
The recovery experiment in 5.14.4.4 was repeated for concentrations 50 and 100 ng/ml 
except this time the swab was rinsed with methanol and sonicated in an ultrasonic bath for
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10 minutes after it had been squeezed to remove the saliva/buffer mixture. This experiment 
was carried out to see if the recovery from the swab could be improved.
Table 5.6: Recoveries from Omni-Sal® swab after sonication in methanol
Concentration % Recovery % Recovery % Recovery .
(ng/ml saliva) Norfluoxetine (RSD %) Fluoxetine (RSD %) Paroxetine (RSD %)
50 59.2(1.3) 51.9 (4.7) 68.5 (4.3)
100 70.5 (5.9) 66.2 (3.3) 49.7(11.3)
This method was reproducible at both concentrations for each drug. Coefficients of 
variation were less than 6.0 % for fluoxetine and norfluoxetine and less than 12 % for 
paroxetine. However, the recoveries at the different concentrations were not reproducible. 
There were differences of 11 -  19 % in recovery at the two different concentrations. These 
variations may be a result of the swab being squashed and therefore access of methanol to 
the bound drug may be hindered more in some cases than in others. A larger volume of 
methanol and a longer period of sonication could help to release a higher percentage of 
each drug. However, this would increase the length o f time of the step.
5.14.4.6 Limit of Detection and Quantitation
Saliva samples were spiked to give concentrations 1.0, 0.5, 0.3, 0.2 and 0.1 ng/ml saliva. 
The limit of detection was defined as the concentration of drug giving a signal to noise 
ratio of 3. This was found to be 0.1 ng/ml for the analytes. The limit of quantitation was 
defined as the concentration of drug giving a signal to noise ratio of 5 and this was found 
to be 0.2 ng/ml for all analytes.
5.14.4.7 Blank saliva controls
Blank saliva controls were extracted to make sure that no constituents in the sample 
coeluted or interfered with the analytes. The extracts were initially analysed by fullscan 
GC/MS and then by selected ion monitoring.
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5.14.5 VALIDATION OF SPITTING METHOD
5.14.5.1 Linearity
1 ml aliquots of saliva were spiked to give concentrations equivalent to 5, 10, 15, 25, 50, 
75, 100 ng/ml saliva. Internal standards, 50 ng of tumoxetine and 25 ng of maprotiline 
were added. Each concentration was extracted five times and calibration graphs of each 
compound were produced. The mean ratios and correlation coefficients were calculated 
and displayed in Table 5.7.
Table 5.7: Intra-day Variation (Spitting)
Concentration 
(ng/ml saliva)
Mean m/z 330/344 ratio 
NFLU/TUM (RSD %)
Mean m/z 344/344 ratio 
FLU/TUM (RSD %)
Mean m/z 525/445 ratio 
PAR/MAP (RSD %)
5 0.096(14.1) 0.130(4.8) 0.045 (10.8)
10 0.224(12.4) 0.246 (6.3) 0.089 (6.3)
15 0.345 (9.2) 0.360 (3.9) 0.133(0.9)
25 0.591 (10.9) 0.599 (4.4) 0.217(1.7)
50 1.171 (4.1) 1.23 (4.7) 0.452 (4.1)
75 1.958 (5.7) 1.924 (2.2) 0.696 (2.2)
100 2.633 (3.5) 2.585 (6.4) 0.923 (3.2)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
Coefficients of correlation for fluoxetine, norfluoxetine and paroxetine extracted standards 
were 0.999, 0.998 and 0.999 and x-axis intercepts - 0.0265, - 0.064 and - 0.0068 
respectively.
5.14.5.2 Inter-day variation
The linearity curve was extracted five times over a period of two months in order to assess 
the inter-day variation of the method. The relative standard deviation values were less than 
14 % for all cases (Table 5.8).
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Table 5.8: Inter-day Variation (Spitting)
Concentration 
(ng/ml saliva)
Mean m/z 330/344 ratio 
NFLU/TUM (RSD %)
Mean m/z 344/344 ratio 
FLU/TUM (RSD %)
Mean m/z 525/445 ratio 
PAR/MAP (RSD %)
5 0.112(13.5) 0.114(13.4) 0.042(13.0)
10 0.228 (4.0) 0.241 (5.9)' 0.095 (5.2)
15 0.350 (3.5) 0.330(12.2) 0.141 (7.5)
25 0.613(9.6) 0.585 (6.4) 0.208 (6.8)
50 1.219(9.3) 1.110(9.4) 0.497 (9.5)
75 1.963 (5.2) 1.839 (13.6) 0.695 (9.8)
100 2.491 (6.3) 2.389 (9.7) 0.966 (4.5)
NFLU = norfluoxetine, FLU = fluoxetine, TUM = tumoxetine 
RSD = relative standard deviation as a percent
5.14.5.3 Recovery
A recovery study was carried out to cover the range of the calibration curve. Blank saliva 
was spiked to give concentrations 5 - 1 0 0  ng/ml. Each concentration was extracted five 
times and 50 pi of tumoxetine at 1 pg/ml and 25 pi of maprotiline at 1 pg/ml were added 
after the extraction.
Recoveries greater than 90 % were obtained for all three analytes over the linear 
concentration range and relative standard deviations were all less than 12 %.
Table 5.9: Recovery of fluoxetine, norfluoxetine and paroxetine from spiked saliva
Concentration 
(ng/ml saliva)
% Recovery 
Norfluoxetine (RSD)
% Recovery 
Fluoxetine (RSD)
% Recovery 
Paroxetine (RSD)
5 90.5 (9.6) 91.0(11.6) 95.2 (9.3)
10 90.7 (3.7) 96.6 (3.9) 96.4 (4.4)
15 95.2 (7.4) 91.6(11.2) 94.2 (6.9)
25 96.6 (9.0) 96.9 (7.2) 96.5 (4.6)
50 97.8 (5.7) 98.4 (4.8) 90.6 (9.4)
75 95.5 (2.5) 97.8 (3.8) 93.4 (8.3)
100 98.1 (4.2) 95.8 (5.7) 96.0 (5.8)
RSD = relative standard deviation
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5.14.5.4 Limit of Detection and Quantitation
Limit of detection and quantitation were defined as in 5.13.4.6 and these were found to be
• (R)the same as the Omni-Sal method.
5.14.5.5 Blank saliva controls
Blank saliva controls which were extracted and run on fullscan showed that there were no 
interfering peaks arising from the saliva matrix.
5.15 CONCLUSIONS
The solid phase extraction method developed to extract fluoxetine, norfluoxetine and 
paroxetine from blood also successfully extracted these analytes from saliva. Saliva 
samples were collected by two methods, spitting and with Omni-Sal® devices and both 
methods were fully validated. The largest difference in the two collection methods was in
(R)the recovery. In-vitro recovery from the Omni-Sal swab was found to be reproducible, but 
much lower than the recovery obtained from the sample collected by spitting. This low 
recovery is a result of the analytes not being completely removed from the swab. 
Sonication of the swab in methanol for a period of 10 minutes removed a higher 
percentage of the drugs from the swab. Also, when the saliva is squeezed from the swab, 
100 % of the sample will not be obtained. When using this device to collect samples it is 
therefore necessary to know its limitations and careful interpretation of data is required 
when analyzing saliva samples which have been collected by this method. Both collection 
methods were used to analyze case samples for fluoxetine and paroxetine.
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6 Antidepressants in Hair
6.1 INTRODUCTION
One of the major advantages of using hair as a biological matrix for drug testing is that 
drugs are accumulated and stored in the hair shaft for a long time. This led investigators to 
believe that it may be possible to use hair analysis for compliance monitoring as an 
alternative to blood or urine testing. However, one of the main criteria for this is that there 
is a correlation between the administered dose and the drug concentration in hair.
The reports which have been published providing information on certain drugs and 
compliance monitoring have proved controversial. Some papers have reported correlations 
for drugs such as amitriptyline,173 carbamazepine174 and haloperidol175 whilst others have 
reported no correlation largely due to inter-individual differences in drug incorporation 
into hair.176 Consequently, hair analysis cannot be used for compliance monitoring.
However, hair analysis can be used to assess the constant use of a drug by an individual. If 
an individual is prescribed a constant daily dose of a drug then the measured levels 
incorporated into that individual’s hair should remain relatively constant along the length 
of the sample.
Depression is one of the most common mental disorders in the world today. Treatment can 
be carried out with antidepressants, by psychotherapies or a combination of both. As a 
result, antidepressants have become one of the most commonly prescribed drugs 
worldwide.177 Many different groups of people including geriatric patients, prisoners and 
drug addicts are prescribed antidepressants at sometime or other. In some of these cases 
supervision of drug taking is possible, for example in geriatric hospitals. However, for the 
majority of people who are prescribed these drugs supervision is not possible and they are 
assumed to be taking them as prescribed by their general practitioner. In reality, some 
people do not like to be reliant on these drugs and stop taking them. Hair testing can 
provide information on compliance with the use of such drugs.
Also, the incorporation of prescription drugs into hair may be useful in forensic cases, for 
example, in cases involving decomposed or skeletal remains where identification may be 
difficult.
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A history of drug use in hair can provide information corresponding to a patient’s drug 
history as given in medical records.
6.2 ANALYSIS
Tricyclic antidepressants, amitriptyline, nortriptyline and imipramine were identified in the 
hair of psychiatric patients who had been on long-term treatment with these 
antidepressants.178 Amitriptyline, nortriptyline and clomipramine were detected in 
postmortem hair samples at concentrations o f 0.42 ng/mg, 0.91 ng/mg, and 
0.37 - 0.79 ng/mg respectively.179 A study was conducted on sixty hair samples taken from 
patients receiving amitriptyline treatment to assess the possibility of using hair 
concentrations to monitor patients' therapeutic compliance. Hair concentrations of 
amitriptyline were found to range from 0 - 17.21 ng/mg. Correlation between dose and 
concentration was not good enough to estimate an individual's therapeutic compliance.173 
These methods all used alkaline hydrolysis to solubilize the hair and liquid-liquid 
extraction to remove the drugs from the matrix.
In another study, amitriptyline, nortriptyline, doxepin, dothiepin, imipramine, mianserin 
and trimipramine were detected in postmortem hair samples.55, 180 Comparisons were made 
of methods involving solubilization of hair using sodium hydroxide solution, dilute 
hydrochloric acid, methanol or subtilisin Carlsberg. Stability studies indicated that 
nortriptyline degraded slightly in strong alkaline conditions, but the other antidepressant 
drugs showed no significant losses. The acidic, methanolic and enzymatic methods were 
shown to be less effective than the alkaline method at recovering antidepressants from case 
hair samples. Recoveries of the acidic, enzymatic and solvent methods were given as a 
percentage of the alkaline method and these were 49 %, 51 % and 21 % respectively.101 
Concentrations detected in hair were in the range 3.5 - 34 ng/mg for amitriptyline, 
3.8 - 9.2 ng/mg for nortriptiline, 7.7 - 87 ng/mg for doxepin, 6.7 - 137 ng/mg for dothiepin, 
104 ng/mg for imipramine and 9.2 ng/mg for mianserin.55
Tricyclic antidepressants, amitriptiline, clomipramine, doxepine, imipramine and 
maprotiline were detected in human hair. Concentrations varied between 0.4 and 40 ng/mg 
for the drugs. In the majority of cases the nor-metabolites were found to accumulate less in
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the hair than the parent drug. No correlation between the administered dose and the 
concentration found in hair was established.181
Doxepin and its metabolite, desmethyldoxepin were extracted from hair samples by acidic 
hydrolysis followed by solid phase extraction. GC/MS was used to detect the analytes and 
concentrations varied from 0.09 - 0.59 ng/mg for doxepin and 0.04 - 0.40 ng/mg for 
desmethyldoxepin within a segmented hair sample obtained from a patient receiving a 
25 mg daily dose. The metabolite concentrations was always less than that of the parent 
drug.182
Fluoxetine, clomipramine, amitriptyline and moclobemide were included in a screening 
procedure used to identify and quantify a wide range of drugs in human hair. The method 
involved acidic hydrolysis of hair followed by solid phase extraction on a C l8 phase. 
Analysis was carried out using GC/MS and recovery of fluoxetine was found to be 86 %. 
A presented case sample showed the presence of 4.3 ng/mg of fluoxetine.183
Fluoxetine has also been detected in the hair of rats. Male rats were injected with 10 mg/kg 
fluoxetine for 15 consecutive days and hair samples were shaved from the neck area on 
days five and fifteen. The hair was digested using sodium hydroxide and heated at 56 °C 
for 2 hours. Liquid-liquid extraction was used to clean up the digested supernatant and 
samples were derivatized with pentafluoropropionic anhydride. Fluoxetine concentrations 
were found to be 9.96 ng/mg and 1.12 ng/mg for days five and fifteen respectively.184
The active metabolite, norfluoxetine was not sought for in either of these fluoxetine 
studies.
6.3 AIM
The purpose of this study was to develop a reliable method to extract selective serotonin 
reuptake inhibitor antidepressants, fluoxetine, its metabolite, norfluoxetine and paroxetine 
from hair and to apply the method to case samples to find if  a correlation between dose and 
concentration exists between individuals and within an individual. These concentrations 
were to be compared with those detected in the nails of the individuals supplying the hair 
samples. Ethical approval was obtained for this study.
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6.4 EXPERIMENTAL
6.4.1 CHEMICALS
Fluoxetine, norfluoxetine and internal standard, tumoxetine were obtained as 
hydrochloride salts from Eli Lilly (Windlesham, England). Paroxetine hydrochloride was 
obtained from SmithKline Beechams (Herts, England) and maprotiline from Promochem 
(Herts, England).
6.4.2 STANDARDS
Stock standard solutions of fluoxetine, norfluoxetine, tumoxetine, paroxetine and 
maprotiline were prepared in methanol at a concentration of 1 mg/ml and stored at - 20 °C. 
Each of these stock solutions was diluted with methanol to give working standard solutions 
at 1 pg/ml and 10 pg/ml which were refrigerated at 4 °C.
6.4.3 SOLUTIONS AND BUFFERS 
0.1 M Potassium Phosphate buffer, pH 6
6.81 g of potassium dihydrogen phosphate (FW=136.09) was dissolved in 450 ml distilled 
water. The pH was increased to 6 with 1 M potassium hydroxide solution and this was 
made up to 500 ml with distilled water.
p-glucuronidase solution
Crude P-glucuronidase solution, type helix pomatia (132 500 units/ml) was diluted with 
phosphate buffer in the ratio 1:4 and vortex mixed briefly.
6.4.4 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
A ThermoQuest Trace GC with a Finnigan Trace MS was used to analyze samples. The 
GC was fitted with a HP-5 column, 30 m x 0.25 mm x 0.25 pm film thickness and the 
temperature programme was set from 150 to 270 °C at 10 °C / min. The injector 
temperature was 280 °C and the carrier gas was helium. The temperature o f the source and 
interface were 200 °C and 250 °C respectively. The emission current was 350 pA. lp l was 
injected.
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Ions monitored were m/z 240 and 344 for fluoxetine and tumoxetine, m/z 226 and 330 
for norfluoxetine, m/z 388 and 525 for paroxetine and m/z 445 and 446 for maprotiline. 
Ions marked * were used for quantitation.
6.4.5 DECONTAMINATION OF HAIR
Blank hair was obtained from a volunteer of Malay-Chinese origin. Hair was cut finely 
into 1-2 mm pieces with scissors and decontaminated using several sequential wash 
procedures:
(iv) One ten minute wash with sodium dodecyl sulphate solution (0.1 %).
(v) Three ten minute washes with distilled water.
(vi) Three five minute washes with methanol.
Each step was sonicated in 5 ml of solvent and then the solvent was decanted. The washed 
hair was dried in an oven at 40 °C and used for blank controls and for spiking with the 
drugs o f interest.
6.4.6 SPIKING HAIR
Blank washed hair was spiked in bulk with fluoxetine, norfluoxetine, and paroxetine in 
methanol to give standards equivalent to 5 ng/30 mg, 10 ng/30 mg, 25 ng/30 mg, 
50 ng/30 mg, 75 ng/30 mg, 100 ng/30 mg and 200 ng/30 mg. The samples were ultra­
sonicated at room temperature for 15 minutes and the methanol was allowed to evaporate 
off at room temperature.
6.4.7 EXTRACTION OF ANTIDEPRESSANTS FROM SPIKED HAIR
Twelve 30 mg portions of hair spiked to give concentration 100 ng/ 30 mg were weighed 
out accurately. Four sets of three samples were treated by methanolic treatment, acid 
hydrolysis, alkaline hydrolysis or enzyme hydrolysis as described below. All of the 
samples were then extracted by solid phase extraction.
6.4.7.1 Methanolic treatment
1 ml o f methanol was added to 30 mg of spiked hair and this was incubated for 18 hours at 
45 °C. The sample was allowed to cool and the methanol was transferred to a vial and 
0.5 ml methanol was added to hair, sonicated for 5 minutes and combined with the first 
fraction.
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6.4.7.2 Hydrochloric acid hydrolysis
Hydrochloric acid (1 ml, 0.1 M) was added to 30 mg spiked hair and incubated for 12 
hours at 45 °C. The sample was allowed to cool and 1 ml, 0.1 M sodium hydroxide 
solution was added to neutralize the acid. 2 ml of phosphate buffer was added and the tube 
shaken briefly. The solution was transferred to a clean test tube by pipette. The hair was 
washed with 1 ml phosphate buffer and this was combined with the first fraction.
6.4.7.3 Sodium hydroxide hydrolysis
Sodium hydroxide (1 ml, 1 M) was added to 30 mg spiked hair and this was incubated at 
80 °C for 30 minutes or until the hair had completely dissolved. This was allowed to cool 
and 1 ml of hydrochloric acid (1 M) was added to neutralize the alkali. Phosphate buffer 
(2 ml) was added to the solution.
6.4.7.4 (3-glucuronidase hydrolysis
Phosphate buffer (1 ml) was added to 30 mg spiked hair followed by 50 pi p-glucuronidase 
solution. This was incubated for 2 hours at 45 °C. The sample was allowed to cool and the 
solution was transferred to a clean test tube. The hair was washed with a further 2 ml 
phosphate buffer, sonicated for 5 minutes and this was combined with the first fraction.
6.4.7.5 Solid Phase Extraction
Each of the above treated samples was subsequently extracted by solid phase extraction. 
The procedure used to extract opiates and methadone from hair provided clean extracts 
using ZSDAU020 Clean Screen columns. This method was tested for the extraction of 
antidepreSsants from hair.
World Wide Monitoring Clean Screen® columns (ZSDAU020) were conditioned with 3 ml 
o f methanol, followed by 3 ml of distilled water and then 1 ml phosphate buffer. The 
samples were applied to the columns at 2 ml/min which were then washed with 2 ml 
distilled water, 2 ml 0.1 M hydrochloric acid and 3 ml methanol. The columns were dried 
under full vacuum for 10 minutes and the drugs were eluted with 4 ml of 
dichloromethane/isopropanol/concentrated ammonia (78:20:2). The solvent was 
evaporated to dryness and internal standards, tumoxetine and maprotiline were added
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(100 ng of each) and the methanol evaporated. The residue was derivatized with HFBA as 
previously described.
The samples were injected into the GC/MS (1 pi) along with unextracted standards at 
concentration 100 ng/50 pi.
6.4.7.6 Results
Recoveries using the four methods on spiked hair samples showed that the methanol based 
method gave the highest recoveries followed by the acid hydrolysis, then p-glucuronidase 
and then alkaline hydrolysis (Table 6.1).
Table 6.1: Recoveries of extraction methods on spiked hair
% Recovery (RSD)
Method Fluoxetine Norfluoxetine Paroxetine
1 Methanol extraction 92.2 (7.5) 95.4 (9.4) 86.5 (2.5)
Acid hydrolysis 87.2 (4.1) 85.1 (1.3) 80.8 (6.3)
Alkali hydrolysis 80.1 (4.6) 82.0 (4.3) 73.2 (7.9)
Enzyme hydrolysis 84.8 (7.7) 85.7 (4.5) 85.7(10.8)
RSD = Relative standard deviation
However, these recoveries are only an indication of the extraction method since the hair 
was spiked and the drugs were not actually embedded within the hair shaft. For a more 
realistic indication of the efficiency of the extraction method, the technique had to be 
tested on a real case sample.
Blank extracts from each method were run on the GC/MS using fullscan. The alkali 
hydrolysis and enzyme methods provided less clean extracts than the other two methods. In 
the case o f the alkali hydrolysis this is due to the complete dissolution of the hair matrix. 
The other two methods were comparable. For this reason, it was decided to compare the 
methanol and hydrochloric acid methods using a real case sample. Lack of sample 
prevented all four methods being tested. The use of these less extreme methods could also 
allow the possibility of using this method to screen for other drugs which may be unstable 
in harsh alkaline conditions.
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6.4.8 COMPARISON OF METHANOL EXTRACTION AND ACID HYDROLYSIS 
Two postmortem hair samples were taken from a fluoxetine user (Case HF/1) and a 
paroxetine user (Case HP/1). The hair samples are described below.
Case HF/1: Hair sample was 16.5 cm long. The first 1.5 cm from root end was naturally
brown in colour and rest of length was bleached blond.
Case HP/1: Hair sample was 11.5 cm long and naturally dark brown.
6.4.8.1 Case HF/1
The roots were cut off (0.5 cm) and the rest of the hair was segmented into 1 cm segments. 
For this experiment segments 1 (0.5-1.5 cm) and 2 (1.5-2.5 cm) were selected since these 
had no bleaching and minimum amount of bleaching on them respectively. These were 
washed using the decontamination protocol (see 6.4.5) and the methanolic washes were 
analyzed. Washes were carried out until no drug was detected in the final wash. Segments 
1 and 2 were split into two fractions for analysis by methanolic extraction and acidic 
hydrolysis. The weights of each fraction are shown in Table 6.2.
Table 6.2: Weight of hair samples
Case, Segment Methanol extraction Acid hydrolysis
Weight (mg) Weight (mg)
HF/1, 0.5-1.5 cm 9.01 9.35
HF/1, 1.5-2.5 cm 9.48 9.07
HP/1, 0.5-2.5 cm 9.72 9.70
6.4.8.2 Case HP/1
The roots were cut off (0.5 cm) and the rest of the hair was segmented into 2 cm segments. 
These larger segments were chosen because the sample was not nearly as thick as the 
previous one. Using 1 cm segments may have prevented detection due to lack of sample. 
Segment 1 (0.5-2.5 cm) was selected for this experiment. This was washed using the 
decontamination protocol and the methanolic washes were analyzed. Washes were carried 
out until no drug was detected in the final wash. The segment was split into two fractions
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for analysis by methanolic extraction and acidic hydrolysis. The weights of each fraction 
are shown in Table 6.2.
The samples were extracted as previously along wijh blank and spiked samples at 
concentrations 5 ng/30 mg, 10 ng/30 mg, 25 ng/30 mg, 50 ng/30 mg, 75 ng/30 mg, 
100 ng/30 mg and 200 ng/30 mg.
6.4.8.3 Results
Fluoxetine and norfluoxetine were detected in the first two methanol wash fractions of case 
HF/1, but neither was detected in the third wash fraction. No paroxetine was detected in 
the washes of case HP/1. Calibration graphs were constructed for the three analytes by the 
two extraction methods and for unextracted standards. The results are displayed in 
Table 6.3.
Table 6.3: Linearity for spiked hair samples
I Fluoxetine Norfluoxetine Paroxetine
Methanol y -  mx + c 1 y = 0.020x - 0.033 
R2 0.999
y = 0.017x - 0.066 
0.994
y = 0.005x + 0.029 
0.995
Acid y = mx + c 
R2
y = 0 .019x- 0.038 
1.000
y = 0 .016x- 0.001 
0.992
y = 0.006x + 0.010 
0.998
unextracted y = mx + c 
R2
y = 0 .0 1 9 x -0.059 
0.999
y = 0 .0 1 4 x -0.027 
0.997
y = 0.007x + 0.017 
0.995
Analysis of the two case samples showed that the acid based method provided higher 
recoveries of fluoxetine, norfluoxetine and paroxetine from hair than the methanolic 
method. In the fluoxetine case the acidic method improved the recovery by a factor of 4 
for norfluoxetine and 2.5 for fluoxetine and in the paroxetine case it improved the recovery 
by a factor of 2.5. The results of the extractions are given in Table 6.4.
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Table 6.4: Concentrations of analytes from hair by methanol and acid methods
Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Paroxetine
(ng/mg)
Methanol HF/1, 0.5-1.5 cm 2.36 2.57 - ve
HF/1, 1.5-2.5 cm 2.28 2.17 - ve
HP/1,0.5-2.5 cm - ve - ve 0.17
Acid HF/1, 0.5-1.5 cm 5.55 10.92 - ve
HF/1, 1.5-2.5 cm 6.35 8.41 - ve
HP/1,0.5-2.5 cm - ve - ve 0.43
For the fluoxetine case sample, concentrations of fluoxetine and norfluoxetine were similar 
when extracted by the methanol method but norfluoxetine was much higher than fluoxetine 
when the acid hydrolysis was used. A further experiment was conducted to ensure that 
none of the fluoxetine has been hydrolyzed to norfluoxetine using this method.
6.4.9 RECOVERY OF FLUOXETINE AND NORFLUOXETINE AFTER ACID 
HYDROLYSIS
An initial recovery study of the acidic method was carried out. Three vials were spiked 
with 50 ng of fluoxetine and 50 ng of norfluoxetine, another three vials with 50 ng of 
fluoxetine only and a further three vials with norfluoxetine only. 1 ml of 0.1 M 
hydrochloric acid was added to each vial and incubated in the oven for 12 hours at 50 °C. 
The samples were further treated as previously mentioned in 6.4.7.5.
Table 6.5: Recoveries of fluoxetine and norfluoxetine after acidic hydrolysis
% Fluoxetine % Norfluoxetine
Fluoxetine and norfluoxetine 94.9 95.7
Fluoxetine only 96.4 -
Norfluoxetine only - 96.2
Recoveries were high for both analytes and the acid method did not appear to cause any 
chemical alteration of the drugs. The acid hydrolysis method was chosen for all further 
extractions.
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6.4.10 METHOD VALIDATION
6.4.10.1 Intra-day variation
Each calibration concentration, 5 ng/30 mg, 10 ng/30 mg, 25 ng/30 mg, 50 ng/30 mg, 75 
ng/30 mg, 100 ng/30 mg and 200 ng/30 mg was extracted five times to calculate the intra­
day variation of the assay. Ratios of drug to internal standard are displayed in Table 6.6 
along with the coefficient of variation in parenthesis. Values of correlation coefficient, R 
and intercept and slope values for regression equations are displayed in Table 6.7.
Table 6.6: Intra-day variation
Concentration 
(ng/30 mg hair)
Mean FLU/TUM ratio 
m/z 344/344 (RSD %)
Mean NFLU/TUM ratio 
m/z 330/344 (RSD %)
Mean PAR/MAP ratio 
m/z 525/445 (RSD %)
5 0.069 (5.7) 0.090(10.1) 0.028 (7.9)
10 0.148 (6.9) 0.165 (9.8) 0.054 (8.8)
25 0.410(6.6) 0.419(7.7) 0.158(5.4)
50 0.813(6.3) 0.724 (4.8) 0.339 (4.3)
75 1.266 (5.8) 1.233 (5.2) 0.488 (6.2)
100 1.787(4.3) 1.778 (7.9) 0.653 (4.8)
200 3.721 (6.6) 3.595 (3.4) 1.228 (5.3)
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine, TUM = tumoxetine, MAP = maprotiline 
RSD = relative standard deviation as a percent
Table 6.7: Linear Regression Values
Fluoxetine Norfluoxetine Paroxetine 1
R2 0.9987 0.9971 0.9981
Intercept - 0.0726 -0.0585 0.0099
Slope 0.0188 0.0181 0.0062 1
6.4.10.2 Inter-day variation
The calibration curve was extracted over five different days and the inter-day variation was 
assessed and displayed in Table 6.8.
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Table 6.8: Inter-day variation
Concentration 
(ng/30 mg hair)
Mean FLU/TUM ratio 
m/z 344/344 (RSD)
Mean NFLU/TUM ratio 
m/z 330/344 (RSD)
Mean PAR/MAP ratio 
m/z 525/445 (RSD)
5 0.077(11.0) 0.084 (6.4) 0.032 (9.8)
10 0.172 (9.6) 0.154 (6.4) 0.069 (12.2)
25 0.438 (8.3) 0.377 (9.8) 0.168(5.7)
50 0.884 (6.1) 0.813 (11.8) 0.336 (8.8)
75 1.355 (4.3) 1.240(11.5) 0.507(11.3)
100 1.857 (4.0) 1.772 (8.4) 0.679 (9.2)
200 3.894 (4.7) 3.444 (7.5) 1.269 (8.1)
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine, TUM = tumoxetine, MAP = maprotiline 
RSD = relative standard deviation
6.4.10.3 Limit of Detection (LOD)
Hair was spiked to give concentrations 1, 0.5 and 0.1 ng/30 mg. These were extracted and 
analyzed by GC/MS to find out the limit of quantitaion and detection. 1.0 ng/30 mg was 
easily quantified for all drugs. All were detected at concentration 0.5 ng/30 mg, but none at 
0.1 ng/30 mg.
6.5 CONCLUSIONS
Extraction of fluoxetine and paroxetine from spiked hair samples was carried out using 
alkaline hydrolysis, enzyme hydrolysis, acid hydrolysis and methanol extraction. As a 
result of complete dissolution of hair, it was shown using fullscan analysis that alkaline 
hydrolysis provided less clean extracts than the other three methods. Acid hydrolysis and 
methanol methods were compared using a real case sample to indicate which method 
provided the highest recovery from hair. The acidic method provided fluoxetine, 
norfluoxetine and paroxetine concentrations 2.5, 4 and 2.5 times respectively higher than 
those detected using the methanol method. The acidic method was successfully validated 
for fluoxetine, its metabolite and paroxetine and used to extract these antidepressants from 
hair case samples.
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7 Antidepressants in Nails
7.1 INTRODUCTION
Nails have been used to detect poisons for the past two centuries. Elemental analysis of 
nails has been investigated for various reasons. Cadmium, copper, lead, zinc, iron and 
magnesium have been detected in the nails of children for the purpose of environmental 
exposure,185, 186 lead in the nails of smelt workers for occupational exposure187 and mercury 
in the nails for dental, industrial, domestic and medical exposure.188 Arsenic has been 
detected in forensic cases.189, 190, 191 Nail analysis has also been investigated for therapeutic 
drug monitoring of the drug haloperidol.192 Drugs of abuse which have been investigated 
in nail to date have included amphetamine193, 194, 195, cocaine196, 197, 198 cannabinoids199, 200 and 
opiates.201 The methods used for analysis of these drugs will be discussed later.
Nail as a biological specimen for drug analysis has similar advantages to hair analysis. 
Collection is non-invasive, it can provide a longer record of drug use than conventional 
fluids and the stability of the matrix means that drugs can be retained over long periods of 
time. In cases where decomposed remains are involved, conventional fluids may produce 
negative results due to the instability of the drugs in these fluids or there may be not be any 
fluids to analyze. Nail analysis can be used as an alternative to hair for the detection of 
chronic drug use. The samples can be easily stored and transported without special 
requirements such as refrigeration and one added advantage over hair analysis is that bias 
resulting from different amounts of hair pigment is not an issue with nails.
7.2 THE NAIL AND SURROUNDING COMPONENTS
The nail plate has a complex chemical structure made up of keratin cells which are closely 
packed together. Along the length of the plate on the outer and inner surfaces are parallel 
striations, fine ones on the outer surface and thicker ones on the inner surface. The nail bed 
consists of soft tissue which lies beneath the nail plate and its surface mirrors that o f the 
inner surface of the nail plate. The proximal part of the nail is set into a depression on the 
dorsal surface and it is this part of the nail which separates the dorsal and ventral matrices 
which make up the nail fold. The skin on the dorsal surface of the nail fo ld  is called the 
nail wall from which a thin membrane, the eponychium (cuticle) emerges onto the dorsum
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of the nail. The lunula, a white convex shaped area extends from the eponychium and may 
or may not be present on all digits. The hyponychium lies beneath the distal nail, in 
between the continuous nail bed and epidermis which covers the ventral surface of the 
digits (Figure 7.1).202,203
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Figure 7.1: Structure of the nail (Copyright © American Society for Surgery of the Hand, 
1980)
The mature nail consists of three layers: the dorsal nail, the intermediate nail and ventral 
nail which are formed in different regions of the nail fold by different processes.203
7.3 COMPOSITION OF NAILS
Nails are primarily made up of a substance called keratin, which is a complex mixture of 
proteins. Other keratin containing substances include hair, claws, feathers, scales and 
hooves. Substances containing keratin are naturally insoluble, pliable and durable.
Keratin can exist in a soft or hard form. The former is present in stratum comeum, corns, 
callouses and the eponychium of nails whilst the latter occurs in hair, nails, claws, beaks 
and quills. These forms have different compositions, the hard keratins containing more 
sulphur than the soft ones.204
7.4 NAIL FORMATION
There have been conflicting views as to whether the nail is produced solely by the nail 
matrix or if the nail bed contributes to the nail formation. Initial studies into nail 
production led scientists to believe that the nail matrix was the sole origin of nail 
production.205 Further investigations using a silver protein staining method suggested that 
the nail was made up of three layers produced by a combination of the matrix, the bed and
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the proximal nail fold.206 Other studies later supported this work.207, 208,209 A thioflavin T- 
fluorochroming technique provided evidence that the three nail layers were developed 
from different sites.210 However despite these results, conclusions were drawn from 
radioautographic experiments that the matrix was the only source of nail formation.211 
Glycine-labelled cells were traced from the matrix into the plate, but none were traced 
from the proximal nail fold or nail bed to the plate. Other authors also used 
radioautography to label cells.212 They found that labelled cells were not present in the nail 
bed after one hour, but were present after one and two week intervals. This was explained 
to be the result of cell migration from the nail matrix to the nail bed.
A more recent study has shown that only 80 % o f nail was produced by the germinal 
matrix of the lunula and that 20 % was produced by the nail bed.213 These authors found 
that nail thickness and mass increased along the length of the nail indicating that the nail 
bed must contribute to the formation of the nail plate. In a further study, it was concluded 
that nail is continuously formed along the length o f the nail as it grows out. These findings 
provide a source of entry of drugs into the distal nail plate and provided an explanation for 
the rapid access of antifungal drugs into the nail plate.214
7.5 DRUG INCORPORATION INTO NAILS
The mechanism of drug incorporation into nails is not fully understood, but it is believed 
that drugs are incorporated into the cells which form nails. In light of recent evidence into 
the formation of the nail this would mean that drugs are incorporated into cells producing 
the nail matrix and the nail bed. Rapid access to the distal nail would arise from 
incorporation of drugs into cells forming the nail bed.214
Other possible routes o f drug incorporation could be through environmental contamination 
and biological fluids such as sweat, urine, saliva and sebum.
Drug properties which influence incorporation o f drugs into hair such as lipophilicity, 
basicity and structural factors and the composition of matrix may also play a role in the 
incorporation of drugs into nails.
Chapter 7: Antidepressants in Nails Page 108
7.6 NAIL GROWTH
Complete growth from the production in the nail fold to the free margin has been reported 
differently by several authors as 130 - 160 days215, 70 - 138 days216 and 1.5 inches per 
year.217 Growth rate differs depending on a number of factors. It has been reported that the 
growth rates of the five digits on an individual’s hand are different and that the third digit 
has been found to be consistently greater and the little finger nail consistently lower than 
that of the others. Age plays a large part in nail growth and has been reported to be highest 
for those between 3 and 30 years. Above 30 years, rate is inversely proportional to age. 
Below 3 years and above 80 years growth rate is lowest.217 In another study using Japanese 
subjects it was reported that nail growth was most rapid in the first two decades of life and 
decreased steadily thereafter. Growth was also affected by the season, faster in summer 
than in winter and has been found to be more rapid in nail biters.218
Injury to the nail has been reported to alter the thickness of the nail over 100 days of 
growth and the speed of nail growth was also altered.219 Fingernails have been shown to 
grow faster than toenails by a ratio of 4 to 1.216
7.7 COLLECTION OF NAILS
The considerations which are necessary when collecting nail samples are the location from 
which the nail is taken. Is the sample fingernail or toenail and from which digit was the 
sample taken? Also, the sample should be taken with clean, non-contaminated scissors or 
clippers. In reality if several samples are being taken at once from different people it may 
not be convenient to wash these tools in between samples. To prevent the possibility of 
contamination between samples a new pair of scissors or clippers should be used.
7.8 ANALYSIS
Nail analysis for drugs involves four steps similar to hair analysis.
7.8.1 DECONTAMINATION
Prior to extraction, nail specimens should undergo a decontamination protocol to ensure 
that any external drug material along with extraneous material such as dirt are removed. 
This procedure should remove any drug bound to the outer surface without removing drug 
from within the nail. Wash steps often use methanol and water and sometimes a weak 
detergent.
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7.8.2 REMOVAL OF DRUG FROM THE NAIL MATRIX
Drugs have been removed from nail by alkaline hydrolysis,199 methanol reflux,197 soaking 
in phosphate buffer,198 crushing the nail with acid194 and by a cryogenic method.200 The 
alkaline hydrolysis is the only method which completely dissolves the nail but can only be 
used if  the drug is stable in strong alkaline conditions. Methanol and phosphate buffer 
methods require the nail to be cut into small pieces.
7.8.3 EXTRACTION
Extraction procedures used for nail analysis are usually conventional liquid-liquid or solid 
phase extraction methods.
7.8.4 ANALYSIS
Analytes in nails are usually detected using gas chromatography-mass spectrometry, but 
other methods such as high performance liquid chromatography with electrochemical 
detection201 have also been used.
7.9 NAIL ANALYSIS FOR DRUGS
Methamphetamine and amphetamine were the first drugs of abuse to be detected in 
fingernails and toenails. Nails were decontaminated by scraping and sonication in a 
mixture of methanol and water 1:1 and were then dissolved by alkaline hydrolysis with
2.5 N sodium hydroxide solution at 80 °C. This solution was extracted by liquid-liquid 
extraction with «-pentane and trifluoroacetic derivatives were prepared and detected by gas 
chromatography-mass spectrometry with chemical ionisation. Recoveries for this method 
were 91.6 % and 88.9 % for methamphetamine and amphetamine respectively and it was 
found that the two drugs were more concentrated in toenails than in fingernails. This 
observation was explained by the differences in growth rates of toenails and fingernails 
which were quoted as 1.1 mm/month and 3-5 mm/month respectively. The 
methamphetamine and amphetamine levels detected were 0.32 - 17.7 ng/mg and 
0.03 - 0.40 ng/mg respectively in fingernails and 0.06 - 9.93 ng/mg and 0.03 - 1.60 ng/mg 
respectively in toenails. The methamphetamine levels were similar to those found in hair.193
Other authors have also detected methamphetamine and amphetamine in nails. 
Decontamination was carried out using alternate water and methanol washes. The nails 
were then crushed with 0.6 N hydrochloric acid in a mortar and pestle, the pH adjusted
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with sodium carbonate solution and the drugs extracted using chloroform:isopropanol 3:1. 
Trifluoroacetic derivatives were prepared and detected using gas chromatography-mass 
spectrometry with electron ionisation. Methamphetamine was detected in 13 out of 20 nail 
samples and amphetamine in 3 out of the 13 positive methamphetamine cases. The other 
major metabolite of methamphetamine, p-hydroxymethamphetamine was not detected in 
any of these cases. The concentrations of methamphetamine and amphetamine detected 
ranged from 0.4 - 642 ng/mg and 0.3 - 23.2 ng/mg respectively.194
Other authors have identified amphetamine, 3,4-methylenedioxyamphetamine (MDA) and 
3,4-methylenedioxymethamphetamine (MDMA) in a fingernail. The nail was scraped and 
washed in dichloromethane and incubated in sodium hydroxide at 95 °C for 10 minutes. 
The homogenate was extracted using liquid-liquid extraction and derivatized using 
pentafluoropropionic anhydride and pentafluoropropanol. The analytes were detected using 
gas chromatography-mass spectrometry. Levels of amphetamine, MDA and MDMA in the 
fingernail were 10.2 , 8.0 and 53.4 ng/mg respectively and these values were found to be 
similar to those detected in the hair sample of this individual.195
Cocaine and benzoylecognine have been detected in nails. Cocaine was extracted from the 
hair, nails and other tissues of a cocaine overdose victim. Nails were washed for two 
minutes in methanol. They were cut into small pieces and extracted with methanol in an 
ultrasonic bath for 5 hours at 55 °C. The extracts were quantified using gas 
chromatography with nitrogen phosphorus detection and confirmed by gas 
chromatography-mass spectrometry. The concentration of cocaine detected in the left and 
right hand fingernail tips were 2300 and 2200 ng/mg respectively.196
A reflux method using methanol at 40 °C for 16 hours was used to extract cocaine, 
benzoylecognine and other cocaine metabolites from toe and fingernail clippings. Prior to 
this step the nails were cut into small pieces and washed with methanol. Solid phase 
extraction was used to clean up the extracts following the reflux stage and 
bis-(trimethylsilyl)trifluoroacetamide (BSTFA) derivatives were prepared. Gas 
chromatography-mass spectrometry analysis in the SIM mode allowed a limit of detection 
of 0.10 ng/mg and a limit of quantitation of 0.25 ng/mg for cocaine and benzoylecognine 
which were the predominant analytes in the positive samples. The range o f cocaine and 
benzoylecognine found in fourteen samples was less than 0.25 to 16.1 ng/mg and 0.27 to
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greater than 10.0 ng/mg respectively and the concentration of cocaine analytes was 
generally greater in fingernails than in toenails. Hydrolysis of cocaine using this method 
was reported to be less than 5 %. Wash fractions were positive in five out of fourteen 
positive samples and ranged from 0.10 to 10.0 ng/mg. Blood and urine samples were 
found to be positive for 27.7 % compared with 82.3 % for nails. This indicated the 
usefulness of nail analysis for long term exposure to cocaine.197
Cocaine, benzoylecognine, norcocaine, cocaethylene, morphine, 6-monoacetylmorphine, 
codeine and hydrocodone were all detected in postmortem nail clippings. The nails were 
cut into small pieces, decontaminated with methanol and solubilized in 0.1 M potassium 
phosphate, pH 5.0. Solid phase extraction was used to clean the extracts, followed by 
derivatization with A-methyl-A-trimethylsilyl-trifluoroacetamide (MSTFA). Gas 
chromatography-mass spectrometry gave a limit of quantification o f 0.3 ng on column. 
Concentrations ranged from 0.20 to 140.17 ng/mg for cocaine and 0.30 to 315.44 ng/mg 
for benzoylecgonine. Two samples were found to contain norcocaine (6.78 and 
0.66 ng/mg) and cocaethylene (2.60 and 0.73 ng/mg). Morphine and 6- 
monoacetylmorphine were detected in three cases with average concentrations 0.37 ng/mg 
and 0.89 ng/mg. Codeine was detected in two samples (3.07 and 1.02 ng/mg) and 
hydrocodone in one sample (0.62 ng/mg). The phosphate buffer, pH 5.0 was reported to 
give less than 3 % loss of analyte.198
Morphine has been detected in fingernails by other authors. The fingernails were washed 
by a series of steps involving sodium dodecyl sulphate, water and methanol. Alkaline 
hydrolysis with 1 M sodium hydroxide solution at 60 °C was used and the homogenate was 
evaporated to dryness, redissolved in water and extracted using Toxi Tubes A. Initial 
analysis was carried out using radioimmunoassay and confirmation using high 
performance liquid chromatography with electrochemical detection (HPLC-ECD). Positive 
radioimmunoassay results were obtained in 25 out of 26 cases and the levels ranged from 
0.06 -  4.69 ng/mg. Using HPLC-ECD, 22 of the 26 cases were positive with levels ranging 
from 0.14 to 6.90 ng/mg.201
The same authors also detected cannabis in fingernails of users. The washing protocol was 
the same as that previously mentioned, a series of steps involving sodium dodecyl 
sulphate, water and methanol and nails were incubated in 1 M sodium hydroxide at 95 °C.
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A simple extraction method was used and analytes were detected by radioimmunoassay 
and confirmation by gas chromatography-mass spectrometry after derivatization with 
BSTFA. Cannabinoids were detected in 6 cases by RIA and levels ranged from 
0.23 - 2.80 ng/mg. Tetrahydrocannabinol was detected in 11 out of 14 case samples by 
GC/MS and levels ranged from 0.13 - 6.97 ng/mg. The metabolite, 1 l-nor-delta-9- 
tetrahydrocannabinol-9-carboxylic acid was not detected under basic pH but under acidic 
pH was found positive in two out of three cases with concentrations ranging from
9.82 - 29.67 ng/mg.199
In a further study of cannabinoids in nails these authors cryogenically ground the nail in 
liquid nitrogen using a freezer mill fitted with a micro vial grinding set and washed the 
resulting nail powder from the micro-vial set with various solvents. Methanol was selected 
as the solvent of choice for extraction. Gas chromatography-mass spectrometry following 
derivatization with BSTFA was used to analyze the extracts and this method was compared 
with the previously reported cannabinoid method. The extracts produced by alkaline 
hydrolysis were found to contain mean concentrations of 1.73 ng/mg tetrahydrocannabinol, 
2.48 ng/mg cannabidiol and 0.10 ng/mg 11-hydroxy-tetrahydrocannabinol. The results 
obtained by crygenic grinding were comparable, but this method also detected the 
carboxylic acid metabolite. Average concentrations obtained using this method were 
0.54 ng/mg tetrahydrocannabinol, 0.7 ng/mg 11-nor-delta-9-tetrahydrocannabinol-9- 
carboxylic acid, 3.2 ng/mg cannabidiol and 0.15 ng/mg 11-hydroxy- 
tetrahydrocannabinol .20°
To date the number of works published on the detection of drugs in nail is far fewer than 
those for hair. Hair analysis for drugs has not only included drugs o f abuse, but many 
prescription drugs including antidepressants, antipsychotics and hallucinogens have been 
investigated. On the other hand, nail analysis for drugs has mainly involved the detection 
o f drugs of abuse and research into prescription drugs in nails is sparse.
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7.10 AIM
The aim of this study was to use a simple method to extract fluoxetine, norfluoxetine and 
paroxetine from the nails of users and to compare the concentrations detected in nails with 
those detected in the hair. Thereby, the possibility of using nail analysis as an alternative to 
hair analysis to indicate chronic use of these drugs was assessed.
7.11 EXPERIMENTAL
Several methods have been used to separate drugs from the nail matrix. The choice of 
method depends on the stability of the drug and on the capability of the method to recover 
as much of the drug as possible from the matrix. Alkaline hydrolysis of the nail matrix has 
the ability to completely dissolve the nail and assuming that the drugs within the nail are 
not destroyed then the recovery by this method has the potential to be high. The possibility 
of using this method199 to extract antidepressants from nails was investigated.
7.11.1 DECONTAMINATION OF NAIL
Blank fingernails were obtained from volunteers undergoing no treatment with Prozac® or 
Seroxat® and decontaminated using the same wash protocol as that used for hair samples:
(i) One ten minute wash with sodium dodecyl sulphate solution (0.1 %).
(ii) Three ten minute washes with distilled water.
(iii) Three five minute washes with methanol.
Each step was sonicated in 5 ml of solvent and the solvent was decanted after sonication. 
The washed nail samples were dried at room temperature and used for blank controls and 
for spiking with the drugs of interest.
7.11.2 ALKALINE HYDROLYSIS
Drug free nails were dried in an oven at 40 °C and weighed. The nail was hydrolyzed using 
1 M sodium hydroxide solution. 1 ml of solution was added for every 10 mg of nail and the 
sample was incubated at 80 °C for approximately 1 hour or until the nail was completely 
hydrolyzed.
7.11.3 SPIKING NAILS
When the temperature of the solution had fallen to room temperature, 1 ml portions of this 
hydrolysate were pipetted into vials and spiked with fluoxetine, norfluoxetine and
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paroxetine to give standards with concentrations 5, 10, 15, 25, 50, 75 and 100 ng/10 mg 
nail. Internal standards tumoxetine and cannabinol were added at concentrations 
50 ng/10 mg and 116 ng/10 mg respectively.
7.11.4 EXTRACTION AND DERIVATIZATION
The analytes were extracted from the nail matrix using a simple liquid-liquid method.199 
Several solvent mixtures were tested to find which gave the highest recoveries without the 
nail matrix interfering with the analytes. This involved mixing 5 ml of solvent with the 
spiked hydrolysate for 15 minutes, centrifuging the samples for 5 minutes at 2500 rev/min., 
separating the organic layer and evaporating the solvent to dryness under nitrogen at 
40 °C. Derivatization of the nail extracts was carried out as previously described in 
4.13.16.2. GC/MS conditions were the same as for the hair analysis of these drugs (6.4.4). 
Solvents tested included ethyl acetate, dichloromethane, dichloromethane/isopropanol 8:2 
and chloroform. Initially, only fluoxetine and norfluoxetine were investigated.
Table 7.1: Recoveries of fluoxetine and norfluoxetine from nail hydrolysate
1 Solvent % Recovery Fluoxetine 
(RSD %)
Norfluoxetine 
(RSD %)
Ethyl acetate 88.1 (2.3) 84.4 (6.8)
Dichloromethane 65.3 (7.1) 78.9 (3.2)
Chloroform 25.6 (5.5) 35.0 (5.8)
Dichloromethane/ 
isopropanol 8/2
33.8(2.1) 49.9 (9.1)
RSD = Relative Standard Deviation as a percent
Ethyl acetate gave the highest recoveries of the solvents tested for both analytes followed 
by dichloromethane. The extracts obtained with these two solvents were injected into the 
GC/MS and analysed using fullscan analysis. Although the recoveries were higher for the 
ethyl acetate extracts, the amount of extracted impurities was also greater than for the 
dichloromethane extracts. However, since these did not interfere with the derivatized 
fluoxetine and norfluoxetine peaks it was decided to use ethyl acetate because of the 
higher recoveries obtained.
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7.11.5 ALKALINE TREATMENT OF DRUGS
The hydrolysis step was investigated to find if there was any loss of drug as a result of the 
harsh alkaline conditions. 100 pi of fluoxetine, norfluoxetine and paroxetine at 1 pg/ml 
were put into separate vials and 1 M sodium hydroxide solution was added to each. This 
was carried out in triplicate. The samples were placed in the oven at 80 °C for 30 minutes. 
Another set of standards at the same concentration was prepared in 1 ml of water. Both sets 
of standards were extracted using ethyl acetate, derivatized and injected into the GC/MS. 
It was found that there were no significant differences in recovery between the two sets of 
standards and therefore alkaline treatment did not appear to destroy these drugs using these 
conditions. Further validation of recovery was carried out later on (7.11.6.3).
7.11.6 METHOD VALIDATION
7.11.6.1 Intra-day variation
Calibration standards at concentrations 5 ng/10 mg, 10 ng/10 mg, 25 ng/10 mg, 
50 ng/10 mg, 75 ng/30 mg, 100 ng/10 mg and 200 ng/10 mg were extracted five times to 
calculate the intra-day variation of the assay. Drug/internal standard ratios and relative 
standard deviations were calculated for each concentration and linear calibration curves 
were produced for each drug (Table 7.2). Values of correlation coefficient, R2 and intercept 
and slope values for the regression equations are displayed in Table 7.3. Relative standard 
deviations were less than 13 % across the calibration curve.
Table 7.2: Intra-day variation
Concentration 
(ng/10 mg nail)
Mean FLU/TUM ratio 
m/z 344/344 (RSD)
Mean NFLU/TUM ratio 
m/z 330/344 (RSD)
Mean PAR/CAN ratio 
m/z 525/506 (RSD)
5 0.082 (6.6) 0.076 (5.4) 0.219(9.3)
10 0.154 (7.4) 0.198 (8.9) 0.291 (7.6)
15 0.266 (2.9) 0.281 (6.1) 0.439 (5.8)
25 0.494 (8.1) 0.498 (0.5) 0.673 (8.8)
50 1.067 (8.8) 0.974 (8.5) 1.282(5.7)
75 1.641 (5.9) 1.450 (2.5) 2.009 (9.9)
100 2.096 (5.3) 1.961 (8.8) 2.749(12.8)
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine, TUM = tumoxetine, CAN = cannabinol 
RSD = relative standard deviation as a percent
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Table 7.3: Linear Regression Values
Fluoxetine Norfluoxetine Paroxetine
R2 0.9985 0.9997 0.9976
Intercept - 0.0439 - 0.0082 0.0282
Slope 0.0218 0.0196 0.0267
7.11.6.2 Inter-day variation
The calibration curve was extracted over five different days and the inter-day variation was 
assessed and displayed in Table 7.4. Relative standard deviations were less than 11 % for 
the concentrations at the higher end of the calibration curve and less than 23 % for the 
lowest calibrator.
Table 7.4: Inter-day variation
Concentration 
(ng/10 mg nail)
Mean FLU/TUM ratio 
m/z 344/344 (RSD)
Mean NFLU/TUM ratio 
m/z 330/344 (RSD)
Mean PAR/CAN ratio 
m/z 525/506 (RSD)
5 0.070 (9.8) 0.085 (11.1) 0.176 (22.6)
10 0.148 (4.4) 0.203 (7.7) 0.261 (10.1)
15 0.253 (4.7) 0.319(13.1) 0.399(11.5)
25 0.455 (8.4) 0.543 (7.2) 0.597(13.3)
50 0.979 (8.8) 1.245 (1.9) 1.216(11.8)
75
1.488 (10.4) 1.657 (8.1) 1.969 (8.7)
100 1.962 (4.8) 2.160 (5.6) 2.556(10.6)
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine, TUM = tumoxetine, CAN = cannabinol 
RSD = relative standard deviation as a percent
7.11.6.3 Recovery
Nail hydrolysate was spiked to give the concentrations used to produce the calibration 
curves. Each of these was extracted five times and internal standards were added following 
the extraction. Recoveries were calculated for each concentration and these are displayed 
in Table 7.5 with relative standard deviations in parentheses. Recoveries were greater than 
80 % in all cases.
Chapter 7: Antidepressants in Nails Page 117
Table 7.5: Recoveries from spiked nail hydrolysate
I Concentration 
(ng/10 mg nail)
% Recovery Fluoxetine 
(RSD %)
% Recovery Norfluoxetine 
(RSD %)
% Recovery Paroxetine j 
(RSD %) 1
5 81.0(11.4) 81.4 (7.8) 82.9(10.4)
10 90.2 (0.7) 87.9 (4.9) 89.6 (4.6)
15 93.8 (0.3) 84.2 (8.5) 87.0 (7.0)
25 91.3(1.9) 79.9 (4.6) 90.7 (8.6)
50 88.1 (6.7) 83.1 (5.3) 88.8 (8.8)
75 85.7(10.1) 83.6 (3.0) 84.2 (4.4)
100 90.6 (5.8) 84.3(1.7) 88.2 (8.8) |
7.11.6.4 Limit of Detection (LOD) and limit of quantitation (LOQ)
Hydrolyzed nail was spiked to give concentrations 0.5, 0.75, 1.0 and 2.0 ng/10 mg nail and 
these were extracted to determine the limit of quantitation and limit of detection. The limit 
o f detection was taken to be three times the baseline noise of a blank nail hydrolysate 
sample and the limit of quantitation five times the baseline noise of a blank nail 
hydrolysate sample at the relevant retention time of each drug. The limits of quantitation of 
the drugs was 2.0 ng/10 mg and the limit of detection was 0.75 ng/10 mg for norfluoxetine 
and paroxetine and 1.0 ng/ 10 mg for fluoxetine.
7.12 CONCLUSIONS
A simple method was used to extract fluoxetine, norfluoxetine and paroxetine from nails. 
Alkaline hydrolysis was used to completely dissolve the nail and the drugs were extracted 
with ethyl acetate followed by derivatization with heptafluorobutyric anhydride and 
subsequent analysis by gas chromatography-mass spectromety. Alkaline hydrolysis was 
shown to cause no significant destruction of the drugs. Recoveries greater than 80 % were 
obtained for each drug along the calibration curve and limits of detection were suitably 
sensitive. The method was used to analyze case samples.
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8 Case Samples
8.1 OPIATES AND METHADONE IN HAIR
8.1.1 SAMPLE COLLECTION
Hair samples were collected from cadavers at Glasgow City Mortuary by pathologists from 
the Department of Forensic Medicine and Science, University of Glasgow. Hairs were 
plucked prior to postmortem to ensure that the hair had the least amount of exposure to 
blood which causes external contamination to hair. Prevention of hair contamination by 
blood, however, is not always possible especially in cases involving head injuries. The hair 
samples were placed in individual plastic tubes and labelled. Blood samples were collected 
during the postmortem.
8.1.2 SECTIONING OF HAIR
Hair samples matched to blood samples which were found positive for opiates and/or 
methadone were analyzed. The analytical results obtained from the blood samples from the 
selected cases are displayed in Table 8.1. The root end was cut 0.5 cm from the root and 
each successive sample was cut at 1 or 2 cm intervals, depending on the bundle of hair 
received. Some samples were analyzed in entirety because of the lack of sample.
8.1.3 DECONTAMINATION OF HAIR
Hair case samples were decontaminated after sectioning as in 3.12.7. The third methanol 
wash was evaporated to dryness at room temperature under a stream of nitrogen. Internal 
standards were added (50 ng), evaporated to dryness and derivatized with 40 pi of BSTFA 
with 1 % TMCS. The washes were analyzed by GC/MS and if they were found to contain 
morphine, codeine, 6-MAM, methadone or EDDP then the methanol washing procedure 
was repeated until the washes were free of drug. It has been postulated that there are 
different regions in the hair which are accessible and inaccessible to the external 
environment. These same authors have suggested that when hair is exposed to large 
amounts of external contamination that a small percentage of the drug will be incorporated 
within the hair shaft, an accessible interior region of the hair whilst the majority will 
remain on the hair surface. If the hair is analyzed immediately after this exposure then 
much of the surface drug would be removed and a high external contamination would be 
detected. This portion of removed drug would have a low binding affinity to the hair. On
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the otherhand, if the hair was analyzed several weeks later after numerous normal hygiene 
washes then most of the loosely bound surface drug would have been removed leaving 
only the drug within the hair shaft. The decontamination procedure in this case may 
indicate that there is no external contamination in this case because of the high affinity of 
drug in hair. This could provide a possible explanation for decreasing amounts of drug 
being found in successive wash solutions
8.1.4 EXTRACTION OF CASE SAMPLES
The decontaminated hair was allowed to dry at room temperature, weighed and cut into 
1-2 mm pieces with scissors. The samples were extracted as in 3.12.12.
8.1.5 RESULTS
31 hair samples were segmented to give a total o f 109 sections. Each section was washed 
and analyzed separately. O f the 31 hair cases, 27 had at least one segment positive for 
morphine (87.1 %), 23 for codeine (74.2 %), 23 for 6-MAM (74.2 %), 8 for methadone 
(25.8 %) and 6 for EDDP (19.3 %).
Out of the 109 sections, 85 were found positive for morphine (78.0 %), 72 for codeine 
(66.0 %), 67 for 6-MAM (61.5 %), 19 for methadone (17.4 %) and 11 for EDDP (10.1 %).
8.1.5.1 Root Analysis
Roots were analyzed for 24 out of the 31 cases. Morphine was found positive in 18 of 
these cases (75 %), codeine in 18 cases (75 %), 6-MAM in 11 cases (45.8%), methadone in 
5 (20.8 %) and EDDP in 4 (16.7 %). For these same 24 cases, 20 blood samples were 
found positive for morphine (83.3 %), 13 for codeine (54.2 %), one for 6-MAM (4.2 %), 7 
for methadone (29.2 %) and 2 for EDDP (8.3 %). These values are displayed in Figure 8.1.
In 14 cases (58.3 %), the hair roots and corresponding blood samples were both found 
positive for morphine. In 4 cases (16.7 %), the hair root was positive and the blood sample 
negative and in 6 (25 %) cases, the hair root was negative and the blood sample positive 
(Figure 8.2). For the latter cases it may be expected that the hair sample should be positive 
since the blood is positive. It has been shown that codeine can incorporate into the hair 
bulb within 30 minutes after administration.23 However, in 4 cases out of the 6 there was a 
history of sudden collapse immediately after injecting, or there was the possibility of
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sudden collapse. In the latter of these cases, the position the deceased was found suggested 
that sudden collapse was likely. In situations such as these, the drugs would not have had 
time to incorporate into the hair and if the user had not taken heroin in the time it took for 
this section of hair to grow then no morphine would be detected. In cases where there was 
no history of sudden collapse this may be accounted for by the root sample size being too 
small and in the case of occasional heroin users the low concentrations present in the 
sample may be below the limit of detection of the method.
Out of 8 cases where methadone was positive in blood and/or root hair samples, the 
number of methadone positives in hair root and corresponding blood sample was three 
(37.5 %), positive hair root and negative blood was one (12.5 %) and negative hair root 
and positive blood was four (50.0 %) (Figure 8.3). Again for some of the root samples, 
there was insufficient sample available, only 1 - 2 mg.
Concentration ranges detected in root samples were 0.51 - 4.66 ng/mg (mean 1.75 ng/mg) 
morphine, 0.32 - 3.93 ng/mg (mean 1.27 ng/mg) codeine, 0.35 - 7.80 ng/mg (mean 2.03 
ng/mg) 6-MAM, 0.21 - 2.78 ng/mg (mean 1.32 ng/mg) methadone and 0.42 - 1.85 ng/mg 
(mean 1.07 ng/mg) EDDP. 6-MAM/morphine ratios for the roots varied from 0.09 - 3.01 
(mean 0.87). Morphine/codeine ratios in roots varied from 0.69 - 2.80 (mean 1.59). The 
ratio of methadone/EDDP in root samples was 1.07 - 2.23 (mean 1.43). The results for the 
root analysis are displayed in Tables 8.2 - 8.3 for opiates and Table 8.4 for methadone.
□  Hair root 
■  Blood
Morphine Codeine 6MAM Methadone EDDP
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■  root + ve, blood + ve ■  root + ve, blood - ve □  root - ve, blood + ve  
Figure 8.2: Morphine findings in hair root and corresponding blood sample.
13%
■  root + ve, blood + ve ■  root + ve, blood - ve □  root - ve, blood + ve 
Figure 8.3: Methadone findings in hair root and corresponding blood sample.
8.1.5.2 H air Segments excluding roots
Concentration ranges detected in segments excluding roots were 0.10 - 9.79 ng/mg 
morphine, 0.12 - 3.47 ng/mg codeine, 0.14 - 70.07 ng/mg 6-MAM, 0.15 - 1.15 ng/mg 
methadone and 0.27 - 1.55 ng/mg EDDP. These values correspond with other studies 
which reported concentrations as high as 21.8 ng/mg morphine, 4.0 ng/mg codeine and
74.2 ng/mg 6-MAM. Methadone and EDDP levels as high as 78.1 ng/mg and 7.76 ng/mg 
respectively have been reported using solid phase microextraction.85 However, the levels 
detected in these case samples were found to be much lower.
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In cases where a constant amount of morphine was detected along the hair shaft, it was 
also noticed that the concentration of 6-MAM increased the further away from the root 
end. This was particularly noticeable in cases HO/06 (Figure 8.4), HO/07 and HO/08. 
Also, as the morphine concentration increased towards the tip of the hair, a larger 
difference in 6-MAM was noted as shown by cases HO/01, HO/09 (Figure 8.5), and 
HO/26. 6-MAM/morphine ratios varied from 0.08 - 19.33 (mean 3.94), and were generally 
greater than 1. This range was much broader than the range obtained for the root sections.
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Hair segment
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□  6-MAM
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Figure 8.4: Hair case HO/06
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Figure 8.5: Hair case HO/09
In the majority of cases (87 %) where morphine was found positive the concentration of 
morphine was greater than that of codeine. The morphine/codeine ratio varied from 
0.14- 4.41 (mean 1.96).
The ratio of methadone/EDDP in segment samples varied from 0.71 - 2.36 (mean 1.45). 
Figure 8.4 also shows a good example of a previous regular methadone user. 
Concentrations of methadone over three consecutive one centimetre segments were found 
to be similar and these sections of hair would have grown approximately 3 to 7 months 
prior to death. EDDP was also detected in these segments, but the concentrations in the 
separate segments were found to be more variable.
The results for the hair segments excluding roots are displayed in Tables 8.5 - 8.8 for 
opiates and Table 8.9 for methadone.
8.1.5.3 Interpretation of hair findings
The analysis of hair from heroin addicts can prove long term abuse, give a history of the 
use of the drug and to a certain extent give an indication of the drug consumption. The 
presence of 6-MAM in hair is definitive evidence of heroin exposure. In 23 of the 31 cases 
tested, at least one section of hair was found positive for 6-MAM indicating that 23 of the
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individuals had used heroin at some point. Out of the other 8 cases, 3 were negative for 
opiates and 5 had at least one section positive for codeine and/or morphine. For these 5 
cases the ratio of codeine to morphine was studied.
Other authors have defined criteria to distinguish between heroin use and other forms of 
opiate use in hair. This criteria stated that for cases where no 6-MAM is detected and the 
morphine concentration is < 1 ng/mg then the morphine/codeine ratio must be > 5 and for 
cases where no 6-MAM is detected and the morphine concentration is > 1 ng/mg then the 
morphine/codeine ratio must be > 2.97 In applying these criteria to the 5 cases, heroin use 
could not be established solely on the information provided from the hair results since the 
morphine/codeine ratios did not uphold these rules. However, the drug histories of these 
five cases showed that two were known heroin users although the extent was not known, 
one was a casual user, another had a long history of heroin use and only one had no known 
drug use history. These cases will be discussed further in 8.1.5.4.
In a study investigating dose and hair concentration findings, good proportionality was 
observed between the quantities of heroin a drug user self-reported to have taken and the 
amount of 6-MAM detected in the hair. These authors proposed three levels of 
consumption in terms of the concentration of 6-MAM detected in hair. These were low < 2 
ng/mg, medium 2-10 ng/mg and high > 10 ng/mg.220 Other authors have also reported good 
correlation between self-report and amount of codeine, morphine and 6-MAM detected in 
hair.221 Using this criteria, out of the 23 cases where 6-MAM was detected, 10 (43.5 %) 
could be classed as low users, 8 (34.8 %) as medium users and 5 (21.7 %) as high users.
A final consensus o f the Hair Testing Work Group after its third meeting in Texas, 1999 
recommended that cut-off levels for morphine, codeine and 6-MAM in hair should be 
0.2 ng/mg and that 6-MAM could not be reported unless another opiate analyte was 
present above its cut-off level.
In 7 of the hair cases, levels were detected below this cut-off level for at least one segment 
of hair and in one case 6-MAM was detected without another opiate present.
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8.1.5.4 Regular, intermittent or nai’ve user?
The hair findings, blood findings and information about drug use history obtained from 
police reports were analyzed for each case to obtain an overall picture of drug use. The 
interpretation of these results are tabulated in Tables 8.10-8.13.
Hair findings provided evidence of whether the user was a regular user. The term "regular 
heroin user" is used where concentrations of morphine and 6-MAM were detected 
throughout the length of the sectioned hair. In cases where whole hair was analyzed this 
term was not used. An indication of the extent of drug use was given by the terms "low", 
"medium" or "high" as previously discussed in 8.1.5.3 and an estimation of the length of 
time of use was given by using the approximation that 1 cm of hair is equivalent to 1 
months hair growth. For whole hair samples which were classified as "low user" it must 
also be recognised that this could indicate intermittent use. However, since the hair was not 
sectioned this could not be proven.
Blood findings provided evidence of recent use of heroin and/or methadone. For blood 
findings, the term "heroin user" was only used when codeine and morphine concentrations 
were detected in blood with a morphine/codeine ratio greater or equal to 2.
Drug use history was taken from police reports. For this part it was essential to include any 
information about methadone or drug rehabilitation programmes to assist with the 
interpretation.
Out of the 31 cases analyzed, 9 were found to be low users, 8 medium users and 5 high 
users of heroin. 3 cases were found to be intermittent users, one of which was on a 
methadone programme, one on drug rehabilitation programmes and the other on unknown 
tablets to help with withdrawal. Only one of the users was described as a naive user having 
no previous history of drug use and the hair was found entirely negative.
Five of the cases were termed inconclusive. Part of the problem for these samples was the 
small sample size of hair available. For one o f these cases (HO/04) low concentrations of 
codeine and morphine were detected in a hair segment equivalent to three months growth 
(hair equivalent to months 4-7 prior to death) and morphine was detected in the blood. The 
deceased was known to have taken heroin prior to death and he was a known heroin
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abuser. The amount of hair available for this case was low. The root section was less than 
2 mg and the other two sections 6.8 mg and 9.1 mg respectively. These results indicated a 
possible low user or intermittent user, however the codeine/morphine ratio in hair did not 
fulfil criteria meeting heroin use. Hair findings could therefore not be used to categorize 
the extent of heroin use. The drug history indicated that this individual was a heroin user 
but the extent was not known.
In the second of these cases, (HO/24), the roots were found negative. The rest o f hair was 
found positive for morphine and codeine, however the morphine/codeine ratio again did 
not meet criteria and the morphine concentration was below the cut-off level recommended 
by the Hair Testing Work Group. A sample size of 17 mg was tested for the bulk of the 
hair which is adequate to determine medium or high usage. This indicates that the user was 
most likely an occasional user in which case concentrations in hair would be low. Blood 
findings were conclusive of heroin use and the drug use history indicated that the deceased 
was an occasional user. However, hair findings could not conclusively determine this.
For case HO/28, hair findings could not conclusively indicate heroin use. In the blood, 
morphine was detected and the drug use history indicated that this individual was 
intermittently taking heroin with tablets prescribed for withdrawal. It was probable that this 
was an intermittent user.
For cases HO/29 and HO/30 morphine/codeine ratios detected in hair were again not 
conclusive of heroin use. Blood findings were both positive for heroin use and in one case 
drug use history was not known and in the other case a long history of heroin use was 
known. However, hair findings did not prove heroin use.
For case HO/11, only 6-MAM was detected in the tip section of hair analyzed. The Hair 
Testing Work Group defined criteria stating that a lone 6-MAM concentration could not be 
reported. In this case the blood findings were indicative of a heroin user. The drug history 
confirmed this and the deceased had also been known to have attended several drug 
rehabilitation programmes. The combined evidence indicated that this hair sample 
belonged to an intermittent drug user.
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Case HO/12 was the only example of an intermittent heroin user where methadone was 
detected in hair, but opiates were not detected in the hair at the same time. In other words 
this individual was complying with the methadone programme and from the drug history it 
was indicated that methadone prescription had ceased two weeks prior to death. 
Methadone was not detected in the root sample. Blood findings indicated heroin use, but 
no use of methadone.
8.1.6 CONCLUSIONS
Hair testing for drugs provides a longer time window than urine or blood analysis and can 
be used to provide information on an individual's drug use which blood and urine analysis 
fail to achieve. A drug use history can be compiled by sectioning the hair to indicate extent 
of use, periods of abstinence, periods of treatment with methadone or alternatively 
unprescribed use of methadone.
For the majority of the hair cases tested, the results were conclusive of regular heroin use 
and it could be established if these users were low, medium or high users, this being 
determined from the quantities detected in the hair. For cases which were determined 
inconclusive, the underlying problem was generally due to a lack of hair samples. In some 
cases only a few milligrams of hair were available and it was therefore necessary to 
analyze larger sections equivalent to several months of hair growth. An adequate size of 
greater than 10 mg per section of hair would be preferable.
The levels of opiates and methadone detected using the developed method were in the 
range of those seen by other authors.
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Table 8.1: Opiate and methadone findings in blood case samples
T Case 
sample
Codeine
(mg/L)
Morphine
(mg/L)
6-MAM
(mg/L)
Methadone
(mg/L)
EDDP
(mg/L)
HO/01 - ve - ve -ve 0.3 0.3
HO/02 - ve 0.5 -ve - ve - ve
HO/03 - ve 0.3 -ve - ve - ve
HO/04 - ve 0.3 -ve - ve - ve
HO/05 0.1 0.2 -ve - ve - ve
HO/06 - ve 0.1 -ve 0.03 - ve
HO/07 - ve 0.2 -ve - ve - ve
HO/08 0.01 0.1 -ve - ve - ve
| HO/09 0.02 0.2 -ve - ve - ve
| HO/10 - ve 0.04 - ve - ve - ve
1 HO/11 0.1 0.3 - ve - ve - ve
| HO/12 0.04 0.4 - ve - ve - ve
| HO/13 0.01 0.1 - ve - ve - ve
I HO/14 0.02 0.1 - ve - ve - ve
HO/15 0.1 0.5 - ve - ve - ve
| HO/16 0.004 0.1 - ve - ve - ve
HO/17 -ve 0.3 -ve 0.02 -ve
HO/18 0.02 0.1 0.01 -ve -ve
HO/19 - ve - ve - ve 0.02 - ve
HO/20 0.1 0.5 - ve - ve - ve
HO/21 - ve - ve - ve 0.14 - ve
HO/22 0.01 0.1 - ve - ve - ve
HO/23 0.03 0.29 - ve 0.02 0.001
HO/24 0.06 0.4 0.01 - ve -ve
HO/25 -ve 0.38 -ve - ve -ve
HO/26 0.02 0.18 - ve 0.05 -ve
HO/27 0.02 0.11 -ve - ve -ve 1
HO/28 -ve 0.03 -ve - ve -ve 1
HO/29 0.01 0.02 -ve - ve -ve 1
HO/30 0.08 0.56 -ve - ve -ve I
HO/31 -ve -ve -ve -ve -ve 1
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Table 8.2: Blood, hair root and drug history results for opiates
1 Case Blood Hair roots Drug
sample Morphine
(mg/L)
Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
history
HO/01 - ve 1.49 0.59 0.89 0.396 1.674 Known illicit drug 
user
HO/02 0.5 1.28 1.05 0.71 0.820 1.802 Known heroin 
user for 12 years
HO/03 0.3 NA NA NA - - Known heroin 
user for two years
HO/04 0.3 - ve - ve - ve - - Known heroin 
user
HO/05 0.2 0.34 - ve 0.32 - 1.062
HO/06 0.1 0.51 0.36 0.41 0.706 1.243 Known heroin 
user
HO/07 0.2 0.87 0.71 0.52 0.816 1.673 Known heroin 
user for 20 years
HO/08 0.1 1.03 0.63 0.62 0.611 1.661 Known heroin 
user
HO/09 0.2 2.59 7.80 1.14 3.011 2.272 Known heroin 
user
HO/10 0.04 NA NA NA - - Known heroin 
user for 3 years
HO/11 0.3 - ve - ve - ve - - Known heroin 
user for 5 years
HO/12 0.4 - ve - ve - ve - - Known heroin 
user for 5 years
HO/13 0.1 NA NA NA - - Known drug user
HO/14 0.1 NA NA NA - - Long history o f  
drug abuse
HO/15 0.5 NA NA NA - - History o f  drug 
abuse 2-3 years
HO/16 0.1 NA NA NA - - Known heroin 
user
HO/17 0.3 - ve - ve - ve • Possible heroin 
user 1 month prior 
to death
HO/18 0.1 - ve - ve - ve - - Known drug user
HO/19 - ve 2.86 3.18 1.40 1.111 2.042 Known drug user 
over 18 years
HO/20 0.5 4.66 6.05 3.93 1.298 1.186 Known heroin 
user over 5 years
HO/21 - ve 1.05 1.21 0.55 1.152 1.909 Known heroin 
user
HO/22 0.1 - ve - ve - ve ” Known heroin 
user 10 years 
prior to death
HO/23 0.29 0.55 - ve 0.80 - 0.688 Occassional 
heroin user
HO/24 0.4 - ve - ve - ve - - Occassional user 
o f  heroin
HO/25 0.38 3.95 0.37 1.45 0.094 2.724 History o f
morphine
addiction
HO/26 0.18 1.66 - ve 1.18 - 1.407 Registered heroin 1 
addict |
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Table 8.3: Blood, hair root and drug history results for opiates
Case
sample
Blood Hair roots Drug
historyMorphine
(mg/L)
Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
HO/27 0.11 0.81 - ve 0.46 - 1.761 Known regular 
heroin user
HO/28 0.03 0.67 - ve 1.32 0.508 Known heroin 
user prescribed 
withdrawal tablets
HO/29 0.02 3.36 - ve 2.80 1.200 Overdose 3 days 1 
prior to death 
(tablets not 
known)
HO/30 0.56 3.95 - ve 3.82 - 1.034 Long history o f  
heroin abuse
HO/31 -ve 1.54 0.35 0.55 0.227 2.800 Not known
Table 8.4: Blood, hair root and drug history results for methadone
1 Case Blood Hair roots Methadone
sample Methadone
(mg/L)
EDDP
(mg/L)
Methadone
(ng/mg)
EDDP
(ng/mg)
Methadone/
EDDP
history
HO/01 0.3 0.3 1.14 0.51 2.235 No methadone history
HO/06 0.03 - ve - ve - ve - Took wife's methadone 
prescription day prior to death
HO/17 0.02 - ve - ve - ve - No methadone history
HO/19 0.02 - ve 1.98 1.85 1.070 Placed on numerous 1 
methadone programmes
HO/20 - ve - ve 2.78 1.50 1.853 Referred to drug rehabilitation 1 
unit
HO/21 0.14 - ve 0.47 0.42 1.119 Not on a methadone I 
programme
HO/23 0.02 0.001 0.21 - ve - No methadone history
HO/26 0.05 - ve - ve - ve - No methadone history
Cases which are not mentioned for methadone were negative in blood and hair
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Table 8.5: Blood, hair segment and drug history results for opiates
1 Case Hair segments excluding roots Blood Drug 1
sample Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
Morphine
(mg/L)
history
HO/01 2 .3 4 5 .11 0 .8 7 2 .1 8 3 2 .6 9 0 - ve Known illicit drug J
1-2 cm user
HO/01 2 .0 9 4 .5 6 0 .6 7 2 .1 8 1 3 .1 1 9
2-3 cm
HO/01 2 .8 1 7 .2 7 0 .9 3 2 .5 8 7 3 .0 2 2
3-4 cm
HO/02 
1-2 cm
2 .8 6 2 .1 5 1 .4 6 0 .7 5 1 1 .9 5 9 0 .5 Known heroin 1 
user for 12 years
HO/02 2 .1 6 2 .21 1 .0 4 1 .0 2 3 2 .0 7 7
2-3 cm
HO/03 0 .1 6 0 .1 6 0 .1 2 1.000 1 .3 3 3 0 .3 Known heroin
whole user for 2 years
HO/04 - ve - ve - ve - - 0 .3 Known heroin
1-4 cm user
HO/04 0 .3 9 - ve 0 .1 6 - 2 .4 3 8
4-7 cm
HO/05 0 .3 7 0 .4 9 0 .3 9 1 .3 2 4 0 .9 4 9 0 .2
1-2 cm
HO/05 - ve - ve - ve - -
2-3 cm
HO/06 0 .3 5 0 .2 9 0 .2 7 0 .8 2 9 1 .2 9 6 0 .1 Known heroin
1-2 cm user
HO/06 0 .4 7 0 .4 7 0 .3 5 1.000 1 .3 4 2
2-3 cm
HO/06 0 .6 8 0 .7 4 0 .4 6 1 .0 8 8 1 .4 7 8
3-4 cm
HO/06 0 .6 5 1 .03 0 .4 1 1 .5 8 4 1 .5 8 5
4-5 cm
HO/06 0 .6 0 1 .79 0 .3 2 2 .9 8 3 1 .8 7 5
5-7 cm
HO/07 
1-2 cm
1 .0 4 1 .8 9 0 .6 3 1 .8 1 7 1 .651 0 .2 Known heroin 
user for 20 years
HO/07 1 .1 4 3 .4 3 0 .7 3 3 .0 0 9 1 .561
2-3 cm
HO/07 1 .1 8 5 .2 2 0 .7 4 4 .4 2 3 1 .5 9 5
3-4 cm
HO/07 1 .1 9 6 .6 0 0 .7 6 5 .5 4 6 1 .5 6 6
4-5 cm
HO/07 1 .1 9 7 .5 2 0 .7 2 6 .3 1 9 1 .6 5 3
5-6 cm
HO/07 1 .23 9 .5 0 0 .7 8 7 .7 2 4 1 .5 7 7
6-7 cm
HO/07 1 .3 6 1 2 .5 3 0 .8 4 9 .2 1 3 1 .6 1 9
7-9 cm
HO/08 1 .8 0 2 .0 4 0 .8 5 1 .1 3 3 2 .1 1 8 0 .1 Known heroin 1
1-2 cm user
HO/08 1 .6 0 3 .0 9 0 .7 0 1 .931 2 .2 8 6
2-3 cm
HO/08 0 .8 1 3 .4 4 0 .3 9 4 .2 4 7 2 .0 7 7
3-4 cm
HO/08 0 .7 4 3 .9 4 0 .3 3 5 .3 2 4 2 .2 4 2
1 4-5 cm
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Table 8.6: Blood, hair segment and drug history results for opiates
Case Hair segments excluding roots Blood Drug
sample Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
Morphine
(mg/L)
history
HO/09 3 .9 4 2 7 .0 4 1.23 6 .8 6 3 3 .2 0 3 0 .2 Known heroin 1
1-2 cm user
HO/09 5 .9 6 5 6 .7 5 1 .6 0 9 .5 2 2 3 .7 2 5
2-3 cm
HO/09 5 .71 7 0 .0 7 1 .3 0 1 2 .2 7 1 4 .3 9 2
3-4 cm |
H O /10 - ve 0.91 - ve _ 0 .0 4 Known heroin 1
0.5-1.5 cm user for 3 years
HO/10 0 .8 1 1 .24 - ve 1 .5 3 0 -
1.5-2.5 cm
H O /10 1.55 2 .21 - ve 1 .4 2 6 -
2.5-3.5 cm
HO /10 0 .4 7 2 .6 8 - ve 5 .7 0 0 -
3.5-5.5 cm
HO/11 - ve - ve - ve _ _ 0 .3 Known heroin
| root-0.5 cm user for 5 years
H O /11 - ve - ve - ve - -
I 0.5-1.5 cm
H O /11 
1.5-2.5 cm
- ve - ve - ve - -
HO/12 - ve - ve - ve _ _ 0 .4 Known heroin
0.5-1.5 cm user for 5 years
H O /12 - ve - ve - ve - -
1.5-2.5 cm
HO/13 
Whole hair
0 .1 0 0 .2 8 - ve 2 .8 0 0 - 0 .1 Known drug 
user
HO/14 
Whole hair
0 .3 5 0 .5 4 2 .1 6 1 .5 4 2 0 .1 6 2 0 .1 Long history o f  
drug abuse
H O /15 
Whole hair
0 .1 9 0 .4 0 - ve 2 .1 0 5 - 0 .5 History o f drug 
abuse 2-3 years
HO/16 
Whole hair
2 .9 5 2 7 .3 1 .1 4 9 .2 5 0 2 .5 8 8 0 .1 Known heroin 
user
HO/17 - ve -ve -ve _ _ 0 .3 Possible heroin
0.5-2.5 cm user 1 month
HO/17 - ve -ve -ve _ - prior to death
2.5-4.5 cm
HO/17 - ve -ve -ve - -
4.5-6.5 cm
H O /17 - ve -ve -ve - -
6.5-8.5 cm
H O/17 - ve -ve -ve - -
8.5-10.5 cm
HO/17
10.5-13.5
- ve -ve -ve - -
cm
HO/18 
Whole hair
- ve -ve -ve - - 0 .1 Known drug 
user
HO/19 1 .4 2 2 .1 2 0 .7 5 1 .4 9 0 1 .8 9 3 - ve Known drug
0.5-2.0 cm user over 18 
years
HO/20 0 .1 7 1 .58 0 .2 4 9 .2 9 4 0 .7 0 8 0 .5 Known heroin
0.5-2.0 cm user over 5 
years
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Table 8.7: Blood, hair segment and drug history results for opiates
Case Hair seg ments excluding roo ts Blood Drug
sample Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
Morphine
(mg/L)
history
HO/21 
0.5-1.5 cm
0.22 0.24 0.16 1.091 1.375 - ve Known 
heroin user
HO/21 
1.5-2.5 cm
0.25 0.22 0.25 0.880 1.000
HO/21 
2.5-3.5 cm
0.21 0.22 0.23 1.048 0.913
HO/21 
3.5-4.5 cm
0.39 0.15 0.59 1.307 0.661
HO/21 
4.5-5.5 cm
0.19 0.42 0.27 2.211 0.704
HO/21 
5.5-6.5 cm
- ve - ve - ve - -
HO/22 
1-3 cm
0.26 - ve - ve - - 0.1 Known 1 
heroin user
HO/22 0.15 0.23 - ve 1.533 - 10 years
3-5 cm  
HO/22 0.13 - ve - ve
prior to 
death
| 5-7 cm
HO/22 
7-9 cm
0.10 - ve - ve - -
HO/22 
9 -1 1cm
0.10 - ve - ve - -
HO/22 
11-13 cm
0.11 - ve - ve - -
HO/22 
13-15 cm
0.10 - ve - ve - -
HO/22 
15-17 cm
0.10 - ve - ve - -
HO/22 
17-19 cm
0.10 - ve - ve - -
HO/23 
1-3 cm
0.35 3.31 0.43 9.457 0.814 0.29 Occassional 
heroin user
HO/24 
0.5-2.0 cm
0.10 - ve 0.22 - - 0.4 Occassional 
heroin user |
HO/25 
1-2 cm 
HO/25
8.15
9.79
2.42
7.62
3.08
3.47
0.297
0.778
2.646
2.821
0.38 History o f  1 
morphine J 
addiction
2-3 cm
HO/26 
1-2 cm
2.31 5.62 0.79 2.433 2.924 0.18 Registered 
heroin addict
HO/26 2.43 5.53 0.79 2.276 3.076
2-3 cm
HO/26 
3-4 cm
3.39 15.60 1.10 4.602 3.081
HO/26 4.18 33.48 1.31 8.009 3.191
j 4-5 cm
HO/27 
1-3 cm
0.40 6.78 0.36 16.950 1.111 0.11 Known
regular
HO/27 
3-5 cm
0.59 10.59 0.33 17.949 1.787 heroin user
HO/27 
5-7 cm
0.70 13.53 - ve 19.329 -
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Table 8.8: Blood, hair segment and drug history results for opiates
1 Case Hair see ments excluding roolts Blood Drug
sample Morphine
(ng/mg)
6MAM
(ng/mg)
Codeine
(ng/mg)
6MAM/
Morphine
Morphine/
Codeine
Morphine
(mg/L)
history
HO/28 
1-3 cm
- ve - ve 0.49 - - 0.03 Known 
heroin user
HO/28 
3-5 cm
- ve - ve - ve
'
prescribed
withdrawal
tablets
HO/29 
1-3 cm
0.42 - ve 2.23 - 0.188 0.02 Overdose 3 
days prior to
HO/29 
3-5 cm
0.85 - ve 0.43 - 1.977 death
(tablets not
HO/29 
5-8 cm
0.13 - ve 0.93 - 0.140 known)
HO/30 
1-4 cm
0.57 - ve 0.51 - 1.118 0.56 Long history 
o f heroin 
abuse
HO/31
1-2 cm 
HO/31
2-3 cm 
HO/31
| 3-4 cm
1.33
2.03
2.27
0.14
0.18
0.18
0.36
0.46
0.52
0.105
0.008
0.008
3.694
4.413
4.365
- ve Not known
Chapter 8: Case Samples Page 135
Table 8.9: Blood, hair segment and drug history results for methadone
Case Hair segments excluding roots Blood Drug
sample history
Methadone EDDP Methadone/ Methadone
(ng/mg) (ng/mg) EDDP (mg/L)
HO/01 - ve -ve _ 0.3 No methadone
1-2 cm 
HO/01 - ve -ve
history
2-3 cm
HO/01 - ve -ve -
3-4 cm
HO/06 
1-2 cm
- ve - ve - 0.03 Took wife's 
methadone
HO/06 
2-3 cm
0.54 0.27 2.000 prescription day prior 
to death
HO/06 1.15 1.40 0.821
3-4 cm
HO/06 1.15 0.75 1.533
4-5 cm
HO/06 1.10 1.55 0.710
5-7 cm
HO/17 - ve -ve _ 0.02 No methadone
0.5-2.5 cm 
HO/17 - ve -ve
history
2.5-4.5 cm
HO/17 - ve -ve -
j 4.5-6.5 cm
HO/17 
6.5-8.5 cm
- ve -ve -
HO/17 - ve -ve -
8.5-10.5 cm
H O/17 - ve -ve -
10.5-13.5
cm
HO/19 
0.5-2.0 cm
0.67 0.52 1.288 0.02 Placed on numerous
methadone
programmes
HO/20 
0.5-2.0 cm
0.52 0.22 2.364 - ve Referred to drug 
rehabilitation unit
HO/21 0.15 - ve - 0.14 Not on a methadone
0.5-1.5 cm 
HO/21 - ve - ve
programme
1.5-2.5 cm
HO/21 - ve - ve -
2.5-3.5 cm
HO/21 - ve - ve -
3.5-4.5 cm
HO/21 - ve - ve -
4.5-5.5 cm
HO/21 - ve - ve -
5.5-6.5 cm
HO/23 0.34 - ve _ 0.02 No methadone
1-3 cm history
HO/26 - ve - ve _ 0.05 N o methadone
1-6 cm history
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Table 8.10: Conclusions drawn from hair and blood findings and drug use history
Case Hair Findings Blood
Findings
Drug use history Conclusions
HO/01 Regular, medium user 
of heroin for at least 4 
months. Methadone 
user for 1 month.
Methadone
user
Known cannabis 
and other illicit 
drug user.
Regular, medium 
heroin user
HO/02 Regular, medium user 
of heroin for at least 3 
months.
Morphine
user
Known heroin user. Regular, medium 
heroin user
HO/03 Heroin user. Low 
concentrations.
Morphine
user
Known heroin user. 
Previously on 
methadone 
programme.
Low heroin user
HO/04 Low concentrations of 
morphine and codeine 
in months 4-7 prior to 
death. Insufficient hair 
root sample. 
Inconclusive of heroin 
use
Morphine
user
Known heroin user Findings indicate not 
a regular user, but 
may be due to 
insufficient hair 
sample. Heroin user, 
extent inconclusive
HO/05 Low user of heroin for 
2 months.
Heroin user Not known. Low heroin user 1
HO/06 Regular, low user of 
heroin for at least 7 
months. Methadone 
user for months 2-7 
prior to death.
Morphine
and
methadone
user
Known heroin user. Regular low heroin 1 
user
HO/07 Regular, high user of 
heroin for at least 9 
months.
Morphine
user
Known heroin user 
for 20 years.
Regular, high heroin 
user
HO/08 Regular, medium user 
of heroin for at least 5 
months.
Heroin user Known heroin user. Regular, medium 1 
heroin user
HO/09 Regular, high user of 
heroin for at least 4 
months.
Heroin user Known heroin user 
for 5 years. 
Prescribed 
methadone one 
month prior to 
death.
Regular, high heroin 
user
HO/10 Regular, medium user 
of heroin for at least 5 
months. Methadone 
user for months 2-5 
prior to death.
Morphine
user
Known heroin user 
for 3 years 
(smoked). Came 
off methadone 
programme 2 
months prior to 
death.
Regular, medium 
heroin user
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Table 8.11: Conclusions drawn from hair and blood findings and drug use history
Case Hair Findings Blood
Findings
Drug use 
history
Conclusions
HO/11 6-MAM only detected 
1.5-2.5 months prior 
to death. Insufficient 
hair root sample.
Heroin user Known heroin 
user. Attended 
several drug 
rehabilitation 
programmes.
Intermittent heroin user 1
HO/12 Methadone user. Not 
detected in root 
sample.
Heroin user Known heroin 
abuser for 5 
years. On 
methadone 
programme. 
Intake reduced 
from 60 to 8 ml 
and had stopped 
taking it 2 weeks 
prior to death.
Intermittent heroin user
HO/13 Low heroin user Heroin user Known drug user Low heroin user
HO/14 Low heroin user Heroin user Long history of 
drug abuse
Low heroin user
HO/15 Low heroin user Heroin user Known drug 
abuser for 2-3 
years
Low heroin user
HO/16 Regular, high heroin 
user. Methadone user.
Heroin user Known heroin 
user
Regular, high heroin 1 
user. N.B. Cause of 
death was hanging.
HO/17 No indication of 
heroin or methadone 
use. (Root sample size 
very small.)
Morphine
and
methadone
user
Possible 
diamorphine 
user over 4 
weeks prior to 
death.
Naive user of heroin. 1
HO/18 No indication of 
heroin use.
Heroin user Known drug 
user. Drug 
rehabilitation 
programme. 
Claimed he had 
been clean for 4 
weeks(one 
month prior to 
death).
Intermittent heroin user 1
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Table 8.12: Conclusions drawn from hair and blood findings and drug use history
Case Hair Findings Blood
Findings
Drug use 
history
Conclusions 1
HO/19 Regular, medium user 
of heroin for at least 2 
months. Methadone 
user for same period.
Methadone
user
Long history of 
drug abuse. 
Numerous 
methadone and 
detoxification 
programmes.
Regular, medium 1 
heroin user
HO/20 Regular medium user 
for at least two 
months. Methadone 
user for same period.
Heroin user Known heroin 
user for 5 years
Regular, medium 
heroin user
HO/21 Low heroin user for at 
least 6 months. 
Methadone user for 
two months prior to 
death.
Methadone
user
Known drug 
user. Not on 
methadone 
programme.
Low heroin user.
HO/22 Low concentrations of 
morphine detected in 
hair. 6-MAM detected 
only in one segment.
Heroin user Regular heroin 
user 10 years 
prior to death. 
Denied using 
heroin in last 10 
years.
Low heroin user.
HO/23 Medium heroin and 
methadone user for at 
least two months
Heroin and 
methadone 
user
Occasional 
heroin user. Not 
known if regular 
user of heroin.
Regular, medium 
heroin user.
HO/24 Low concentrations of 
morphine detected. 
Inconclusive of heroin 
use
Heroin user Occasional 
heroin user.
Findings indicate not a 
regular user, but may 
be due to insufficient 
hair sample. Heroin 
user, extent 
inconclusive
HO/25 Regular, medium 
heroin user for at least 
3 months.
Morphine
user
History of
morphine
addiction.
Regular, medium I 
heroin user.
HO/26 Regular, high heroin 
user for at least 6 
months.
Heroin and 
methadone 
user
Known drug 
user. Registered 
heroin addict.
Regular, high heroin 1 
user.
HO/27 Regular, high heroin 
user for at least 7 
months.
Heroin user Known heroin 
user.
Regular, high heroin 
user.
-
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Table 8.13: Conclusions drawn from hair and blood findings and drug use history
Case Hair Findings Blood
Findings
Drug use 
history
Conclusions
HO/28 Low concentration of 
morphine detected. 
Inconclusive of heroin 
use
Morphine
user
Known heroin 
user in past. 
Believed to be 
intermittently 
taking heroin 
with tablets 
prescribed for 
withdrawal.
Intermittent heroin user
HO/29 Low concentration of 
morphine detected. 
Inconclusive of heroin 
use
Heroin user Not known Low heroin user
HO/30 Morphine detected 
over a 4 month period. 
Inconclusive of heroin 
use
Heroin user Long history of 
heroin use.
Low heroin user
j HO/31 Low heroin user for at 
least 4 months.
Not analyzed Not known Regular, low heroin 
user |
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8.2 CASE SUMMARIES
Case HO/01 Sex: Male Age: 25 years
Drug abuse history: Known to have abused cannabis and other illicit drugs
Medication at time of death: Not known
Circumstances of death: Released from prison 6 weeks prior to death. Last contact with 
deceased was phone call with sister. Deceased could not be awakened. Ambulance 
technicians found him dead. CPR. Life pronounced extinct at hospital. No track marks 
indicating intravenous drug abuse.
Toxicology: desmethyldiazepam 1.7 mg/L, diazepam 0.4 mg/L, EDDP 0.3 mg/L,
methadone 0.3 mg/L
COD: la Methadone and diazepam intoxication
Case HO/02 Sex: Male Age: 32 years
Drug abuse history: Abused various drugs for entire adult life. At age 13 he abused 
solvents then made transition to harder drugs, injecting Temegesic tablets and at age 20 
started injecting heroin.
Medication at time of death: Not known
Circumstances of death: Booked into a hostel and was last seen alive by a member of 
staff. Following day found lying on floor apparently dead, with trousers around his ankles. 
Signs of drug misuse about the room. Surgeon pronounced life extinct. Hypodermic needle 
found protruding from groin. No suspicious circumstances.
Toxicology: desmethyldiazepam 0.3 mg/L, morphine 0.5 mg/L 
COD: la Heroin intoxication
Case HO/03 Sex: Male Age: 28 years
Drug abuse history: Drug misuse problem became apparent in 1999. Prescribed 
methadone, 40 mg/day at start of programme. He was not on methadone at time of death. 
Medication at time of death: None
Circumstances of death: Deceased found lying on floor of toilets in hostel. CPR. 
Ambulance crew did not carry out further medical assistance. Casualty surgeon
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pronounced life extinct. Diazepam tablets and a paper wrap containing a small quantity of 
white crystals were found on body. Syringe was also later obtained.
Toxicology: desmethyldiazepam 0.7 mg/L, diazepam 0.6 mg/L,
1 l-nor-delta-9-THC-COOH 75 ng/ml, codeine 0.1 mg/L, morphine 0.7 mg/L 
COD: la Acute heroin poisoning
Case HO/04 Sex: Male Age: 46 years
Drug abuse history: Known heroin abuser and known to drink alcohol frequently. 
Medication at time of death: Betablockers and antidepressant, Cipramil 
Circumstances of death: Deceased consumed 6 pints of beer and 2 whiskeys in bar with 
friends. Went to friend's house to snort heroin. Deceased appeared to fall asleep, breathing 
heavily and looked unwell. CPR. Ambulance staff found him dead. Casualty surgeon 
pronounced life extinct. A set of miniature scales and assorted literature in relation to HIV 
and drugs was found.
Toxicology: alcohol 194 mg/100 ml (blood), alcohol 294 mg/100 ml urine, morphine 0.3
mg/L
COD: la Heroin and alcohol intoxication
Case HO/05 Sex: Male Age: 24 years
Drug abuse history: Known intravenous drug user.
Medication: diazepam, dihydrocodeine, thioridazine, prothiaden.
Circumstances of death: Two friends of deceased arrived at house and noticed that 
deceased was under influence of drugs. They smoked a bag of heroin. Deceased appeared 
"out of it" and his speech was slurred. Deceased found lying on bed with eyes open, but 
not responding. CPR. Ambulance technicians could not revive deceased. Two packs of 
diazepam tablets lying empty on deceased's bed and a spoon lying beside a hypodermic 
syringe next to the bed. Police surgeon pronounced life extinct.
Toxicology: desmethyldiazepam 0.4 mg/L, diazepam 0.4 mg/L, codeine 0.1 mg/L,
dihydrocodeine 0.3 mg/L, morphine 0.2 mg/L
COD: la Heroin , dihydrocodeine and diazepam intoxication
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Case HO/06 Sex: Male Age: 33 years
Drug abuse history: Known heroin abuser 
Medication at time of death: None
Circumstances of death: Released from prison four days prior to death. Two days after 
release common law wife gave deceased 10 ml of her methadone prescription. He later 
gave her 5 blue valium and at this point he appeared "out of it". Deceased and friend 
injected heroin. Deceased found lying face down, snoring. Following day deceased still 
lying in face down position, apparently dead. Police surgeon pronounced life extinct. A 
spoon with a substance and a sharp bin with used needles and syringes were found. A 
needle and syringe were found beneath deceased where groin area had been.
Toxicology: diazepam 0.4 mg/L, methadone 0.03 mg/L, morphine 0.1 mg/L 
COD: la Heroin intoxication
Case HO/07 Sex: Male Age: 39 years
Drug abuse history: Known intravenous heroin abuser for 20 years.
Medication at time of death: Amoxycillin
Circumstances of death: Two weeks previous to his death deceased injected heroin into 
muscle. He injured leg by falling on stairs. A few days later a hole appeared on knee which 
increased in size over next few days. Doctor prescribed amoxycillin. Three days later 
deceased was in a lot of pain but refused to see doctor again. Friend saw deceased injecting 
heroin into groin. Later no response was obtained from deceased. Friend attempted CPR. 
Police surgeon pronounced life extinct. Drug paraphernalia found in flat.
Toxicology: alcohol 11 mg/100 ml (blood), diazepam 0.2 mg/L, temazepam 0.1 mg/L, 
dihydrocodeine 0.5 mg/L, morphine 0.2 mg/L, paracetamol 3.2 mg/L 
COD: la Multiple organ failure due to
lb clostridium novyi toxaemia/necrotising faciitis due to 
Ic chronic injecting drug abuse
Case HO/08 Sex: Male Age: 44 years
Drug abuse history: History of heroin abuse. No details of seeking assistance for 
problem.
Medication at time of death: None
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Circumstances of death: Deceased was at the flat where he was residing and injected 
heroin. Friend noticed the deceased walking with limp. Deceased complained of pain in his 
left groin. Deceased's breathing was laboured and limping was more noticeable. Friend 
was aware of deceased being sick. Deceased refused to go to see a doctor and sickness 
continued. Following day deceased showed friend that his nails were blue in colour and 
friend advised he go visit doctor. He was later found lying on kitchen floor. CPR. Surgeon 
pronounced life extinct.
Toxicology: codeine 0.01 mg/L, morphine 0.1 mg/L 
COD: la  Staphylococcus necrotising fasciitis due to 
lb  Chronic Injecting Drug Abuse
Case HO/09 Sex: Male Age: 26 years
Drug use history: History of heroin abuse since 1995. Previously prescribed methadone. 
He had a £70-80 /day habit in January 1999 and by May 2000 £30-50/day habit (24 days 
prior to death).
Medication: Prescribed 60 ml/day methadone
Circumstances of death: Deceased attended hospital and was diagnosed as having a leg 
ulcer, given antibiotics and released the following day. He injected heroin in front of 
friend. Hostel assistants later found deceased lying on bed and he appeared to be dead. 
Ambulance crew confirmed that deceased was dead. Police surgeon pronounced life 
extinct. Heroin bag and contents retrieved by police.
Toxicology: desmethyldiazepam 0.2 mg/L, diazepam 0.2 mg/L, codeine 0.02 mg/L,
morphine 0.2 mg/L
COD: la Multiple organ failure due to
lb Clostridium novyi toxaemia due to 
Ic cellulitis/necrotising faciitis of right groin due to 
Id chronic injecting drug abuse
Case HO/10 Sex: Male Age: 25 years
Drug abuse history: Heroin user for 3 years (smoked). Placed on a methadone programme 
from May 1999 - March 2000 until he was accepted into a rehabilitation centre.
Medication at time of death: Amitriptyline and diazepam
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Circumstances of death: Deceased last seen alive by flatmate. Flatmate returned from 
work to find deceased lying on floor face down. Police surgeon pronounced life extinct. 
Surgeon pronounced life extinct. Plastic bottle adapted for smoking and two white pills 
were found in room.
Toxicology: morphine 0.04 mg/L 
COD: la Heroin intoxication
Case HO/11 Sex: Male Age: 25 years
Drug abuse history: Abused drugs for 5 years, mainly injecting heroin and taking 
diazepam tablets. He was not on a methadone programme. And had attended several drugs 
rehabilitation programmes in the past, all which failed.
Medication at time of death: Diazepam
Circumstances of death: Deceased was in a snooker/pool hall. He asked to use toilets. 
After twenty minutes he had not returned and worker on the premises became concerned 
He found door locked and requested assistance. Deceased was found slumped on floor 
with trousers at ankles and belt tied round left arm. CPR. Police surgeon pronounced life 
extinct.
Toxicology: diazepam 0.3 mg/L, codeine 0.1 mg/L, morphine 0.3 mg/L 
COD: la Heroin and diazepam intoxication
Case HO/12 Sex: Male Age: 32 years
Drug abuse history: Registered heroin addict in 1995, suffered from an addiction for five 
years. Also known to have abused diazepam in past. He was on a methadone programme. 
Reduced methadone intake from 60 ml to 8 ml. Two weeks prior to death, deceased had 
stopped taking methadone altogether.
Medication at time of death: None
Circumstances of death: Deceased had some cans of lager with girlfriend in park then left 
her to go home. She knocked on door on several occasions and got no reply. She gained 
access to house via neighbour's veranda and found deceased lying face down in bedroom. 
Police surgeon pronounced life extinct. Drug paraphernalia were found at scene. 
Toxicology: alcohol 141 mg/100 ml (blood), alcohol 228 mg/100 ml (urine), codeine 0.04 
mg/L, morphine 0.4 mg/L
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COD: la Suspected drug related death due to 
lb Heroin and alcohol intoxication
Case HO/13 Sex: Male Age: 38 years
Drug abuse history: Known drug user 
Medication at time of death: None
Circumstances of death: Released from prison 1 day prior to death. Deceased arrived at 
friend's house with "4 tenner bags of heroin" They both took drugs intravenously and 
friend left agreeing to meet up later with deceased. They met up and the deceased smoked 
another bag o f heroin. Deceased informed friend he was going to buy more heroin and they 
met up back at flat and injected a bag each. Deceased fell asleep on couch. Following 
morning deceased found lying face down on couch and believed he was dead. Life was 
pronounced extinct by police surgeon. Drug paraphernalia was seized.
Toxicology: codeine 0.01 mg/L, morphine 0.1 mg/L 
COD: la Suspected drug overdose due to 
lb heroin intoxication 
Conditions contributing to death:
II Bronchopneumonia
Case HO/14 Sex: Male Age: 23 years
Drug abuse history: Long history of drug abuse. Overdosed on drugs on four different 
occasions.
Medication at time of death: None
Circumstances of death: Deceased released from prison one day prior to death. He 
returned home with intention of sleeping rough following fall out with mother over drug 
problem. Mother spoke to deceased who was lying in the rear garden. Later that day, 
brother awakened and saw deceased lying face down at back of home. Hypodermic needle 
was found in groin and no vital signs of life. CPR. Life pronounced extinct. Drug 
paraphernalia and brown powder seized.
Toxicology: desmethyldiazepam 0.4 mg/L, diazepam 0.4 mg/L, temazepam 0.5 mg/L 
codeine 0.02 mg/L, morphine 0.1 mg/L 
COD: la Morphine toxicity
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Case HO/15 Sex: Male Age: 24 years
Drug abuse history: History of heroin abuse for 2-3 years (intravenous).
Medication at time of death: None
Circumstances of death: Released from prison 2 weeks prior to death. Deceased's 
girlfriend left him in house and when she returned an hour later she could not gain access 
to house. Contacted concierge. Joiner gained access to home and the deceased was found 
lying face down on living room floor. No signs of life. Surgeon pronounced life extinct. A 
needle puncture mark was found on left arm and hypodermic syringe and other drug 
paraphernalia were seized.
Toxicology: desmethyldiazepam 0.3 mg/L, diazepam 0.3 mg/L, codeine 0.1 mg/L, 
morphine 0.5 mg/L
COD: la Suspected drug related death to 
lb Heroin and diazepam intoxication
Case HO/16 Sex: male Age: 61 years
Drug abuse history: History of heroin abuse and heavy drinker.
Medication at time of death: dihydrocodeine, atenolol, aspirin, glipizide 
Circumstances of death: Deceased had not met neighbour as rearranged. Neighbour 
contacted concierge at deceased's flat. Attended flat but could not enter flat. Contacted 
police. Police found deceased sitting on floor hall with ligature round neck. Surgeon 
pronounced life extinct. Drug paraphernalia were found.
Toxicology: desmethyldiazepam 0.1 mg/L, diazepam 0.4 mg/L, codeine 0.004 mg/L, 
morphine 0.1 mg/L 
COD: la Hanging
Case HO/17 Sex: Female Age: 25 years
Drug abuse history: According to partner she was abusing diamorphine over past 4
weeks.
Medication at time of death: venlafaxine
Circumstances of death: Deceased told partner she was going to buy heroin. She
returned later and stated that she had bought two bags of heroin. They snorted one of the 
bags. Friend arrived to prepare the second bag for smoking. They smoked the contents of
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this bag and left the house before midnight. Deceased settled to sleep on floor with partner. 
Partner woke up two hours later and noted that subject did not move. Partner slept on 
couch and subject had not moved by next morning. Life pronounced extinct. No injection 
sites detected.
Toxicology: alcohol 18 mg/100 ml (blood), alcohol 67 mg/100 ml (urine), temazepam 0.2 
mg/L, methadone 0.02 mg/L, morphine 0.3 mg/L 
COD: la Morphine toxicity
Case HO/18 Sex: Male Age: 51 years
Drug abuse history: Past intravenous drug abuser and alcoholic. Previously abused 
heroin, temazepam, diazepam and cannabis. He was in drug rehabilitation for 4 weeks. 
Medication at time of death: None
Circumstances of death: Deceased and friend bought a "bag" of heroin and went to 
friend's house to inject. They went into the close and injected half of the deal each into 
their own arms. Deceased suddenly collapsed. CPR. Life was pronounced extinct that day 
at hospital.
Toxicology: 194 mg/100 ml alcohol (blood), codeine 0.02 mg/L, morphine 0.1 mg/L,
6-MAM 0.01 mg/L
COD: la Heroin and alcohol abuse
Case HO/19 Sex: male Age: 44 years
Drug abuse history: Long history of alcohol and drug abuse since age of 16. He had been 
on numerous methadone programmes and in and out of drug detoxification programmes. 
Medication at time of death: dihydrocodeine, diazepam
Circumstances of death: Friend entered flat and found deceased sitting on couch in living 
room with hypodermic syringes lying by his side CPR. Surgeon pronounced life extinct. 
Toxicology: alcohol 162 mg/100 mL (blood), alcohol 154 mg/100 mL (urine) 
desmethyldiazepam 1.0 mg/L, diazepam 0.5 mg/L, oxazepam 0.5 mg/L, temazepam 0.2 
mg/L, methadone 0.02 mg/L, morphine 0.2 mg/L 
COD: la Heroin, alcohol and diazepam intoxication.
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Case HO/20
Sex: male Age: 24 years
Drug abuse history: Habitual drug user who started taking temazepam tablets at 18, then 
heroin at age 19. Referred to drug rehabilitation unit.
Medication at time of death: None
Circumstances of death: Deceased was observed sitting on landing outside flat. Witness 
later found him lying on landing and thought he was asleep through drink. When he was 
still lying there sometime later witness became concerned and called for assistance. 
Surgeon pronounced life extinct and a fresh puncture wound/needle mark was noticed on 
the deceased's left arm. Drug paraphernalia were found in flat and outside main door of 
flat.
Toxicology: desmethyldiazepam 0.8 mg/L, diazepam 0.6 mg/L, oxazepam 0.4 mg/L 
temazepam 0.2 mg/L, codeine 0.1 mg/L, morphine 0.5 mg/L 
COD: la Heroin and diazepam intoxication 
II Bronchopnemonia
Case HO/21
Sex: male Age: 23 years
Drug abuse history: Visited doctor on three occasions about drug abuse. Deceased 
informed doctor he was using opiates, diazepam, cannabis and ecstacy. Not placed on 
methadone programme.
Medication at time of death: Ventolin and Becotide
Circumstances of death: Deceased was drinking heavily with two friends at his home 
address. Two friends arrived at house later on in day and tried to rouse deceased. When he 
failed to wake they summoned an ambulance. Police surgeon pronounced life extinct. 
Toxicology: alcohol 40 mg/100 ml (blood), alcohol 84 mg/100 ml (urine), 
desmethyldiazepam 0.28 mg/L, diazepam 0.37 mg/L, oxazepam 0.36 mg/L, delta-9-THC 
0.8 ng/mL, ll-nor-delta-9-THC-COOH 10.5 ng/ml, methadone 0.14 mg/L 
COD: la Fatty degeneration of the liver
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Case HO/22
Sex: female Age: 41
Drug abuse history: Regular heroin user from 17-30 years. Denied abusing drugs since 30 
years of age. Chronic alcohol user since 30 years of age.
Medication at time of death: Human Mixtard Insulin, Vitamin B Strong, dihydrocodeine, 
thiamine, frusemide, spironolactone, lactulose
Circumstances of death: Deceased's aunt was at her house assisting her taking a bath. She 
noticed a severe swelling on her back around site of a recently removed kidney. She made 
a doctor's appointment. Four days later the aunt received a call from deceased claiming she 
was very unwell. She was admitted to hospital with sepsis and swelling to the right, loin 
area. Condition deteriorated over next few days and she lapsed into multi-organ failure. 
Doctor pronounced life extinct. Prior to death deceased vehemently denied abusing drugs 
over past 10 years.
Toxicology: codeine 0.01 mg/L, morphine 0.1 mg/L 
COD: la Multiple Organ Failure due to 
lb Staph aureus sepsis due to 
Ic cirrhosis of the liver and chronic drug abuse
Case HO/23
Sex: male Age: 33
Drug abuse history: Known heavy drinker. Not known if he was a regular drug abuser but 
had smoked heroin on at least one occasion.
Medication at time of death: Not known
Circumstances of death: Deceased was last seen alive by friend and at this time he was 
heavily under the influence o f alcohol. Three days later the deceased's brother became 
concerned about the him, went to his house and found the deceased in a kneeling position 
bent forwards with hands underneath his head. Deceased had cuts to his head, blood 
around his nose. Police surgeon pronounced life extinct. A search of the flat produced drug 
paraphernalia (a burnt spoon, a shoe lace and silver foil).
Toxicology: alcohol 143 mg/100 ml (blood), alcohol 202 mg/100 ml (urine), EDDP 0.001 
mg/L, methadone 0.02 mg/L, codeine 0.03 mg/L, morphine 0.29 mg/L 
COD: la Heroin intoxication
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Case HO/24
Sex: male Age: 37
Drug abuse history: Alcohol abuser for 6 years. Casual drug user who occasionally 
injected heroin.
Medication at time of death: None
Circumstances of death: Deceased consumed two one litre bottles of cider at ex- 
girlfriend's house. He left the flat with girlfriend and was believed to have purchased a 
"tenner bag of heroin" They returned to the flat and injected some heroin. Shortly after 
injecting, the deceased lapsed into unconsciousness with his eyes rolling and stopped 
breathing. CPR. Deceased was taken to hospital and pronounced dead on arrival. Police 
found a stained teaspoon, reefer type cigarettes, cling film and three blister packs 
containing 50, 17 and 106 tablets
Toxicology: alcohol 193 mg/100 ml (blood), alcohol 298 mg/100 ml (urine), 6-MAM 0.01 
mg/L, codeine 0.06 mg/L, morphine 0.4 mg/L 
COD: la Heroin and alcohol intoxication
Case HO/25
Sex: male Age: 42
Drug abuse history: History of intravenous morphine addiction 
Medication at time of death: None
Circumstances of death: Deceased complained of sickness and diahorrea to friend for 
which he had been taking anadin and imodium. Friend tried to contact deceased and after 
several attempts visited with other friends. On receiving no reply they forced the door and 
found him dead on bed. Police surgeon pronounced life extinct.
Toxicology: alcohol (blood) 308 m g/100 ml, desmethyldiazepam 0.17 mg/L, diazepam 
0.09 mg/L, morphine 0.38 mg/L, paracetamol 15.41 mg/L 
COD: la Heroin and alcohol intoxication
Case HO/26
Sex: male Age: 42
Drug abuse history: History o f intravenous drug abuse. Registered heroin addict (£100 
per day habit). Known alcohol abuser.
Medication at time of death: None
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Circumstances of death: Wife of deceased returned from local shop to find deceased 
lying unconscious on kitchen floor. His trousers were round his ankles and needles were 
lying at his sides. CPR. Life was pronounced extinct at hospital. Recent injection marks 
found on groin.
Toxicology: desmethyldiazepam 0.35 mg/L, diazepam 0.25 mg/L, methadone 0.05 mg/L,
codeine 0.02 mg/L, morphine 0.18 mg/L
COD: la Heroin, diazepam and methadone intoxication
Case HO/27
Sex: male Age: 19
Drug abuse history: Known drug user. Admitted to doctor that he was smoking 4 bags of 
heroin a day. Referred to detoxification clinic.
Medication at time of death: None
Circumstances of death: Deceased and friend came to Glasgow to attend Drug 
Rehabilitation Unit to get off heroin. The deceased had in his possession 1 gram of heroin 
and blue valium tablets. Deceased left room where they were staying to buy some beer and 
sweets. An hour later he returned and appeared to be under the influence of drugs. Two 
hours later, the friend went to his bed leaving the deceased sitting in the chair. The 
following morning friend returned to the room after breakfast with guest house manager 
who was collecting payment for the room. At this time, they observed the deceased 
sleeping on the chair, snoring. Friend went for a shower and on returning to the room he 
noticed the deceased had stopped breathing. CPR. Life was pronounced extinct at hospital. 
Police found a small metal smoking pipe in the deceased's bag.
Toxicology: desmethyldiazepam 1.11 mg/L, diazepam 0.95 mg/L, oxazepam 0.1 , mg/L, 
codeine 0.02 mg/L, morphine 0.11 mg/L 
COD: la Heroin and diazepam intoxication
Case HO/28
Sex: male Age: 25
Drug abuse history: Known heroin user. Prescribed tablets to help with withdrawal from 
heroin
Medication at time of death: Not known
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Circumstances of death: Deceased was ejected from night club for being too drunk. 
About two and a half hours later he appeared at dwelling house o f two friends. They 
smoked three cannabis joints supplied by the deceased and the deceased informed them 
that he had just taken a bag of heroin. They all fell asleep. The following morning the two 
friends awoke and commented on the deceased's loud snoring and tried to wake him, but 
could not. They both left the house with the deceased still sleeping. Returning later in the 
evening the friends found the deceased lying in same position as they had left him and 
found his body very cold. Paramedics found deceased lying in living room floor apparently 
dead. Life was pronounced extinct by police surgeon. A syringe cap was found near the 
deceased's body.
Toxicology: alcohol 23 mg/100 ml (blood), alcohol 137 mg/100 ml (urine), 
desmethyldiazepam 0.22 mg/L, diazepam 0.18 mg/L, dihydrocodeine 0.04 mg/L, morphine 
0.03 mg/L
COD: la Multiple drug and alcohol intoxication 
Case HO/29
Sex: male Age: 31
Drug abuse history: Not known. Three days prior to death he was admitted to hospital 
after taking an overdose of tablets (type not known).
Medication at time of death: Not known
Circumstances of death: Deceased and brother reported missing by parents. Brother 
phoned parents telling them that deceased had commited suicide. He returned home next 
d a y  informing his parents his brother was dead in a dwelling house. The body was found in 
a bedroom in dwelling house, lying on back on bed. Police surgeon pronounced life 
extinct. Drug paraphernalia (sin bin containing syringes) were found at scene. Brother 
admitted buying three valium tablets and a bag of heroin for the deceased so he could take 
his own life. Householder of dwellinghouse entered bedroom occupied by deceased and 
watched brother inserting syringe into deceased's arm. Householder and brother checked 
on deceased regularly and found him asleep, breathing heavily and on one occasion he had 
been sick.
Toxicology: diazepam 0.07 mg/L, codeine 0.01 mg/L, morphine 0.02 mg/L 
COD: la Bronchopneumonia
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Case HO/30
Sex: male Age: 32
Drug abuse history: Long history of heroin abuse and had also been treated for injecting 
diazepam. Last time he was seen by doctor he was treated for injecting heroin.
Medication at time of death: None
Circumstances of death: Deceased was released from prison four months prior to death 
and since then he had been residing in a hostel. He appeared normal the day prior to death. 
On the following day a hostel worker entered the deceased's room and observed the 
deceased with his head under a dressing table and his trousers round his ankles. A needle 
was found on the dressing room table. Police surgeon arrived and pronounced life extinct. 
Police seized a syringe and a wrap which was suspected to have contained controlled 
drugs.
Toxicology: desmethyldiazepam 0.5 mg/L, codeine 0.08 mg/L, morphine 0.56 mg/L 
paracetamol 6.11 mg/L 
COD: la Heroin intoxication
Case HO/31 
Sex: male
No other information available
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8.3 ANTIDEPRESSANTS IN BLOOD
8.3.1 WHOLE BLOOD
The developed solid phase extraction method in Chapter 4 was used to extract fluoxetine 
and paroxetine from postmortem peripheral blood samples and also blood samples 
obtained from live patients which were collected by standard venipuncture 
procedure.Ethical approval was obtained for this study.
8.3.2 FLUOXETINE CASES
21 postmortem blood samples were analyzed for fluoxetine and its metabolite. The results 
of these analyses are displayed in Table 8.14. Fluoxetine concentrations were found to vary 
from 0 - 1.916 mg/L and norfluoxetine concentrations from 0.018 - 1.736 mg/L. 
Fluoxetine/norfluoxetine ratios varied from 0.181 - 14.406.
Drug concentrations in 6 fatalities have ranged from 1.3 - 6.8 (mean 3.8) mg/L blood for 
fluoxetine and 0.9 - 5.0 (mean 2.1) mg/L blood for norfluoxetine.62 However, in four of 
these cases at least one other drug codeine, meperidine, clozapine or diphenhydramine was 
detected in the blood.
There were three cases where the levels of fluoxetine and/or norfluoxetine were higher 
than normal therapeutic values. For case BP/10, an overdose level of fluoxetine and 
norfluoxetine was detected at 0.631 and 1.736 mg/L respectively. The half-life of 
fluoxetine is 1 - 3 days. Since a higher level of metabolite was detected than parent drug 
then this individual must have lived for several hours after taking the dose. On the other 
hand, case BP/20 showed an overdose level of fluoxetine at 1.916 mg/L and a much lower 
concentration of norfluoxetine 0.133 mg/L. This person was either a poor metabolizer of 
fluoxetine or died relatively shortly after taking the dose.
Case BP/13 also gave values higher than maximum therapeutic levels. All other cases gave 
values within the therapeutic range.
Examples of chromatograms obtained for the fluoxetine blood analyses are shown in 
Figures 8.6-8.9.
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Table 8.14: Fluoxetine Postmortem Blood Cases
Case
sample
Fluoxetine
(mg/L)
Norfluoxetine
(mg/L)
Fluoxetine/ 1 
Norfluoxetine |
BP/01 0.180 0.210 0.857
BP/02 0.100 0.130 0.769
BP/03 0.070 0.090 0.778
BP/04 0.110 0.296 0.372
BP/05 0.125 0.197 0.635
BP/06 0.064 0.098 0.653
BP/07 0.179 0.369 0.485
BP/08 0.210 0.018 11.667
BP/09 0.017 0.094 0.181
BP/10 0.631 1.736 0.363
BP/11 0.122 0.195 0.626
BP/12 0.103 0.154 0.669
BP/13 0.664 0.752 0.883
BP/14 0.429 0.442 0.971
BP/15 0.073 0.052 1.403
BP/16 - ve 0.072 -
BP/17 0.057 0.047 1.213
BP/18 0.007 0.028 0.250
BP/19 0.114 0.317 0.360
BP/20 1.916 0.133 14.406
BP/21 0.054 0.058 0.931 |
Twelve clinical blood samples obtained from patients who were known to have been 
prescribed Prozac were analyzed. The results obtained using the solid phase extraction 
procedure are displayed in Table 8.15 along with the ratio o f parent drug to metabolite in 
each case. For these cases, fluoxetine concentrations were found to vary from 
0.013 - 0.196 mg/L and norfluoxetine concentrations from 0.011 - 0.199 mg/L. 
Fluoxetine/norfluoxetine ratios varied from 0.155 - 2.649. All of these patients had been 
prescribed 20 mg/day. Steady state serum concentrations of fluoxetine and its metabolite 
have been shown to vary from 0.025 - 0.473 (mean 0.109) mg/L and 0.018 - 0.466 (mean 
0.130) mg/L respectively for patients who were receiving 20-60 mg of the drug daily.100 
One of the samples produced negative results for fluoxetine and norfluoxetine. Medical 
notes indicated that this patient had commenced treatment 24 hours prior to the sample 
being taken. A single 40 mg oral dose in adults produced peak plasma fluoxetine levels of 
0.015 - 0.055 mg/L withing 6-8 hours.62 Therefore, a 20 mg oral dose would produce 
significantly lower peak plasma levels and after 24 hours these levels may have decreased 
to levels below the limit of detection of the method.
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Table 8.15: Fluoxetine Clinical Blood Cases
Case
sample
Fluoxetine
(mg/L)
Norfluoxetine
(mg/L)
Fluoxetine/ 
Norfluoxetine |
BV/21 0.042 0.185 0.227
BB/22 0.156 0.068 2.294
BB/23 0.196 0.074 2.649
BL/02 0.114 0.109 1.046
BL/03 0.024 0.155 0.155
BL/04 0.103 0.199 0.518
BL/05 0.079 0.128 0.617
BL/06 - ve - ve -
BL/07 0.059 0.119 0.496
BL/12 0.013 0.015 0.867
BL/13 0.062 0.075 0.827
BL/15 0.029 0.011 2.636
8.3.3 PAROXETINE CASES
14 postmortem blood samples which were known to be positive for paroxetine were 
analyzed. The results obtained using the solid phase extraction procedure are displayed in 
Table 8.16. Paroxetine concentrations were found to vary from 0.021 - 0.593 mg/L. Peak 
plasma paroxetine concentrations were found to have a mean value of 0.062 mg/L after 
treatment with 30 mg/day. It would therefore appear that at least 10 of these cases were 
overdose cases with values from 0.143 - 0.593 mg/L.
Drug concentrations in 4 fatalities have ranged from 1.4 - 4.0 (mean 2.7) mg/L blood. 
However, in two of these cases imipramine or moclobemide were detected in significant 
quantities in the blood.62
Table 8.16: Paroxetine Postmortem Blood cases
Case sample 
| Postmortem
Paroxetine
(mg/L)
Case sample 
Postmortem
Paroxetine I 
(mg/L)
BP/22 0.165 BP/29 0.398
BP/23 0.202 BP/30 0.327
BP/24 0.258 BP/31 0.143
BP/25 0.593 BP/32 0.021
BP/26 0.085 BP/33 0.078
BP/27 0.558 BP/34 0.367
BP/28 0.310 BP/35 0.027 I
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1 clinical blood sample obtained from a patient who was known to have been prescribed 
Seroxat® was analyzed. For this case the concentration of paroxetine detected was 
0.048 mg/L. This patient had been prescribed 20 mg/day for a period of one year and this 
level is within the therapeutic range for this dose. Examples of chromatograms obtained for 
the paroxetine blood analyses are shown in Figures 8.10-8.12.
8.3.4 CONCLUSIONS
The developed method was successfully evaluated using clinical and postmortem blood 
samples. Fluoxetine, norfluoxetine and paroxetine levels determined in postmortem 
samples gave values ranging from therapeutic to overdose levels and in clinical samples 
only therapeutic levels were detected.
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Figure 8.6: Chromatogram of extract of blank blood spiked with 100 ng/ml internal 
standard
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Figure 8.7: Chromatogram of extract of blood spiked to give 100 ng/ml fluoxetine and 
norfluoxetine
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Figure 8.8: Chromatogram of extract of blood from Case BP/19
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Figure 8.9: Chromatogram of extract of blood from Case BP/20
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Figure 8.10: Chromatogram of extract of blank blood spiked with 50 ng/ml internal 
standard
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Figure 8.11: Chromatogram of extract of blood spiked to give 100 ng/ml paroxetine
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Figure 8.12: Chromatogram of extract of blood from case BP/34
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8.4 ANTIDEPRESSANTS IN SALIVA
8.4.1 SAMPLE COLLECTION AND STORAGE
Saliva and blood samples were collected simultaneously where possible from patients
attending clinics and geriatric patients who were receiving Prozac® or Seroxat® treatment 
for depression. Blood was collected by fully qualified medical staff by standard 
venipuncture procedure and saliva samples were collected using Omni-Sal® devices.
Samples were transferred to the laboratory and stored at - 4 °C.
8.4.2 EXTRACTION OF SAMPLES
Blood and saliva samples were extracted using the validated method in Chapter 5 and 
analyzed by GC/MS.
8.4.3 PATIENT DETAILS
Twelve saliva samples were obtained from nine patients receiving treatment with Prozac®.
One of these volunteers (SV/1) provided five samples over different days and the other
seven provided one sample each. Only seven blood samples were collected from the
• • •patients simultaneously. One patient receiving Seroxat treatment provided a saliva and 
blood sample. Information received from the volunteers where possible was age, sex, 
dosage of drug, length of time drug had been prescribed (Table 8.17), when the last dose 
was taken and information regarding other medications which may affect analysis.
Table 8.17: Patient details
Patient Sex Age Drug prescribed Dosage
(mg/day)
Duration patient has 
been prescribed drug
SV/1 F 58 Fluoxetine 20 1 year
SV/2 F 56 Fluoxetine 40 2 years
SB/1 M 58 Fluoxetine 20 4 years
SB/3 F 41 Fluoxetine 20 3 months
SL/2 M 68 Fluoxetine 20 5 weeks
SL/3 M 56 Fluoxetine 20 10 weeks
SL/11 F 68 Fluoxetine 20 16 weeks
SL/12 M 88 Fluoxetine 20 1 week
SB/2 M 71 Paroxetine 20 1 year
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8.4.4 RESULTS
8.4.4.1 Fluoxetine Saliva Samples
Fluoxetine and its metabolite were detected in all saliva samples collected by Omni-Sal 
devices. The results of these and corresponding blood samples are given in Table 8.18. 
Fluoxetine concentrations in saliva were found to range from 22.1 - 223.2 ng/ml (mean 
62.8 ng/ml) and norfluoxetine concentrations 11.0 - 143.3 ng/ml (mean 69.2 ng/ml). Out 
of these twelve cases, seven gave higher concentrations for the metabolite and five gave 
higher concentrations for the parent drug. In one case, there was a fluoxetine concentration 
o f 223.2 ng/ml which was considerably higher than for other cases. It may have been 
suggested that this was due to oral contamination, however, the individual claimed not to 
have taken his medication in 24 hours. He had also been prescribed the drug for a longer 
period of time than the other volunteers and this may account for a certain amount of drug 
accumulation. It was postulated that this individual was in fact a poor metabolizer of 
fluoxetine.
Table 8.18: Fluoxetine in blood and saliva
I Case 
Sample
Time
lapse
Saliva
pH
Blood (ng/ml) Saliva (ng/ml) Saliva/Blood
FLU NFLU FLU NFLU FLU NFLU
SV /la 5 hr - NA NA 38.9 53.4 - -
SV/lb 1 hr - NA NA 57.5 83.4 - -
SV/lc NK - NA NA 22.1 33.2 - -
SV/ld NK - NA NA 35.9 44.5 - 1
SV/1 e NK - 51.8 101.3 57.0 48.6 1.10 0.48 !
SV/2 NK - NA NA 67.5 143.3 - i
SB/1 24 hr - 155.8 68.2 223.2 73.7 1.43 1.10
SB/3 3 hr - 73.7 196.4 73.8 117.8 0.38 1.60
SL/2 1 hr 6.2 114 109 40.2 22.8 0.35 0.21
SL/3 1 hr 6.5 24 155 41.7 139.8 1.74 0.90
SL/12 2 hr - 13.4 14.8 27.6 11.0 2.06 0.74
NK - Not Known, NA - Not Analyzed
Time lapse is the time between the patients last dose and the time the saliva sample was taken.
Chapter 8: Case Samples Page 164
Saliva/blood ratios were calculated for six case samples and were found to vary from 
0.35 - 2.06 for fluoxetine and 0.21 - 1.60 for norfluoxetine. These variations in ratios are a 
result of the differences in salivary pH of individuals. The pH of blood and saliva in an 
individual will dictate the amount o f ionization a specific drug will have in each of these 
biological specimens. The theoretical range of saliva/blood ratios for fluoxetine can be 
calculated using the Henderson-Hasselbalch equation for basic drugs (Chapter 5.5). For 
fluoxetine the pKa is 9.5. The non protein bound fraction of total drug in plasma, fp is 0.06 
for fluoxetine since 94 % of drug is plasma bound. Saliva/blood ratios were calculated for 
the saliva pH varying from 6.0 - 7.2. Using these values the theoretical saliva/blood ratio 
can vary from 1.495 - 0.095. Therefore a relatively small change in pH can result in a 
significant change in saliva/blood ratio. It can be noticed from these results that two of the 
experimental saliva/blood values fell out with this theoretical range.
The drug/metabolite ratios in blood and saliva for the six sets of corresponding samples 
ranged from 0.15 - 2.28 (mean 0.88) and 0.30 - 3.03 (mean 1.16) respectively. In each case 
the drug/metabolite ratio for saliva was always higher than that calculated for blood (Table 
8.19).
Table 8.19: Fluoxetine/norfluoxetine ratios in blood and saliva
1 Case Sample Drug/metabolite ratio
Blood Saliva
SV/1 a . 0.73
SV/lb - 0.69
SV/lc - 0.67
SV/ld - 0.81
SV/le 0.51 1.17
SV/2 - 0.47
SB/1 2.28 3.03
SB/3 0.38 0.63
SL/2 1.05 1.76
SL/3 0.15 0.30
SL/12 0.90 2.51 1
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8.4.4.2 Paroxetine Saliva Samples
One saliva sample containing paroxetine was collected. The time between administration 
of the drug and sample collection was approximately 12 hours and the amount detected in 
saliva was 31.5 ng/ml. A saliva/blood ratio of 0.65 was calculated. This volunteer had been 
prescribed the medication for 1 year.
Table 8.20: Paroxetine in blood and saliva
Patient/ 
Sample No.
Time lapse Saliva pH Blood
(ng/ml)
Saliva
(ng/ml)
Saliva/Blood
Ratio
P/1 12.5 hr - 48.3 31.5 0.65
The theoretical range of saliva/blood ratios for paroxetine was calculated using the 
Henderson-IIasselbalch equation for basic drugs (Chapter 5.5). For paroxetine, the pKa is 
9.9. The non protein bound fraction of total drug in plasma, fp is 0.05 for paroxetine since 
95 % of drug is plasma bound. The saliva/blood ratio was calculated for the saliva pH 
varying from 6.0 - 7.2. Using these values the theoretical saliva/blood ratio was found to 
vary from 1.252 - 0.079. The experimental saliva/blood value fell in between these limits.
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8.4.5 EFFECT OF COLLECTION METHOD ON SALIVA FLUOXETINE 
CONCENTRATION
One 20 mg Prozac® tablet was administered to three healthy volunteers who had not 
previously taken this medication. Saliva samples were collected at intervals of 1, 3, 5, 7, 
12, 24, 48, 72 hours by spitting and by collection with Omni-Sal® devices. These samples 
were analysed for fluoxetine and norfluoxetine. Tables 8.21 and 8.22 give the 
concentrations detected using the two collection methods.
(fbTable 8.21: Fluoxetine saliva concentrations detected using Omni-Sal devices
Time after 
administration 
(hours)
Volunteer 1 
(ng/ml)
Volunteer 2 
(ng/ml)
Volunteer 3 (ng/ml)
FLU NFLU FLU NFLU FLU NFLU
1 0.11 - 0.16 - 0 -
3 0.33 - 1.54 - 0.1 -
5 1.06 0.28 2.79 - 0.69 -
7 2.0 0.28 4.06 0.21 0.84 "
12 1.7 0.47 3.67 0.24 0.57 -
24 1.37 1.26 2.44 0.30 0.48 0.15
48 1.0 2.47 1.55 0.32 0.41 0.38
72 0.28 1.32 1.0 0.35 0.40 0.78
Table 8.22: Fluoxetine saliva concentrations detected in spitting samples
Time after 
administration 
(hours)
Volunteer 1 
(ng/ml)
Volunteer 2 
(ng/ml)
Volunteer 3 (ng/ml) 1
FLU NFLU FLU NFLU FLU NFLU
1 0.21 - 0 - 0 -
3 0.89 - 1.37 - 0 -
5 1.8 0.29 2.83 - 0.74 -
7 3.4 0.29 4.58 0.80 2.58 -
12 3.16 0.38 4.38 0.82 1.91 -
24 2.32 0.54 4.0 0.70 0.97 -
48 1.42 1.42 2.34 - 0.40 -
72 0.63 1.26 1.16 - 0.30 0.29
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Peak saliva concentrations were reached at approximately 7 hours for the three volunteers. 
Concentrations obtained at 7 hours after administration varied for the three individuals and 
these ranged from 0.84 - 4.06 ng/ml using the Omni-Sal® devices. Norfluoxetine 
concentrations were not detected until at least 5 hours after administration. The fluoxetine 
graphs of concentration detected in saliva versus time are shown below in Figure 8.13 and 
8.14.
Fluoxetine in saliva (Omni-Sal)
4.5
-♦— V olun teer 1
- •— V olunteer 2
V olunteer 3
0 20 40 60 80
Time (hours)
-♦— V olunteer 1 
• — V olunteer 2 
V olunteer 3
• (R)Figure 8.13: Graphs of concentration versus time for fluoxetine in saliva using Omni-Sal 
collection method
Fluoxetine in saliva (Spitting)
20 40 60
Time (hours)
Figure 8.14: Graphs o f concentration versus time for fluoxetine in saliva using spitting 
collection method
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Peak saliva concentrations detected in whole saliva collected by spitting were higher than 
those detected with the Omni-Sal® devices. This can be explained by the lower recovery 
obtained from the Omni-Sal® cotton swab. The peak concentrations detected for the three 
volunteers varied from 2.58 - 3.4 ng/ml, with volunteer 2 still giving the highest peak 
concentration and volunteer 3 giving the lowest (Figure 8.14).
The saliva elimination half-life for fluoxetine was determined to be between 1 and 2 days 
for the three individuals by both collection methods. This is comparable to plasma the 
plasma elimination half-life which is between 1 and 3 days.62
8.4.6 EFFECT OF COLLECTION METHOD ON SALIVA PAROXETINE 
CONCENTRATION
One 20 mg Seroxat® tablet was administered to two healthy volunteers who had not 
previously taken this medication. Saliva samples were collected at intervals of 1, 3, 5, 7, 
12, 24, 48, 72 hours by spitting and by collection with Omni-Sal® devices. These samples 
were analysed for paroxetine. Table 8.23 gives the concentrations detected using the two 
collection methods.
Table 8.23: Paroxetine saliva concentrations detected in saliva samples
Time after 
administration 
(hours)
(R)Paroxetine in saliva (Omni-Sal ) Paroxetine in saliva (Spitting)
Volunteer 1 
(ng/ml)
Volunteer 2 
(ng/ml)
Volunteer 1 
(ng/ml)
Volunteer 2 
(ng/ml)
1 2.53 0.65 3.89 3.06
3 0.71 0.16 1.67 0.42
5 0.52 0.65 0.83 4.17
7 0.99 0.52 1.81 4.31
12 0.71 0.26 0.97 L69
24 0.1 0.11 0.28 0.69
48 0 0 0 0.28
72 0 0 0 0
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Graphs of concentration versus time after administration for the two collection methods are 
shown below (Figures 8.15 and 8.16). These graphs differ from those obtained for the 
fluoxetine samples in that the highest concentration detected for each volunteer was 
observed one hour after administration. This concentration rapidly fell within 3 hours after 
administration and an increase in concentration was seen with peak levels obtained at 5 and 
7 hours for the two individuals. This initial high concentration at one hour following 
administration is a result of oral contamination. The Seroxat® tablets unlike the Prozac® 
capsules do not have the protective capsule covering which seemed to prevent oral 
contamination.
Paroxetine in saliva (Omni-Sal)
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-■— V olunteer 2
Tim e (hours)
Figure 8.15: Graphs of concentration versus time for paroxetine in saliva using Omni-Sal 
collection method
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Figure 8.16: Graphs of concentration versus time for paroxetine in saliva using spitting 
collection method
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Similarly to the fluoxetine study, peak saliva paroxetine concentrations in saliva collected 
by spitting were higher than those detected with the Omni-Sal® devices. The peak
• (B)concentrations detected for the two volunteers by Omni-Sal collection were 0.99 and 0.65 
ng/ml and by spitting collection were 1.81 and 4.31 ng/ml respectively. Figures 8.17 and 
8.18 show this difference in concentration.
The apparent saliva elimination half-life for paroxetine was 5 - 8  hours. Plasma elimination 
half-lives have been reported as 7 - 37 hours.62
Paroxetine in Volunteer 1
-♦— Spitting 
» -  Omn i-sal
Time (hours)
-♦— Spitting 
-«— Omn i-Sal
Figure 8.17: Graphs of concentration versus time for paroxetine in volunteer 1
Paroxetine in Volunteer 2
0 20 40 60 80
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Figure 8.18: Graphs of concentration versus time for paroxetine in volunteer 2
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Examples of chromatograms obtained for the fluoxetine and paroxetine saliva analyses are 
shown in Figures 8.19-8.24.
8.4.7 CONCLUSIONS
Fluoxetine and norfluoxetine or paroxetine were detected in the saliva samples obtained 
from patients receiving chronic treatment with Prozac® or Seroxat®. Saliva/blood ratios for 
fluoxetine and norfluoxetine were shown to vary between individuals as a result of 
differences in salivary pH. Fluoxetine/norfluoxetine ratios in blood and saliva within an 
individual were always shown to be higher in saliva than in blood.
Saliva samples obtained from volunteers taking a single 20 mg dose of Prozac® or 
Seroxat® were collected by spitting and by Omni-Sal® devices. Concentrations in saliva 
were found to vary between the individuals. Peak concentrations were found to be less than 
5 ng/ml and were obtained at 7 hours for fluoxetine and 5 - 7  hours for paroxetine. The 
elimination half-lives were 1 - 2 days for fluoxetine and approximately 5 - 8  hours for 
paroxetine.
Concentrations were always found to be higher in the samples collected by spitting
(B) •because of the lower recovery obtained using the Omni-Sal collection devices. At these 
low concentrations the collection method is important because it could mean the difference 
between detecting and not detecting a substance especially in cases where a drug has been 
administered as a single dose. However, for the majority of people being prescribed these 
drugs, chronic administration is necessary and in these cases the concentrations are easily 
detected using the Omni-Sal® collection devices.
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Figure 8.19: Chromatogram of extract of saliva spiked with 50 ng/ml tumoxetine
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Figure 8.20: Chromatogram of extract of saliva spiked with 25 ng/ml fluoxetine and 
norfluoxetine
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Figure 8.22: Chromatogram of extract of saliva spiked with 25 ng/ml maprotiline
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Figure 8.23: Chromatogram of extract of saliva spiked with 10 ng/ml paroxetine
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Figure 8.24: Chromatogram of extract of saliva sample obtained from volunteer 1, one 
hour after 20 mg single dose
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8.5 ANTIDEPRESSANTS IN HAIR
8.5.1 POSTMORTEM CASES
Certain segments of postmortem hair samples HF/1 and HP/1 were extracted by methanol 
extraction and acid hydrolysis by the method described in 6.4.7 and compared in a 
recovery validation experiment. The other segments of these samples were extracted using 
acid hydrolysis and the results are tabulated in Tables 8.24 and 8.25.
8.5.2 RESULTS AND DISCUSSION
Fluoxetine and norfluoxetine were detected in all the segments of case HF/1. The 
concentration of fluoxetine was found to increase from the root to the second segment and 
thereafter it decreased with length of hair. The concentration of norfluoxetine along the 
length behaved similarly, increasing from root to first segment and thereafter decreasing 
with length. Assuming that fluoxetine was used regularly over the period of hair growth, 
then this decrease in concentration is most likely due to drug leaching from hair as a result 
of damage from bleaching. Bleaching hair causes the hair to become more porous and 
therefore the possibility of drugs being removed from the hair by washing is greater. The 
concentrations of cocaine, benzoylecgonine, methylecgonine, codeine, morphine and 6- 
MAM in the hair of a drug user were shown to be a third or less in bleached hair than in 
natural hair.222
In a period of five months, the fluoxetine hair concentration was found to decrease by 
50 %. A similar decrease in concentration was reported for the drug methoxyamphetamine 
in natural hair.16
The concentration of metabolite, norfluoxetine was higher than fluoxetine for the first four 
segments. Steady state concentrations of fluoxetine and norfluoxetine in blood will affect 
the levels which are detected in hair. At steady state, concentrations of norfluoxetine in 
plasma are generally higher than that of fluoxetine and these do not vary greatly within an 
individual when the drug is administered for a long time. Factors affecting the 
incorporation of a drug into hair include the lipophilicity of the drug. It may be expected 
that chemically nonpolar parent drugs are more likely to be successful at crossing the cell 
membrane from blood capillary to hair follicle and in this case would imply that fluoxetine 
would incorporate more easily than norfluoxetine. However, if steady state concentrations 
in plasma are higher for norfluoxetine this may compensate for the decrease in
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incorporation compared to fluoxetine and produce a higher concentration of norfluoxetine 
in hair. Out of 43 cases determining tricyclic antidepressants, amitriptyline, clomipramine, 
doxepine and imipramine in hair only three showed a higher concentration of nor- 
metabolite in hair than the parent drug.181 The parent drug was most frequently at a higher 
concentration than the metabolite and this was explained by the polar metabolites having a 
higher affinity to bind to the hair matrix than the parent drug. For the remaining twelve 
segments of hair it was found that fluoxetine concentrations were greater than 
norfluoxetine concentrations. The rate of decrease in fluoxetine concentration with length 
was also less than the rate of decrease of norfluoxetine with length. The parent 
drug/metabolite ratios were calculated for the length of the hair and these were found to 
increase with length. The bleaching of the hair seems to not only have caused a loss of 
drug, but also appeared to cause a larger loss of the metabolite compared to the parent drug 
as the section of hair got further away from the root. This is shown in Figure 8.25.
Table 8.24: Findings for case HF/1
1 Segment Weight
(mg)
Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Drug/Metabolite
Ratio
I Roots 9.16 3.69 10.08 0.37
0.5-1.5 9.35 5.55 10.92 0.51
1.5-2.5 9.07 6.35 8.41 0.76
2.5-3.5 17.0 4.78 4.95 0.96
3.5-4.5 18.81 3.06 3.14 0.97
4.5-5.5 19.78 2.26 2.04 1.11
5.5-6.5 16.78 2.00 1.69 1.18
6.5-7.5 17.25 1.72 1.24 1.39
7.5-8.5 19.47 1.54 1.16 1.33
8.5-9.5 17.86 1.42 0.91 1.56
9.5-10.5 18.19 1.22 0.70 1.75
10.5-11.5 16.97 1.26 0.72 1.75
11.5-12.5 16.27 1.16 0.60 1.92
12.5-13.5 18.96 1.03 0.44 2.33
13.5-14.5 15.45 1.00 0.43 2.33
14.5-15.5 14.46 1.06 0.47 2.27
15.5-16.5 14.62 1.20 0.64 T89 1
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Case Sample HF/1
0  Fluoxetine 
■  NorfluoxetineCone, (ng/mg)
Segment
Figure 8.25: Graph showing concentrations of fluoxetine and norfluoxetine along length 
of hair sample HF/1.
Paroxetine was detected in case HP/1. The concentration was highest in the root section 
and was found to decrease in the following section and was not detected in the second or 
following segments. A medical history was not available to check how long the individual 
had been taking paroxetine, but from the hair results it appears that paroxetine treatment 
could only have been for about two months (Table 8.25).
Table 8.25: Findings for case HP/1
Segment Weight
(mg)
Paroxetine
(ng/mg)
Roots 4.82 4.32
0.5-2.5 9.70 0.43
2.5-11.5 Approx. 10 mg, 2 cm sections -ve  |
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8.5.3 CLINICAL SAMPLES
Hair samples were obtained from volunteers receiving fluoxetine or paroxetine treatment. 
The patients were either in a geriatric hospital or attending clinics. Hair was cut from the 
posterior vertex as close to the scalp as possible. It was then wrapped in cigarette papers, 
the root end labelled and inserted into a plastic universal. A total of 19 samples were 
collected and information including the age, sex, hair colour, dosage and length of time the 
drug had been prescribed was recorded. This information is tabulated in Table 8.26.
8.5.4 RESULTS
19 hair samples were taken from patients receiving fluoxetine or paroxetine treatment. 
These samples were segmented into 60 sections. O f the 19 hair samples, 14 (73.7 %) were 
found positive for fluoxetine, 14 (73.7 %) for norfluoxetine, 4 (21.0%) for paroxetine and 
one (5.3 %) was found entirely negative for these drugs. The results of these are tabulated 
in Tables 8.27 - 8.29.
Concentration ranges detected in the segments were 0.34 - 5.52 ng/mg for fluoxetine, 
0.15 - 8.09 ng/mg for norfluoxetine and 0.22 - 6.23 ng/mg for paroxetine. The 
fluoxetine/norfluoxetine concentration ratio was determined to vary from 0.30 - 3.85 
(mean 1.33). In all cases where fluoxetine was detected, the metabolite was also detected. 
Out of the 27 sections found positive for fluoxetine and norfluoxetine, 15 (55.6 %) gave a 
parent drug to metabolite ratio > 1 and 12 (44.4 %) gave values < 1.
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Table 8.26: Patient details
Case
Number
Sex / age 
(Years)
Drug Dosage
mg/day
Length o f time 
Prescribed *
1 Hair
Colour |
HB/1 M / 5 8 Fluoxetine 20 4 years Dark grey
HB/2 M/ 7 1 Paroxetine 20 1 year White
HB/3 F / 41 Fluoxetine 20 3 months Dark brown
HL/1 M/ 7 1 Fluoxetine 20 10 weeks, stopped 5 
weeks prior
White/grey
HL/2 M / 6 8 Fluoxetine 20 6 weeks Grey
HL/3 M / 5 6 Fluoxetine 20 10 weeks Black
HL/4 F / 7 1 Fluoxetine 20 4 weeks Grey/white
HL/5 M / 7 4 Fluoxetine 20 6 weeks Grey
HL/6 F / 8 9 Fluoxetine 20 2 days White/few black
HL/7 F / 8 9 Fluoxetine 20 6 weeks White
HL/8 M / 8 0 Fluoxetine 20 5 weeks Grey
HL/9 M / 6 0 Fluoxetine 20 12 weeks Grey
HL/10 F / 6 8 Fluoxetine 20 16 weeks Dark grey
HL/11 F / 6 8 Paroxetine 20 16 weeks Grey
HL/12 M / 8 8 Fluoxetine
Paroxetine
20
20
1 week 
5 days, stopped 6 
weeks prior
White/few black
HL/13 F / 8 3 Fluoxetine 20 4 weeks Black/few white
HL/14 F / 8 6 Fluoxetine 20 9 weeks White
HL/15 M / 7 2 Fluoxetine 20 3 days Light grey/white
HD/1 F / 3 2 Fluoxetine 20 3 months Brown
* Length o f  time drug was prescribed previous to hair being sampled unless stated otherwise.
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Table 8.27: Fluoxetine, norfluoxetine and paroxetine findings in hair case samples
Case sample Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Fluoxetine/
Norfluoxetine
Paroxetine
(ng/mg)
HB/1 
Scalp-1 cm
5.52 1.64 3.37 - ve
HB/1 
1 - 2 cm
5.7 1.48 3.85 - ve
HB/2 
Scalp-1 cm
- ve - ve - 1.48
HB/3 
Scalp-1 cm
5.38 7.24 0.74 - ve
HB/3 
1 -2  cm
5.53 6.94 0.80 - ve
HB/3 
1 2 - 3 cm
3.18 3.37 0.94 - ve
1 HL/1 
Scalp-1 cm
3.02 7.55 0.40 - ve
HL/1 
1 1 - 2 cm
2.83 5.33 0.53 - ve
HL/2 
Scalp-1 cm
1.51 1.42 1.06 - ve
HL/2 
1 - 2 cm
0.22 0.15 1.47 - ve
HL/2 
2 - 3  cm
- ve - ve - - ve
HL/3 
Scalp-1 cm
2.58 8.09 0.32 - ve
HL/3 
1 - 2 cm
2.09 6.90 0.30 - ve 1
HL/3 
2 - 3 cm
0.97 2.80 0.35 - ve 1
HL/4 
Scalp-1 cm
0.81 1.35 0.60 - ve 1
HL/4 
1 - 2 cm
- ve - ve - - ve 1
HL/4 
2 - 3 cm
- ve - ve - - ve 1
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Table 8.28: Fluoxetine, norfluoxetine and paroxetine findings in hair case samples
Case sample Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Fluoxetine/
Norfluoxetine
Paroxetine
(ng/mg)
HL/5 
Scalp-1 cm
4.30 3.56 1.21 - ve
HL/5 
1 -  2 cm
1.95 1.14 1.71 - ve
HL/6 
Scalp-1 cm
- ve - ve - - ve |
HL/6 
1 -  2 cm
- ve - ve - - ve
HL/6 
2 - 3 cm
- ve - ve - - ve
HL/6 
3 - 4 cm
- ve - ve - - ve
HL/6 
4 - 5 cm
- ve - ve - -v e
HL/6 
5 -  6 cm
- ve - ve - - ve
HL/7 
Scalp-1 cm
0.57 0.56 1.05 - ve
HL/7 
1 -  2 cm
- ve - ve - - ve
HL/7 
2 - 3 cm
- ve - ve - - ve
HL/8 
Scalp-1 cm
1.81 0.99 1.83 - ve
HL/8 
1 - 2  cm
- ve - ve - - ve
HL/8 
2 - 3  cm
- ve - ve - - ve 1
HL/9 
Scalp-1 cm
3.51 1.45 2.42 - ve
HL/9 
1 -  2 cm
2.13 0.95 2.25 - ve
HL/9 
2 - 3 cm
0.45 0.42 1.07 - ve
HL/10 
Scalp-1 cm
1.23 1.03 1.19 - ve I
HL/10 
1 -  2 cm
0.91 0.30 3.03 - ve 1
HL/10 
2 - 3 cm
0.80 0.45 1.78 - ve I
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Table 8.29: Fluoxetine, norfluoxetine and paroxetine findings in hair case samples
Case sample Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Fluoxetine/
Norfluoxetine
_
Paroxetine
(ng/mg)
HL/11 
Scalp-1 cm
- ve - ve - 5.73
HL/11 
1 -  2 cm
- ve - ve - 6.23
HL/12 
Scalp-1 cm
- ve - ve - - ve
HL/12 
1 -  2 cm
- ve - ve - 0.22
HL/12 
2 - 3 cm
- ve - ve - 0.79
HL/12 
3 - 4 cm
- ve - ve - 1.59
HL/13 
Scalp-1 cm
0.47 0.51 0.93 - ve
HL/13 
1 - 2 cm
- ve - ve - - ve
HL/13 
2 - 3  cm
- ve - ve - - ve
HL/13 
3 - 4 cm
- ve - ve - - ve
HL/13 
4 - 5  cm
- ve - ve - - ve
HL/14 
Scalp-1 cm
1.85 1.97 0.94 - ve
HL/14 
1 - 2 cm
0.34 0.33 1.03 - ve
HL/14 
2 - 3 cm
- ve - ve - -v e
HL/15 
Scalp-1 cm
- ve - ve - 0.29
HL/15 
1 -2  cm
- ve - ve - 0.41
HD/1 
Scalp-1 cm
0.48 0.63 0.76 - ve
HD/1 
1 - 2 cm
- ve - ve - - ve
HD/1 
2 - 3 cm
- ve - ve - - ve
HD/1 
3 - 4 cm
- ve - ve - - ve
HD/1 
4 - 5  cm
- ve - ve - - ve
HD/1 
4 - 5  cm
- ve - ve - - ve
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8.5.5 CORRELATION OF HAIR SAMPLES WITH MEDICAL HISTORY 
The majority of hair samples provided positive or negative results which correlated with 
information obtained from patients' medical records. Hair growth was estimated to be 1.0 
cm/month. In cases HL/2 and HL/5 where fluoxetine had been prescribed for 6 weeks, it 
would be expected to find the drug in the first 1.5 cm from the scalp if the growth rate was 
1.0 cm/month. Fluoxetine was in fact detected in two sections of hair for these cases. The 
section closest to the scalp contained a higher concentration of the drug and metabolite 
than the second centimetre section which would be expected. However, in one other case 
where fluoxetine had been prescribed for 6 weeks, the drug was only detected in the first 
one centimetre section. Reasons for this could include the hair sample not having been cut 
as close as possible to the scalp or simply that hair growth was slower for this individual 
compared to the average individual. It should also be noted that hair growth is slower in 
the elderly and this hair sample was obtained from an individual who was 89 years old, 21 
and 15 years older than the individuals who supplied hair samples HL/2 and HL/5 
respectively.
In two cases, HL/12 and HL/15 where fluoxetine was prescribed 5 and 3 days respectively 
prior to sampling no fluoxetine or metabolite was detected in the hair. This is most likely 
because the section o f hair where the drug was incorporated was not present. The sample 
may not have been cut close enough to the scalp or the hair had not had sufficient time to 
grow. In the first o f these cases, however, paroxetine was detected in sections 2, 3 and 4 
from the scalp. Information in the supplied medical cards only indicated that paroxetine 
had been taken for 5 days, 6 weeks prior to sampling and there was no drug information in 
the medical cards regarding months prior to this. The hair sample, however, indicated that 
the patient had been taking paroxetine for at least 2 months. In case HL/15 paroxetine was 
also detected in the two centimetres of hair closest to the scalp. In the centimetre section 
closest to the scalp the concentration detected was less than that detected in the second 
centimetre section indicating that the treatment had been ceased for approximately one to 
two weeks prior to sampling. This information was not available from the available 
medical cards.
The only other case where medical information did not correlate directly with the results 
was case HD/1. In many of the other cases, hair was obtained from geriatric patients who
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were supervised when given medication to ensure it was taken regularly. This sample, 
however, was obtained from a heroin drug user and the hair results showed that this 
individual had not taken the medication as instructed by a general practitioner. This 
individual had been prescribed Prozac® for 3 months, but fluoxetine and its metabolite 
were only detected in the centimetre section closest to the scalp.
All other hair samples appeared to give a reasonable correlation with the medical history of 
each individual.
In cases where fluoxetine had been taken for a period of 8 weeks or longer (HB/1, HB/3, 
HL/1 and HL/3) it was shown that the concentrations detected in the two centimetre 
sections were similar indicating that the amount of drug incorporated into hair was 
consistent within an individual. These samples also showed that the drug/metabolite ratio 
was constant within an individual. The amount of drug incorporated into hair, however, 
varied greatly between individuals despite them being administered the same amount of 
drug. Also, the drug/metabolite ratios widely varied and therefore such an analysis would 
not be of value for compliance monitoring.
8.5.6 HAIR COLOUR
All of the hair samples were taken from patients receiving the same quantity of drug on a 
daily basis. However, the quantities of drug detected in the different hair samples were 
found to vary. This is largely due to inter-individual differences such as hair growth rate, 
the stage of hair growth and possibly also hair colour or the quantity of pigment in the hair. 
The majority of samples were obtained from elderly patients and therefore there was less 
variation in hair colour than within a younger population. However, hair colour and the 
concentrations detected in the hair were assessed for this group of samples.
One of the problems with assessing hair colour is the subjective nature of such a study. The 
majority of the samples collected were obtained from geriatric patients many of which 
contained a mixture of white and/or grey and/or black hairs in different shades and 
proportions. The assessment of proportions of colours and shade of colour is very 
subjective and for this reason the concentration of drug detected in hair was compared for
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three groups o f hair. The first o f these groups was hair which was completely white in 
colour, the second group included hair which contained any grey hairs and the third group 
hair which was brown or black in colour. None of the samples obtained were blond or red 
in colour.
As a result o f the large variation in drug/metabolite ratios between individuals, the total 
amount of fluoxetine and norfluoxetine detected in an individual's hair was calculated. 
Mean values o f these total concentrations were also calculated for each group. These 
results showed that white hair incorporated the least amount o f drug. Also, hair which had 
a proportion of grey hair in it incorporated a larger amount of drug than white hair, but less 
than that incorporated into brown or black hair (Figure 8.26).
There were insufficient paroxetine case samples to assess hair colour and concentration 
adequately. However, one sample containing a large proportion o f black hair with a small 
proportion of grey was found to have a much higher concentration o f paroxetine than white 
hair.
Concentration v 's  hair colour
B white 
Bgrey
□  brown/black
Cone (ng/mg) 6
Hair Colour
Figure 8.26: Mean concentrations of total fluoxetine and norfluoxetine in different hair 
colours
Examples of chromatograms obtained for extraction o f fluoxetine and paroxetine from hair 
are shown in Figures 8.27-8.32.
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8.5.7 CONCLUSIONS
The developed extraction method easily detected fluoxetine and paroxetine in the hair of 
users and it was found that the majority o f hair cases tested for these drugs gave results 
which corresponded well with patients’ case notes. The concentrations of the drugs 
detected in the various hair samples showed variation between individuals, not only in the 
amounts found, but in the case of fluoxetine, also in the ratio of parent drug/metabolite. 
The ratio of fluoxetine to norfluoxetine was found to vary from 0.30 - 3.85 and a 
preference for incorporation of one or other into hair was not highlighted. Other factors 
such as bleaching and washing of hair clearly affected this ratio. Hair colour or amount of 
pigment in hair appeared to affect the amount of drug incorporated into the hair. The 
results obtained indicated that dark hair incorporated more drug than grey hair which in 
turn incorporated more than white hair. This corresponds with other studies investigating 
the incorporation of drugs into hair.
Concentrations detected within an individual who had taken fluoxetine over two or three 
months were found to be relatively constant, indicating that incorporation is constant 
within an individual as is the parent drug to metabolite ratio. Factors which affected this 
included bleaching of hair.
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Figure 8.27: Chromatogram of extract of hair spiked with 50 ng/30 mg tumoxetine
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Figure 8.28: Chromatogram of extract of hair spiked with 25 ng/30 mg fluoxetine and 
norfluoxetine
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Figure 8.29: Chromatogram of extract of hair case sample HL/13, section 0-1 cm
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Figure 8.30: Chromatogram of extract of hair spiked with 25 ng/30 mg maprotiline
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Figure 8.31: Chromatogram of extract of hair spiked with 10 ng/30 mg paroxetine
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Figure 8.32: Chromatogram of extract of hair case sample HL/15, section 1-2 cm
Chapter 8: Case Samples Page 190
8.6 ANTIDEPRESSANTS IN NAIL
8.6.1 CLINICAL SAMPLES
Nail samples were obtained from volunteers receiving fluoxetine or paroxetine treatment. 
Both hair and nails were collected simultaneously from patients. A total of 23 nail samples 
were collected and information including the age, sex, hair colour, dosage and length of 
time the drug had been prescribed was recorded. This information has already been 
tabulated in Table 8.26 of Antidepressants in Hair. However, other nail samples were 
collected from two other patients who did not provide hair samples and their details are 
displayed in Table 8.30. The samples were extracted using the method described in 
Chapter 7.11.
Table 8.30: Patient details
Case Sex / age Drug Dosage Length o f time
Number (Years) mg/day Prescribed *
NV/1 F/ 58 Fluoxetine 20 1 year
NV/2 F/ 56 Fluoxetine 20 2 years
8.6.2 RESULTS
23 nail samples were taken from 20 patients receiving fluoxetine or paroxetine treatment. 
One of these volunteers provided three samples, another volunteer two samples and the rest 
provided one sample each. Of the 23 nail samples tested, 17 (73.9 %) were found positive 
for fluoxetine, 17 (73.9 %) for norfluoxetine, 4 (17.4 %) for paroxetine and two (8.7 %) 
were found entirely negative for these drugs. In one of these cases only 2 mg o f nail was 
available for analysis. The results of these are tabulated in Table 8.31.
Concentration ranges detected in the segments were 0.16 - 4.49 ng/mg for fluoxetine, 
0.06 - 2.37 ng/mg for norfluoxetine and 0.01 - 0.84 ng/mg for paroxetine. The 
fluoxetine/norfluoxetine concentration ratio was determined to vary from 0.39 - 4.19 
(mean 1.69). In all cases where fluoxetine was detected, the metabolite was also detected. 
Out of the 17 nails found positive for fluoxetine and norfluoxetine, 12 (70.6 %) gave a 
parent drug to metabolite ratio greater than 1 and 5 (29.4 %) gave values less than 1. Three 
o f these 5 gave values greater than 0.90.
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Table 8.31: Fluoxetine, norfluoxetine and paroxetine findings in nail case samples
| Case sample Fluoxetine
(ng/mg)
Norfluoxetine
(ng/mg)
Fluoxetine/
Norfluoxetine
Paroxetine
(ng/mg)
NB/1 4.49 1.07 4.19 - ve
NB/2 - ve - ve - 0.34
NB/3 1.24 1.34 0.93 - ve
NL/1 1.53 2.37 0.65 - ve
NL/2 0.75 0.29 2.59 - ve
NL/3 0.39 1.01 0.39 - ve
NL/4 0.16 0.17 0.94 - ve
NL/5 1.16 1.05 1.10 - ve
NL/6 - ve - ve - - ve
NL/7 0.39 0.15 2.60 - ve
NL/8 - ve - ve - - ve
NL/10 0.52 0.34 1.53 - ve
NL/11 - ve - ve - 0.84
NL/12 - ve - ve - 0.14
NL/13 0.19 0.06 3.17 - ve
NL/14 0.66 0.45 1.47 - ve
NL/15 - ve - ve - 0.01
ND/1 0.19 0.11 1.73 - ve
N V /la 0.72 0.51 1.41 - ve
N V /lb 0.34 0.38 0.89 - ve
N V/lc 0.30 0.18 1.67 - ve
NV/2a 2.63 1.71 1.54 - ve
NV/2b 3.27 1.72 1.90 - ve
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These results have shown that the parent drug tended to incorporate into nail at a higher 
concentration than the metabolite.
8.6.3 CORRELATION OF NAIL CONCENTRATIONS WITH CASE HISTORY 
Most of the results obtained from the analysis of the nails correlated well with medical 
records. Out of the 23 nails analyzed, two gave entirely negative results. For one of these 
cases (NL/8) there was less than 2 mg of nail available for analysis. In the other case 
(NL/6) the patient had been prescribed fluoxetine for only two days. The section of nail 
collected would have grown well before the drug was taken and since it was no longer 
attached to the nail bed then the possibility o f drug incorporating through the bed is 
unlikely.
Case NL/12 was found to be negative for fluoxetine and norfluoxetine, but positive for 
paroxetine. Fluoxetine had been prescribed for 1 week prior to sampling and similar to the 
previously mentioned case the drug would not have incorporated into the section of nail 
collected. On the other hand, paroxetine had been prescribed for 5 days, but this was 
stopped at a time 6 weeks before sampling. The nail with the incorporated paroxetine 
therefore had time to grow away from the nail bed and this section was collected in the 
sample. This sample indicates that one week was not sufficient time for the nail with 
incorporated drug to grow from the bed. Also, this case shows that paroxetine could be 
detected in nail after 5 days of use.
Cases NL/4 and NL/13 showed that fluoxetine and norfluoxetine could be detected in nail 
4 weeks after administration was started although in these patients the concentrations were 
very low. Nail growth in the elderly is slower than that in younger adults and it is possible 
that these concentrations would be higher in younger patients.
Case NL/15 was found positive for paroxetine, but negative for fluoxetine. Fluoxetine had 
only been administered for three days prior to sampling and so would not have been 
detected in sampled nail. Paroxetine was not mentioned in the supplied medical records, 
but for this case paroxetine was also detected in the hair of this individual.
All o f the other cases were found positive for the drug which the patient was prescribed as 
given in their medical records.
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8.6.4 COMPARISON BETWEEN HAIR AND NAIL SAMPLES 
The range of antidepressant concentrations determined within one hair sample and the 
mean concentration detected in positive hair sections were calculated for each hair sample. 
These are shown along with the levels determined in nail samples (Table 8.32).
Table 8.32: Comparison of nail and hair concentrations
Case Nail (ng/mg) Hair (ng/mg)
sample FLU NFLU PAR FLU NFLU PAR
NB/1 4.49 1.07 - ve 5.52-5.70 (5.61) 1.48-1.64(1.56) - ve
NB/2 - ve - ve 0.34 - ve - ve 1.48
NB/3 1.24 1.34 - ve 3.18-5.38 (4.70) 3.37-7.24 (5.85) - ve
NL/1 1.53 2.37 - ve 2.83-3.02 (2.93) 5.33-7.55 (6.44) - ve
NL/2 0.75 0.29 - ve 0.22-1.51 (0.87) 0.15-1.42 (0.79) - ve
NL/3 0.39 1.01 - ve 0.97-2.58 (1.88) 2.80-8.09 (5.93) - ve
NL/4 0.16 0.17 - ve 0.81 1.35 - ve
NL/5 1.16 1.05 - ve 1.95-4.30 (3.13) 1.14-3.56 (2.35) - ve
NL/6 - ve - ve - ve - ve - ve - ve
NL/7 0.39 0.15 - ve 0.57 0.56 -ve
NL/10 0.52 0.34 - ve 0.80-1.23 (0.98) 0.30-1.03 (0.59) - ve
NL/11 - ve - ve 0.84 - ve - ve 5.73-6.23 (5.98)
NL/12 - ve - ve 0.14 - ve - ve 0.22-1.59 (0.87)
NL/13 0.19 0.06 - ve 0.47 0.51 - ve
NL/14 0.66 0.45 - ve 0.34-1.85 (1.10) 0.33-1.07(1.15) - ve
NL/15 - ve - ve 0.01 - ve - ve 0.29-0.41 (0.35)
ND/1 0.19 0.11 - ve 0.48 0.63 - ve
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine
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The concentrations of fluoxetine, norfluoxetine and paroxetine in nails and hair were of the 
same magnitude. Graphs of concentration in nail against mean concentration in hair were 
plotted for each drug. Correlation coefficients for these plots are displayed on the graphs in 
Figure 8.33. These were 0.711, 0.731, and 0.960 for fluoxetine, norfluoxetine and 
paroxetine respectively. All of the plotted graphs gave reasonable correlation. The 
concentration detected in hair generally increased as the nail concentration increased.
Fluoxetine
♦  Fluoxetine
R2 = 0.7112
 Linear
(Fluoxetine)
Nail concentration (ng/mg)
Norfluoxetine
8
♦  N orfluoxetine
  Linear
(N orfluoxetine)R2 = 0 .7307
0
Nail concentration (ng/mg)
Paroxetine
R2 = 0.9595 ♦  Paroxetine
Linear
(Paroxetine)
Nail concentration (ng/mg)
Figure 8.33: Correlations between nail and hair concentrations
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Nail/hair concentration ratios were calculated for each drug and are displayed in Table 
8.33. The range of these for fluoxetine was 0.20-0.86 (mean 0.49), for norfluoxetine was 
0.12-0.69 (mean 0.33) and for paroxetine 0.03-0.23 (mean 0,14). For every sample tested 
the concentration detected in nails was lower than the mean concentration detected in the 
hair. Mean values of nail/hair concentrations indicated that fluoxetine levels were 2 times, 
norfluoxetine concentrations 3 times and paroxetine concentrations 7 times those in nails.
The ratio of parent drug to metabolite was generally found to be higher for nail than hair 
samples within an individual. This was the outcome in 10 out of 12 cases and is shown 
more clearly in Figure 8.34.
Examples of chromatograms obtained for the extraction of fluoxetine and paroxetine from 
nails are shown in Figures 8.35-8.40.
Fluoxetine/norfluoxetine ratios in nails and hair
4.5  
4
3.5  
3
2.5
Ratio
2
1.5 
1
0.5  
0
Case sample
B Nail 
9 Hair
Figure 8.34: Comparison of fluoxetine/norfluoxetine ratio in hair and nail samples
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Table 8.33: Nail/hair concentration ratios and drug/metabolite ratios
Case Nail/hair ratio Nail Hair
sample FLU NFLU PAR FLU/NFLU FLU/NFLU
NB/1 0.80 0.69 - 4.19 3.60
NB/2 - - 0.23 - -
NB/3 0.26 0.23 - 0.93 0.80
NL/1 0.52 0.37 - 0.65 0.45
NL/2 0.86 0.37 - 2.59 1.10
NL/3 0.21 0.17 - 0.39 0.32
NL/4 0.20 0.13 - 0.94 0.60
NL/5 0.37 0.45 - 1.10 1.33
NL/6 - - - -
NL/7 0.68 0.27 - 2.60 1.02
NL/10 0.53 0.58 - 1.53 1.66
NL/11 - - 0.14 - -
NL/12 - - 0.16 - -
NL/13 0.40 0.12 - 3.17 0.92
NL/14 0.60 0.39 - 1.47 0.96
NL/15 - - 0.03 - -
ND/1 0.40 0.17 - 1.73 0.76
FLU = fluoxetine, NFLU = norfluoxetine, PAR = paroxetine
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8.6.5 CONCLUSIONS
In cases where fluoxetine was detected in nails, similar to hair cases, the metabolite, 
norfluoxetine was always detected. Correlation between detection of fluoxetine, 
norfluoxetine and paroxetine in nail with case history was excellent. Cases where negative 
results were obtained were explained by a lack of sample or a short drug administration 
time which did not allow an adequate time for the nail to grow beyond the nail bed. The 
fluoxetine, norfluoxetine and paroxetine hair and nail concentrations were o f similar 
magnitude, but the amounts detected in hair were always greater than those detected in 
nail. The ratios of nail to hair concentrations showed reasonable correlations for the three 
drugs with the concentration of drug detected in nail increasing as the concentration 
detected in hair increased. Therefore, nail analysis appears to be a good alternative to hair 
analysis to demonstrate chronic use of these drugs.
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Figure 8.35: Chromatogram of extract of nail hydrolysate spiked with 50 ng/10 mg 
tumoxetine
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Figure 8.36: Chromatogram of extract of nail hydrolysate spiked with 10 ng/10 mg 
fluoxetine and norfluoxetine
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Figure 8.37: Chromatogram of extract of nail case sample NB/03
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Figure 8.38: Chromatogram of extract of nail hydrolysate spiked with 25 ng/10 mg 
maprotiline
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Figure 8.39: Chromatogram of extract of nail hydrolysate spiked with 10 ng/10 mg 
paroxetine
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Figure 8.40: Chromatogram of extract of nail case sample NB/03
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9 Conclusions
The potential use of hair analysis as a diagnostic tool in Forensic Toxicology was 
investigated by developing a reliable method for the simultaneous analysis of opiates and 
methadone in hair. The development of this method included assessing different 
pretreatment steps to extract the drugs from hair to find which method could be used 
without chemically altering any of the drugs. Out of three possibilities, methanol treatment 
o f hair was shown to be the only tested pretreatment method which did not hydrolyze a 
proportion of 6-monoacetylmorphine to morphine. The validated method was used to 
determine the presence of morphine, codeine, 6-monoacetylmorphine, methadone and its 
metabolite, EDDP in postmortem hair samples obtained from suspected heroin overdose 
cases. Following analysis, the hair concentrations were evaluated to investigate whether an 
individual was a heroin user and to what extent. A drug use history was established for 
each individual from their hair and postmortem blood results and this was evaluated 
against any known drug use history obtained from the police report associated with the 
relevant case. In total, 31 hair case samples were investigated using the validated method 
which corroborated regular heroin usage in a high proportion of these cases. The extent of 
use was shown to vary between users and periods of compliance or non-compliance with 
methadone programmes or drug rehabilitation programmes were also apparent. On the 
whole, the developed method successfully determined the drug use history of heroin users. 
In addition, it provides a means of testing for chronic drug use in cases where heroin use is 
not obvious.
As a result of an increase in the number of postmortem blood cases received into our 
laboratory which required investigation for the antidepressant drugs fluoxetine and 
paroxetine it was necessary to develop an improved method to simultaneously analyze for 
these drugs in whole blood. A solid phase extraction procedure was developed and fully 
validated using high performance liquid chromatography and gas chromatography-mass 
spectrometry. This extraction procedure was shown to produce higher recoveries than 
existing liquid-liquid extraction methods and the use of gas chromatography-mass 
spectrometry achieved higher sensitivities than previous methods used to simultaneously 
extract these drugs from whole blood samples. This improved method was used to 
successfully determine the concentrations of these drugs in postmortem and clinical
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samples and provided the basis for further studies into the diagnostic use of alternative 
biological matrices.
The use of saliva as an alternative sample to blood or urine to indicate recent drug 
exposure was investigated by validating the developed blood extraction method for the 
determination of these antidepressants in saliva samples. Saliva samples were collected 
either by spitting into a universal container and/or using the Omni-Sal® device. The in- 
vitro recovery of the Omni-Sal® devices was assessed and this was determined to be 
reproducible. The recoveries, however, were lower than those obtained from saliva 
collected by the spitting method. Clinical samples were successfully studied using both 
validated collection methods. The concentrations in saliva were found to vary between 
0.022 - 0.223 mg/L for fluoxetine and 0.011 - 0.143 mg/L for norfluoxetine. For one 
paroxetine saliva sample, the concentration detected was 0.031 mg/L. Despite the lower
/gv # #
recoveries obtained using the Omni-Sal swabs, all samples tested using this collection 
method were shown to be positive. In some of the cases, blood and saliva samples were 
collected simultaneously and saliva/blood concentration ratios were determined. These 
were found to vary widely due to the differences in salivary pH of individuals. Four out of 
six saliva/blood ratios for fluoxetine were shown to give values within the theoretical range 
calculated for a saliva pH range of 6.0-7.2. Fluoxetine/norfluoxetine ratios were calculated 
and were shown to be consistently higher for saliva than for blood. The saliva/blood ratio 
obtained for paroxetine fell within the calculated theoretical range. These cases 
demonstrated how inter-individual variability affects the detected saliva concentrations and 
subsequently the saliva/blood ratios.
In addition, saliva samples were collected using both methods, spitting and with Omni- 
Sal® devices, from volunteers who were prescribed either a 20 mg dose o f fluoxetine or 
paroxetine. Concentration - time curves were produced for each volunteer and compared. It 
was apparent that fluoxetine capsules did not seem to produce any noticeable 
contamination of the oral cavity. However, paroxetine tablets did produce this type of 
contamination which was shown by a higher concentration of paroxetine being detected at 
one hour after administration and then a large decrease by 3 hours. Peak saliva 
concentrations were reached at approximately 7 hours following consumption for 
fluoxetine and the saliva elimination half-life was determined to be between 1 and 2 days
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for three individuals. Paroxetine peak saliva concentrations were reached at approximately 
5 and 7 hours for two individuals and the apparent saliva elimination half-life for 
paroxetine was 5 - 8  hours. Saliva was demonstrated to be a useful alternative specimen to 
provide the clinician with a non-invasive procedure to obtain information on recent drug 
exposure.
For many people who are prescribed antidepressants, there is a tendency to either stop 
taking them before they are advised to by their general practitioner or not to fully comply 
by taking them only when they believe they are required. Hair testing as a means of 
providing information on compliance or on the chronic use o f such drugs was assessed by 
modifying the method which was developed to extract opiates from hair. Pretreatment 
steps to extract the drugs from hair were investigated. The developed method involved 
using acid hydrolysis as a pretreatment step since this was shown to produce higher 
recoveries of these drugs from the hair matrix compared with the methanolic treatment. 
The solid phase extraction method was successfully extended to provide clean extracts. 
Initially two postmortem cases were analyzed. In one of these cases fluoxetine and 
norfluoxetine were detected along the hair shaft, but the concentrations were found to 
decrease along the length of the hair. This was partly due to the hair being constantly 
bleached which also caused a larger loss of the metabolite compared to the parent drug as 
the selected section of hair was obtained further away from the root. This hair sample 
demonstrated how chemical treatment affects the concentrations detected along the hair 
shaft.
Hair samples from antidepressant users were investigated using the developed method to 
provide a history of drug use for each individual and these results were evaluated against 
information obtained from each patient's medical records. The quantities of antidepressants 
determined in hair samples were evaluated using the developed method to find if  there was 
any correlation between individuals receiving the same dose. Concentrations detected in 
hair were found to vary between 0.34 - 5.52 ng/mg for fluoxetine, 0.15 - 8.09 ng/mg for 
norfluoxetine and 0.22 - 6.23 ng/mg for paroxetine. The hair samples were shown to 
provide a history of antidepressant drug use which corresponded to the patient's history as 
given in their medical records. Also, the dose-concentration relationship within an 
individual was found to be relatively constant. However, from this data it was also shown 
that a dose-concentration relationship between individuals was non-existent. Hair colour
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was shown to have some influence on the amount of drug detected in hair. Dark hair was 
seen to incorporate a higher concentration of drug than white or grey hair. The diagnostic 
use o f hair as an indicator of chronic drug use was successfully established using the 
validated method. However, no information could be derived from the hair analysis 
relating to the quantity of the drugs administered.
The potential of using nail analysis as an alternative to hair analysis for the determination 
of chronic drug use was studied by validating a simple extraction method and using it to 
determine levels of antidepressants in nails obtained from clinical patients. The detected 
concentrations were evaluated using each patient’s medical records and assessed against 
the concentrations determined in the hair of each individual to find if there was any 
correlation between the concentrations in these different biological samples. Nail 
concentrations were found to be of the same magnitude as hair concentrations and overall 
the detected concentrations showed a good correlation with medical records. Comparisons 
between hair and nail samples showed that the concentration in hair generally increased as 
the nail concentration increased. The use of nails for the detection of these drugs was 
shown to be a good alternative to hair as an indicator of chronic use.
Overall, this project has demonstrated that the use o f alternative biological matrices for the 
detection of drugs is an important tool for both forensic and clinical practitioners. With 
further research this importance will increase.
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10 Further Work
The developed blood method should be extended to include other selective serotonin 
reuptake inhibitor drugs such as fluvoxamine, sertraline and citalopram. A literature search 
indicated that although there have been various combinations of these drugs and selected 
metabolites with fluoxetine and/or paroxetine there has not been a method which extracts 
the five main selective serotonin reuptake inhibitors simultaneously. This method should 
also be applied to these drugs in saliva.
Blood, saliva and urine studies have shown that saliva is a better indicator of blood 
concentration than urine. In order to use saliva values to predict antidepressant blood 
concentrations further studies would be useful to thoroughly investigate the variation of pH 
with saliva concentration.
The hair method for opiates has the potential to include other analytes. The methanolic 
treatment method allows the possibility to extract a wider range of drugs from hair without 
causing hydrolysis or destruction of the drug. This method has in fact been used to include 
other opiates, dihydrocodeine and propoxyphene.
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Solid Phase Extraction of Fluoxetine and Norfluoxetine from Whole 
Blood using HPLC.
Fiona M. Wylie and John S. Oliver
Department of Forensic Medicine and Science, University of Glasgow, G12 8QQ.
The objective o f this research was to develop an efficient solid phase extraction 
procedure to isolate fluoxetine and its active metabolite, norfluoxetine from whole blood.
Fluoxetine (Prozac®) is a selective serotonin reuptake inhibitor which was first 
marketed in the United States in 1988 for the treatment of depression. Since then it has 
become the most widely prescribed antidepressant in the U.S. and one of the most 
commonly prescribed in the U.K. As a result, the analysis of fluoxetine (FLU) and its 
active metabolite, norfluoxetine (NFLU) have become increasingly important in clinical 
environments and also in forensic toxicology.
Both liquid-liquid extraction and solid phase extraction (SPE) methods have been 
published for the isolation of FLU and NFLU from serum and plasma. However, SPE 
methods are far fewer and the majority of these involve analysis by gas chromatography 
with electron capture detection (GC-ECD) which requires a derivatization step. Analysis 
by high performance liquid chromatography with ultra-violet detection (HPLC-UV) avoids 
derivatization, therefore reducing the time required for sample preparation. An SPE 
method using cyanopropyl columns was developed for FLU and NFLU and analysis was 
carried out using HPLC-UV.
Blank blood was spiked with FLU, NFLU and internal standard, clomipramine. The 
samples were homogenized, diluted with 0.1M phosphate buffer, pH 6.0 and were applied 
to the preconditioned cyanopropyl columns. These were selectively washed with various 
solvent and aqueous mixtures. FLU and NFLU were eluted with 
dichloromethane/isopropanol 8:2 containing 2 % concentrated ammonia. The eluates were 
evaporated under nitrogen at 40 °C and reconstituted in 200 pi of mobile phase. Analysis 
of the samples was carried out using HPLC with UV detection at 226 nm. Separation was 
achieved on a Supelcosil LC-PCN 25 cm x 4.6 mm i.d., 5 pm particle column using 
acetonitrile/methanolic buffer as the mobile phase and a flow rate of 2 ml/min. The 
methanolic buffer was prepared by buffering 0.01M potassium dihydrogen phosphate to
228
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pH 7.0 using 1M potassium hydroxide solution and mixing it with HPLC grade methanol 
in the ratio 5:4.
This SPE method was compared with a published liquid-liquid extraction (LLE) 
method. Spiked blood was alkalinized with 0.5 mol/L sodium phosphate buffer, pH 10. 
FLU and NFLU were extracted into hexane/n-amyl alcohol (97:3) followed by back 
extraction into 0.1M hydrochloric acid. Sodium hydroxide (1M) was added to basify the 
aqueous layer followed by hexane/n-amyl alcohol (97:3). The organic phase was separated, 
evaporated to dryness and reconstituted in 200 pi of mobile phase. These extracts were 
analysed using the same chromatographic conditions.
Linear quantitative response curves were produced for FLU and NFLU over the 
concentration range 0 to 2000 ng/ml for both SPE and LLE methods. Relative recoveries 
of FLU and NFLU from whole blood were determined by comparing the peak heights 
obtained from spiked whole blood extracts with unextracted standards. Recoveries > 85% 
were achieved using the SPE method which were higher than those obtained by the LLE 
method: 79% and 80% for FLU and NFLU respectively. The limit o f detection for the 
procedure was 15ng/ml.
This SPE method using cyanopropyl columns provided a simple, rapid, clean and 
selective procedure for the determination of FLU and its active metabolite, NFLU from 
whole blood achieving consistent analytical recoveries throughout the assay range. The 
technique can be applied to detect the drug at therapeutic and toxic levels.
Keywords: Fluoxetine, Norfluoxetine, Solid Phase Extraction
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Detection of Fluoxetine and Norfluoxetine in Saliva and Nails 
Fiona M. Wylie and John S. Oliver
Department of Forensic Medicine and Science, University of Glasgow, G12 8QQ, 
Scotland, U.K.
Fluoxetine and norfluoxetine were identified in the saliva and nails of patients receiving 
treatment for depression. Saliva analysis, like blood and urine analysis can be used to 
indicate recent drug use but has the advantage that sample collection is non-invasive. Nails 
can be used as an alternative matrix to hair in cases where no hair is available and can give 
an indication of long-term drug usage.
Saliva samples were collected with Omni-Sal® devices and the analytes were extracted 
using solid phase extraction with tumoxetine as the internal standard. Samples were 
derivatized with heptafluorobutyric anhydride and detected by gas chromatography/mass 
spectrometry using selective ion monitoring. Ions monitored were m/z 344 for fluoxetine 
and internal standard and m/z 330 for norfluoxetine. Recoveries greater than 86% were 
achieved for both analytes over a linear range of 0-100 ng/ml saliva. The limit of detection 
was 1 ng/ml. Six case samples were analysed and concentrations in the range of 6.6-20.1 
ng/ml (mean 13.9 ng/ml) were obtained for fluoxetine and 8.2-35.4 ng/ml (mean 16.8 
ng/ml) for norfluoxetine. Five out of six of these cases gave higher concentrations for the 
metabolite.
Nail clippings were decontaminated, dried and hydrolyzed with 1M sodium hydroxide 
solution. T umoxetine was added to the cooled hydrolysates and the analytes were extracted 
using ethyl acetate. Derivatization and detection were carried out as previously. Recoveries 
from nail were greater than 80% for fluoxetine and norfluoxetine over the linear range of 
0-100 ng/10 mg. The limit of detection was 1 ng/10 mg. Five case samples from two 
patients gave nail concentrations ranging from 0.30-3.27 ng/mg (mean 1.45 ng/mg) for 
fluoxetine and 0.18-1.72 ng/mg (mean 0.9 ng/mg) for norfluoxetine. In four out of five of 
these cases the fluoxetine concentration was higher than that of the metabolite.
Keywords: Fluoxetine, Saliva, Nails
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